Stable vaccine against Clostridium difficile

By developing a synthetic sugar of formula (I) conjugated with an immunogenic vector, the instability of sugars on the surface of C. difficile PS-II cells in water was solved, and a liquid that is resistant to hydrolysis and long-term stable is achieved Vaccine form, simplifies production and storage and improves protection against Clostridium difficile.

CN113166186BActive Publication Date: 2024-11-26IDORSIA PHARMACEUTICALS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980077346.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-11-22
Filing Date
2019-11-22
Publication Date
2024-11-26
Estimated Expiration
2039-11-22

AI Technical Summary

Technical Problem

The existing Clostridioides difficile The instability of sugars in the surface of PS-II cells in water causes the production and storage of vaccines to be complicated, and the lack of hydrolysis-resistant, long-term stable liquid formulation forms affect prevention and treatment-related Effects of disease.

Method used

A well-defined synthetic sugar of formula (I) has been developed, which can form stable conjugates in acidic, alkaline and thermal by conjugating with immunogenic carriers and using specific linkers and interconnecting molecules. Stabilize under stable conditions and is suitable for liquid preparations.

Benefits of technology

It is achieved to provide hydrolysis-resistant and long-term stable C. difficile vaccine in liquid preparations, which can trigger antibody responses and provide protection against C. difficile, simplifying the production and storage process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113166186B_ABST
    Figure CN113166186B_ABST
Patent Text Reader

Abstract

The present invention relates to synthetic sugars of general formula (I) related to Clostridium difficile PS-II cell surface polysaccharides and conjugates thereof. The synthetic sugars, the conjugates and pharmaceutical compositions comprising the synthetic sugars or the conjugates can be used to prevent and / or treat diseases associated with Clostridium difficile. In addition, the synthetic sugars of general formula (I) can be used as markers for detecting antibodies against Clostridium difficile in immunoassays.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to synthetic sugars of general formula (I) related to Clostridium difficile PS-II cell surface polysaccharides and conjugates thereof. The synthetic sugars, the conjugates and pharmaceutical compositions comprising the synthetic sugars or the conjugates are resistant to hydrolysis, long-term stable, heat stable, and can be used to prevent and / or treat diseases associated with Clostridium difficile [now known as Clostridioides difficile]. In addition, the synthetic sugars of general formula (I) can be used as markers for detecting antibodies against Clostridium difficile in immunoassays. Background Art

[0002] Clostridium difficile, formerly known as Clostridium difficile, is a Gram-positive spore-forming anaerobic bacterium that is considered to be the most important identifiable cause of nosocomial diarrhea. The terms Clostridium difficile and Clostridium difficile are synonymous in this article and are abbreviated as C.difficile. It colonizes in the intestinal tract of people, thereby causing Clostridium difficile infection (CDI). CDI has also become the most commonly diagnosed cause of nosocomial diarrhea, particularly in risk groups including the elderly and immunodeficient patients and those receiving antibiotic treatment. Due to the rapid increase in the incidence of CDI in the last decade, the infection caused by C.difficile is becoming an important challenge, mainly due to the emergence of super-toxic and now main 027 ribotype strains, resulting in an epidemic outbreak of increased morbidity, mortality and high recurrence rates. Treatment costs are greatly increased, particularly in the case of CDI recurrence. Therefore, it is very necessary to prevent the infection caused by Clostridium difficile, and vaccination of risk groups is the most cost-effective and most powerful means. However, vaccines for Clostridium difficile have not yet been developed.

[0003] Carbohydrates exposed on the bacterial cell surface are often immunogenic and constitute potential candidates for vaccine development. Compared with proteins, carbohydrates are evolutionarily more stable and when covalently linked to carrier proteins, oligosaccharide antigens can elicit long-term T cell-dependent protection.

[0004] Three different cell wall polysaccharides expressed by C. difficile cells were identified, termed PS-I, PS-II, and PS-III (Expert Rev. Vaccines 2013, 12, 421). Although the expression of the PS-I sugar may be more restricted, such as in ribotype 027, the PS-II sugar was found in all C. difficile ribotypes examined, suggesting that the PS-II sugar may be a conserved surface antigen.

[0005] The repeating unit of C.difficile PS-II sugar is composed of:

[0006]

[0007] Due to the chemical stability of the (1→6) phosphodiester bonds interconnecting the PS-II repeating units at the anomeric position of mannose, C. difficile PS-II sugars hydrolyze in water, complicating extraction from cells by commonly used hot acetic acid or water / phenol. After cleavage of the O1-C1 phosphodiester bond, the phosphomonoester group is removed, resulting in a PS-II hexasaccharide unit. In the presence of acid, base, or metal ions, cleavage of the phosphodiester bonds of the PS-II sugars is increased. Due to the instability of the C. difficile PS-II sugars in solution, when used as a vaccine, the sugar or its conjugate must be appropriately buffered in a liquid formulation or lyophilized into a solid formulation [which must be reconstituted before use]. However, lyophilization and refrigeration of the vaccine results in increased production costs and complexity of vaccine delivery, as an effective cold chain system is required to ensure optimal temperatures during transportation, storage, and handling. The instability of the C. difficile PS-II sugars is well documented in the art. Therefore, there is a need for new stable C. difficile vaccines in the form of liquid formulations.

[0008] International patent application WO 2009 / 033268 A1 discloses the isolation of PS-I and PS-II cell surface sugars of C. difficile from C. difficile bacteria of ribotype 027, MOH900 and MOH718 strains. Danieli et al. (Org. let. 2011, 13, 378-381), Costantino et al. (WO 2012 / 085668 A2), Seeberger (WO 2012 / 119769 A1) and Oberli et al. (Chemistry & Biology 2011, 18, 580) followed the synthesis of PS-II cell surface sugars of C. difficile. Monteiro (Meth Mol. Biol. 2016, 397-408) reported the isolation of water-soluble PS-I and PS-II and water-soluble and phenol-soluble PS-III polysaccharides from C. difficile biomass by hot water-phenol treatment.

[0009] The object of the present invention is to provide a well-defined synthetic sugar of general formula (I) which is metabolically stable, resistant to hydrolysis and shelf-stable in liquid formulations and which elicits antibodies against diseases caused by C. difficile. The sugar can be conjugated with an immunogenic carrier to provide conjugates and pharmaceutical compositions thereof which can be used to prevent and / or treat diseases associated with C. difficile. In addition, the synthetic sugar of general formula (I) can be used as a marker for detecting antibodies against C. difficile bacteria in immunological assays.

[0010] The object of the present invention is solved by the teaching of the independent claims. Further advantageous features, aspects and details of the present invention are evident from the dependent claims, the description, the drawings and the examples of the present application. Summary of the invention

[0011] definition

[0012] As used herein, the term "joint" encompasses a molecular fragment that can optionally connect the reducing end monosaccharide of a sugar to an immunogenic carrier or a solid support by being bound to at least one interconnected molecule. Therefore, the function of the joint itself or together with the interconnected molecule is to establish, maintain and / or bridge a specific distance between the reducing end monosaccharide and the immunogenic carrier or the solid support. By maintaining a certain distance between the sugar and the immunogenic carrier, the shielding (shielding) of the structure of the immunogenic carrier (e.g., the secondary structure of the carrier protein) to the immunogenic sugar epitope is avoided. In addition, the joint provides a higher efficiency (Methods in Molecular Medicine 2003, 87, 153-174) coupled to sugar by reducing the steric hindrance of the reactive group. More specifically, one end of the joint is connected to an exocyclic oxygen atom at the anomeric center of the reducing end monosaccharide, and the other end is connected to the interconnected molecule via a nitrogen atom, or is directly connected to an immunogenic carrier or a solid support.

[0013] Any linker of sugar conjugates (e.g., sugar-carrier protein conjugates, antibody-drug conjugates) known in the art can be used in the present invention. From a large number of publications on sugar carrier protein conjugates, those skilled in the art can easily foresee suitable linkers for sugars and conjugates disclosed herein (see "Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification" in Chem Soc Rev 2018, Advance Article, DOI: 10.1039 / C8CS00495A; and Acc Chem Res 2017, 50, 1270-1279), because the linker used (i.e., its length and connection type) will not significantly affect the immunogenicity of the sugar conjugate (see PLoS ONE 2017, 12 (12): e0189100; J. Immun. Meth. 1996, 191, 1-10). Such suitable linkers are innocuous (i.e., non-toxic) and non-immunogenic (i.e., do not result in the formation of non-protective antibodies following immunization with the conjugate), and include, but are not limited to, the commercially available bifunctional polyethylene glycol (Journal of Controlled Release). 2013, 172, 382-389; J. Immun. Meth. 1996, 191, 1-10), glutaric acid derivatives (J. Org. Chem. 2005, 70 (18), 7123-7132), adipic acid derivatives, square acid derivatives, alkynes, N-hydroxysuccinimide, such as the commercially available MFCO-NHS (monofluoro-substituted cyclooctyne N-hydroxysuccinimide ester), maleimide (as disclosed in Acc. Chem. Res. 2017, 50, 1270-1279), or hydrophilic alkylene phosphinates and sulfonyl groups (as described in WO2014080251A1).

[0014] As used herein, the term "interconnecting molecule" refers to a bifunctional molecule comprising a functional group X and a functional group Y, wherein the functional group X is capable of reacting with a terminal amino group on the linker L and the functional group Y is capable of reacting with a functional group present on an immunogenic carrier or solid support. Figure 3 Examples of commercially available interconnecting molecules are shown, but the interconnecting molecules that can be used according to the invention are not limited to the examples shown herein. It should be understood that the interconnecting molecules do not form part of the linker or immunogenic carrier or solid support.

[0015] As used herein, the term "adjuvant" refers to an immunological adjuvant, i.e., a material used in a vaccine composition that modifies or enhances the effect of a given antigen contained in the vaccine by enhancing the immune response to the antigen without antigenic association therewith. Examples of adjuvants conventionally recognized by those skilled in the art include:

[0016] - Mineral-containing compositions, including calcium salts and aluminum salts (or mixtures thereof). Calcium salts include calcium phosphates. Aluminum salts include hydroxides, phosphates, sulfates, etc., wherein the salts take any suitable form (e.g., gel, crystals, amorphous, etc.). Preferably adsorbed onto these salts. Mineral-containing compositions can also be formulated as particles of metal salts. Adjuvants known as aluminum hydroxide and aluminum phosphate can also be used. The present invention can use any "hydroxide" or "phosphate" adjuvant commonly used as an adjuvant. Adjuvants known as "aluminum hydroxide" are typically aluminum hydroxide salts, which are typically at least partially crystalline. Adjuvants known as "aluminum phosphates" are typically hydroxyaluminum phosphates, typically also containing a small amount of sulfate (i.e., hydroxyaluminum phosphate sulfate). They can be obtained by precipitation, and the reaction conditions and concentrations during precipitation affect the extent to which the phosphate replaces the hydroxyl group in the salt. A mixture of both aluminum hydroxide and aluminum phosphate can be used in the formulation according to the present invention;

[0017] -Saponins, which are a heterogeneous group of sterol glycosides and triterpenoid glycosides found in the bark, leaves, stems, roots and even flowers of various plant species. Saponins from the bark of Quillaia saponaria, Molina, have been extensively studied as adjuvants. Saponins can also be purchased from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria oficianalis (soap root). Saponin adjuvant preparations include purified preparations, such as QS21, and lipid preparations, such as ISCOM. Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS 7, QS17, QS18, QS21, QH-A, QH-B and QH-C. Saponin preparations can also include sterols, such as cholesterol. The combination of saponin and cholesterol can be used to form unique particles called immunostimulatory complexes (ISCOMs). ISCOMs typically include phospholipids, such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, ISCOMs include one or more of QuilA, QHA & QHC;

[0018] - Microparticles formed of biodegradable and non-toxic materials (i.e., particles with a diameter of 100 nm to 150 pm, more preferably 200 nm to 30 pm, or 500 nm to 10 pm). Such non-toxic and biodegradable materials include, but are not limited to, poly(α-hydroxy acids), polyhydroxybutyric acid, polyorthoesters, polyanhydrides, polycaprolactones;

[0019] - CD1d ligands, such as α-glycosylceramide, phytosphingosine-containing α-glycosylceramide, OCH, KRN7000 [(2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexosylamino)-1,3,4-octadecantriol], CRONY-101,3"-sulfo-galactosyl-ceramide;

[0020] - immunostimulatory oligonucleotides, such as those comprising a CpG motif (a dinucleotide sequence comprising an unmethylated cytosine residue linked to a guanosine residue via a phosphate bond), or those comprising a CpI motif (a dinucleotide sequence comprising a cytosine linked to an inosine), or double-stranded RNA, or an oligonucleotide comprising a palindromic sequence, or an oligonucleotide comprising a poly(dG) sequence. Immunostimulatory oligonucleotides may include nucleotide modifications / analogs, such as phosphorothioate modifications, and may be double-stranded or (except RNA) single-stranded.

[0021] - compounds comprising a lipid linked to a phosphate-containing acyclic backbone, such as MPLA or the TLR4 antagonist E5564;

[0022] - Oil emulsions (eg Freund's adjuvant).

[0023] In theory, every molecule or substance that can promote or amplify a specific event in the cascade of immune events and ultimately lead to a more pronounced immune response can be defined as an adjuvant.

[0024] In principle, by using adjuvants in vaccine formulations, one can:

[0025] - Direct and optimize the immune response to vaccines as appropriate or desired;

[0026] - achieving mucosal delivery of the vaccine, i.e. administration that brings the vaccine into contact with a mucosal surface, such as the buccal or gastric or lung epithelium and associated lymphoid tissue;

[0027] - Promote cell-mediated immune responses;

[0028] - Enhance the immunogenicity of weaker immunogens (e.g. highly purified or recombinant antigens);

[0029] - Reducing the amount of antigen or frequency of immunization required to provide protective immunity; and

[0030] - To improve the efficacy of vaccines in individuals with reduced or diminished immune responses (e.g., neonates, the elderly, and immunocompromised vaccine recipients).

[0031] Although their mode of action is poorly understood, adjuvants are currently thought to enhance the immune response through one of the following mechanisms:

[0032] - Increase the biological or immunological half-life of the antigen;

[0033] - improving the delivery of antigens to antigen presenting cells (APCs), as well as antigen processing and presentation by APCs, for example by allowing the antigen to cross endosomal membranes into the cytosol following uptake of the antigen-adjuvant complex by the APCs;

[0034] - Mimic danger-inducing signals from stressed or damaged cells that can trigger an immune response;

[0035] - Induce the production of immunomodulatory cytokines;

[0036] - bias the immune response towards a specific subset of the immune system; and - block the rapid spread of antigenic attack.

[0037] Sugars are known to those skilled in the art as TI-2 (T cell independent 2) antigens and weak immunogens. Therefore, in order to produce a vaccine based on a sugar, the sugar is conjugated to an immunogenic carrier to provide a conjugate that has a higher immunogenicity than the sugar. In this article, the term "immunogenic carrier" is defined as a structure that is conjugated to a sugar to form a conjugate that exhibits enhanced immunity compared to the sugar itself. Therefore, the conjugation of a sugar to an immunogenic carrier (preferably a protein carrier) actually stimulates an immune response to the sugar without inducing an immune response to the immunogenic carrier.

[0038] Therefore, the present invention relates to sugars of the general formula (I),

[0039]

[0040] in,

[0041] n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;

[0042] T*- represents H- or phosphate group;

[0043] Z stands for

[0044] L represents a linker, and;

[0045] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0046] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0047] or a diastereomer thereof or a pharmaceutically acceptable salt thereof.

[0048] In all general formulae (I), (II), (III) and all sub-formulae, n is preferably an integer from 1 to 8, more preferably an integer from 1 to 6, and represents more preferably 1, 2, 3, 4 or 5, more preferably 1, 2, 3 or 4, more preferably 1, 2 or 3, more preferably 1 or 2, and more preferably 1.

[0049] The linker L contains preferably 2 to 40 carbon atoms (including carbon atoms of optional side chains), more preferably 2 to 30, more preferably 2 to 20, more preferably 2 to 14, more preferably 2 to 12, and still more preferably 2 to 10 carbon atoms.

[0050] The shortest atomic chain between the oxygen atom (i.e. the oxygen of -OL-NH2) and the NH2-group is preferably composed of 2 to 14 atoms, more preferably 2 to 12 atoms, more preferably 2 to 10 atoms, more preferably 2 to 8 atoms. In the case where the shortest chain (which is the shortest possible connection between the oxygen at the center of the anomer and the NH2-group) is composed of 2 to 6 atoms, these atoms are preferably carbon atoms. In the case where the shortest chain is composed of 4 to 8 atoms, the chain may contain 1 or 2 heteroatoms selected from O, N and S. In the case where the shortest chain is composed of 9 to 14 atoms, the chain may contain 1, 2, 3, or 4 heteroatoms selected from O, N and S.

[0051] It is also preferred that the linker-L- or the shortest chain is fully or partially fluorinated. The linker-L- may comprise a 3-membered or 4-membered or 5-membered or 6-membered saturated carbocyclic ring, or a 5-membered partially unsaturated (and non-aromatic) carbocyclic ring, or a 4-membered or 5-membered or 6-membered saturated oxygen heterocyclic ring, or a 4-membered or 5-membered or 6-membered saturated nitrogen heterocyclic ring, or a 6-membered aromatic carbocyclic ring.

[0052] The linker -L- may also contain an amide (-NH-CO-, -CO-NH-) and / or urea (-NH-CO-NH-) residue, preferably only one amide or urea residue. The linker may also contain a substituent, preferably two substituents, such as R 10 and R 11 , or four substituents, such as R 10 , R 11 , R 15 and R14 , which has the meaning as defined herein and is preferably selected from: -F, -Cl, -CH3, -C2H5, -C3H7, -C5H9, -C6H 13 ,-OCH3,-OC2H5,-CH2F,-CHF2,-CF3,-C(O)-NH2,-SCH3,-SC2H5,-NHC(O)CH3,-N(CH3)2, and-N(C2H5)2.

[0053] In case the linker -L- is fluorinated, two or more substituents -F are preferred.

[0054] Preferably, the linker -L- is selected from: -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -,-CF2-,-(CF2)2-,-(CF2)3-,-(CF2)4-,-(CF2)5-,-(CF2)6-,-(CF2)7-,-(CF2)8-,-(CF2)9-,-(CF2) 10 -,-(CH2)2-O-(CH2)2-,-CH2-O-(CH2)3-,-(CH2)3-O-CH2-,-CH2-O-(CH2)2-,-(CH2)2-O -CH2-,-(CH2)3-O-(CH2)2-,-(CH2)2-O-(CH2)3-,-(CH2)4-O-CH2-,-CH2-O-(CH2)4-,-L a -,-L a -L e -,-L a -L b -L e -,-L a -L b -L d -L c -L e -,-L a -L d -L e -;

[0055] in

[0056] –L a –Selected from: -(CH2) o -,-(CF2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2-,-(CR10 R 11 ) o -,

[0057]

[0058] -L b -and-L c - are independently selected from: -O-, -NH-C(O)-NH-, -NH-C(S)-NH-, -NH-C(O)-, -C(O)-NH-, -NH-C(O)-O-, -NR 9 -,-NR 18 -,-SO2-,

[0059]

[0060] -L d - means -(CH2) q -,-(CF2) q -,-(CR 12 R 13 ) q -,

[0061] -(CH2-CH2-O) q -C2H4-,-(CH2-CH2-O) q -CH2-,

[0062]

[0063]

[0064] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0065] -CH2-(O-CH2-CH2) p1 -,-(CH2) p1 -O-(CH2) p2 -,-(CR 14 R 15 ) p1 -,

[0066] -(CR 14 R 15 ) p1 -O-(CR 21 R 22 ) p2 -,

[0067]

[0068] R 9 and R 18 are independently selected from: -CH3, -C2H5, -C3H7 and -C(O)CH3;

[0069] R 10 ,R 11 ,R 12 ,R 13 ,R 14 ,R 15 ,R 16 ,R 17 ,R 19 ,R 20 ,R 21 and R 22 Independently selected from: -H, -F, -Cl, -CH3, -C2H5, -C3H7, -C5H9, -C6H 13 ,

[0070] -OCH3, -OC2H5, -CH2F, -CHF2, -CF3, -C(O)-NH2, -SCH3, -SC2H5, -NHC(O)CH3, -N(CH3)2 and -N(C2H5)2;

[0071] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

[0072] More preferably, –L– means –L a –,–L a –L e –,–L a –L b –L e –, or –L a –L d –L e –

[0073] –L a – means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O) o -CH2;

[0074] –L b – means -O-;

[0075] –L d – means -(CH2) q -,-(CH(OH)) q -,-(CF2)q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0076] –L e – means -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0077] -CH2-(O-CH2-CH2) p1 -or-(CH2) p1 -O-(CH2) p2 ;as well as

[0078] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0079] Most preferably, the sugar of formula (I) has a group -OLE selected from:

[0080]

[0081] wherein R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl or N-succinimidyl;

[0082] X represents -Br, -Cl, -I, -CO2H, -CN, -NO2 or -SAc.

[0083] The linker L may also comprise repeating units of C. difficile PS-II sugars or fragments thereof:

[0084]

[0085] Therefore, the linker L is preferably selected from one of the following structures:

[0086]

[0087]

[0088]

[0089] Therefore, preference is also given to sugars of formula (I) having a group -OLE selected from:

[0090]

[0091]

[0092]

[0093]

[0094] Or preferably the disulfide compound of this part

[0095]

[0096] Or preferably the disulfide compound of this part

[0097]

[0098]

[0099] The sugars of the present invention may be hygroscopic and thus may form various hydrates thereof. The molar ratio of water molecules to sugars is preferably in the range of 1 to 20, more preferably 1 to 10, most preferably 5 to 10.

[0100] The sugars of the present invention carry basic and / or acidic substituents and they can form salts with organic or inorganic acids or bases.

[0101] Examples of suitable acids for forming such acid addition salts are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid, camphorsulfonic acid, mandelic acid, o-methylmandelic acid, hydrobenzenesulfonic acid, picric acid, adipic acid, d-o-tolyltartaric acid, tartronic acid, (o-, m-, p-)toluic acid, naphthylaminesulfonic acid, and other mineral acids or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in a conventional manner.

[0102] Examples of suitable inorganic or organic bases are, for example, NaOH, KOH, NH4OH, tetraalkylammonium hydroxide, lysine or arginine, etc. Salts can be prepared in a conventional manner using methods well known in the art, for example by treating a solution of a compound of formula (I) with a solution of a base selected from the above group.

[0103] It will be apparent to one skilled in the art of carbohydrate chemistry that the sugars of general formula (I) do not contain -OO- bonds and / or sugar fragments linked or bound to each other via their anomers or C-1 carbons.

[0104] Surprisingly, it was found that the sugars of general formula (I) comprise immunogenic protective epitopes and are capable of inducing a protective immune response against Clostridium difficile in human and / or animal hosts. The sugars of general formula (I) elicit antibodies that cross-react with native Clostridium difficile PS-II cell surface sugars, which can specifically recognize Clostridium difficile bacteria and opsonize them to be killed by phagocytes, thereby conferring protection against Clostridium difficile.

[0105] It was also surprisingly found that the sugars of formula (I) are stable in acidic aqueous media, alkaline aqueous media, and suspensions containing aluminum phosphate or aluminum hydroxide (e.g., the commonly used adjuvant aluminum hydroxide gel (Alhydrogel)). Although native Clostridium difficile PS-II sugars hydrolyze within one day in acidic aqueous media, in alkaline aqueous media, or in the presence of aluminum salts, sugars of formula (I) and their conjugates are stable for several days even at high temperatures. The increased stability is particularly advantageous for its use in anti-Clostridium difficile vaccines. Therefore, sugars of formula (I) and their conjugates are particularly suitable for shelf-stable liquid vaccine formulations against Clostridium difficile that can be stored at ambient temperature.

[0106] The sugars of the present invention overcome all the problems associated with sugars and conjugates thereof produced from bacterial sources in terms of purity and ease of production. First, the production of cell wall sugars requires optimized growth conditions. Second, it is necessary to find depolymerization conditions that maintain the structural integrity of the constituent monosaccharides. Finally, it is necessary to determine purification conditions that can separate pure sugars of defined length and structure. In addition to the usual contaminants (e.g., cellular polysaccharides, nucleic acids, lipids, and proteins), unwanted sugars obtained by the depolymerization process must also be excluded. Therefore, the production of pure sugars with defined structures and lengths from bacterial sources is a cumbersome and almost impossible process.

[0107] Preferred are synthetic sugars of formula (I) or (II) or (III) wherein T*- represents a phosphate group (-P(=O)(OH)2 or -P(=O)(O - )(OH) or -PO3 2- ). Therefore, the present invention also relates to sugars of general formula (I) or (II) or (III), wherein n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;

[0108] T*- represents a phosphate group, i.e., T*- represents -P(=O)(OH)2 or

[0109] -P(=O)(O - )(OH) or -PO3 2- ;

[0110] Z stands for

[0111] Preferably, Z represents

[0112] L represents a linker and is preferably a linker disclosed herein;

[0113] and the other substituents have meanings as defined herein.

[0114] Preferred are synthetic sugars of formula (I) wherein T*- represents hydrogen or a phosphate group (-P(=O)(OH)2 or -P(=O)(O - )(OH) or -PO3 2- ). Therefore, the present invention also relates to sugars of general formula (I) or (II) or (III), wherein n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;

[0115] T*-– represents –H or a phosphate group, i.e., T*- represents -H or -P(=O)(OH)2 or -P(=O)(O - )(OH) or -PO3 2- ;

[0116] Z stands for

[0117] Preferably, Z represents

[0118] L represents a linker, and;

[0119] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0120] R' represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl or N-succinimidyl.

[0121] Preferred are synthetic sugars of general formula (II),

[0122]

[0123] wherein n, L, E and T* have the meanings as defined herein.

[0124] Therefore, sugars of the general formula (II-a) or (II-b) wherein n, L and E have the meanings defined herein are particularly preferred.

[0125]

[0126]

[0127] Synthetic sugars of general formula (III) are also preferred,

[0128]

[0129] wherein n, L, E and T* have the meanings as defined herein.

[0130] Therefore, sugars of the general formula (III-a) or (III-b) wherein n, L and E have the meanings defined herein are particularly preferred.

[0131]

[0132]

[0133] Preferably, n represents an integer selected from 1 to 10, more preferably 1 to 6, more preferably 1 to 3, even more preferably 1 to 2. Therefore, sugars of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) are particularly preferred, wherein n represents an integer selected from 1 to 2.

[0134] Preferably, the linker -L- represents -L a -,-L a -L e -,-L a -L b -L e -, or -L a -L d -L e -;

[0135] –L a – means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O) o -CH2;

[0136] -L b - means -O-;

[0137] -L d - means -(CH2) q -,-(CH(OH)) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0138] –L e – means -(CH2) p1 -,-(CF2)p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0139] -CH2-(O-CH2-CH2) p1 -or-(CH2) p1 -O-(CH2) p2 -;as well as

[0140] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0141] Therefore, sugars of any one of the general formulas (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) are particularly preferred, wherein:

[0142] -L- stands for –L a –,–L a –L e –,–L a –L b –L e –, or –L a –L d –L e –

[0143] -L a - means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O) o -CH2;

[0144] -L b - means -O-;

[0145] -L d - means -(CH2) q -,-(CH(OH)) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0146] -L e - means -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0147] -CH2-(O-CH2-CH2) p1 -or-(CH2)p1 -O-(CH2) p2 -;as well as

[0148] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0149] Also preferred are sugars of any one of the general formulas (I), (II), (II-a), (II-b), (III), (III-a) or (III-b), wherein:

[0150] -L-Selected from: -L a -,-L a -L e -,-L a -L b -L e -, and -L a -L d -L e -;

[0151] -L a -Selected from: -(CH2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2;

[0152] -L b - means -O-;

[0153] -L d -Selected from: -(CH2) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, and -(CH2-CH2-O) q -CH2-;

[0154] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0155] -CH2-(O-CH2-CH2) p1 -and-(CH2) p1 -O-(CH2) p2 -;

[0156] o, q, p1 and p2 are each independently an integer selected from 1, 2, 3, 4, 5 and 6; and n represents 1.

[0157] Even more preferred are sugars of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) wherein -L- represents -(CH2) o -, and o is an integer selected from 1, 2, 3, 4, 5 and 6.

[0158] Also preferred are sugars of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) wherein -L- represents -(CH2) o -, o is an integer selected from 1, 2, 3, 4, 5 and 6, and n represents an integer selected from 1 to 2.

[0159] In a most preferred embodiment, -OLE is selected from the following:

[0160]

[0161]

[0162] wherein R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl or N-succinimidyl;

[0163] X represents -Br, -Cl, -I, -CO2H, -CN, -NO2 or -SAc.

[0164] Also preferred are sugars of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b), wherein the group -OLE is selected from the group consisting of:

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171] Also preferred are sugars of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) wherein -L- represents -(CH2) o -, o is an integer selected from 2, 3, 4, 5 and 6, and E represents an amino group.

[0172] Preferred are synthetic sugars of formula (II-b), wherein n is 1 and E is an amino group. More preferred are synthetic sugars of formula (II-b), wherein n is 1, E is an amino group and the linker -L- represents -L a -,-L a -L e -,-L a -L b -L e -, or -L a -L d -L e -;

[0173] -L a - means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O) o -CH2;

[0174] -L b - means -O-;

[0175] -L d - means -(CH2) q -,-(CH(OH)) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0176] -L e - means -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0177] -CH2-(O-CH2-CH2) p1 -or-(CH2) p1 -O-(CH2) p2 -;as well as

[0178] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0179] Particularly preferred are synthetic sugars of formula (II-b) wherein n is 1, E is an amino group, and the linker -L- represents -(CH2) o -, and o is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. Even more preferred is a synthetic sugar of formula (II-b) wherein n is 1, E is an amino group, and the linker -L- represents -(CH2) o- and o is an integer selected from 1, 2, 3, 4, 5 and 6.

[0180] Preferred are synthetic sugars of formula (II-b) wherein n is 2 and E is an amino group. More preferred are synthetic sugars of formula (II-b) wherein n is 2, E is an amino group and the linker -L- represents -L a -,-L a -L e -,-L a -L b -L e -, or -L a -L d -L e -;

[0181] -L a - means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O) o -CH2;

[0182] -L b - means -O-;

[0183] -L d - means -(CH2) q -,-(CH(OH)) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0184] -L e - means -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0185] -CH2-(O-CH2-CH2) p1 -or-(CH2) p1 -O-(CH2) p2 -;as well as

[0186] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0187] Particularly preferred are synthetic sugars of formula (II-b) wherein n is 2, E is an amino group, and the linker -L- represents -(CH2) o-, and o is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. Even more preferred is a synthetic sugar of formula (II-b) wherein n is 2, E is an amino group, and the linker -L- represents -(CH2) o - and o is an integer selected from 1, 2, 3, 4, 5 and 6.

[0188] In another preferred embodiment, the sugars according to the invention are selected from the following:

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202] Where Z represents

[0203] Particularly preferred are sugars of formula (I'a-4) in which Z represents

[0204] Particularly preferred are sugars of formula (I'b-4) in which Z represents

[0205] Chemical synthesis

[0206] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I):

[0207]

[0208] in,

[0209] n is 1;

[0210] T*- represents H– or phosphate group;

[0211] Z stands for

[0212] L represents a linker, and;

[0213] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0214] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0215] The method comprises the following steps:

[0216] A1) provides a monosaccharide of formula 1*:

[0217]

[0218] Where P 1 , P 3 , P 4 and P 22 Represents a protecting group, C represents -LE p , where E p Is a solid support or protected

[0219] terminal groups; and

[0220] A2) reacting a monosaccharide of formula 1* with a compound of formula 2* to obtain compound 3*:

[0221]

[0222] Where P 1 , P 3 , P 4 -P 10 and P 22 Represents a protecting group, C represents -LE p , where E p Is a solid carrier or protected

[0223] Protected end group E, LG 2 represents a leaving group and N p represents a protected amino group; and

[0224] A3) Execution of the protective group P of compound 3* 5 to obtain compound 4*,

[0225]

[0226] Where P 1 , P 3 , P 4 , P 6 -P 10 and P 22 represents a protecting group, C represents

[0227] -LE p , where E p is a solid support or a protected terminal group E, and N p represents a protected amino group; and

[0228] A4) reacting compound 4* with a monosaccharide 5* to obtain compound 6*,

[0229]

[0230] Where P 1 , P 3 , P 4 , P 6 -P 14 and P 22 represents a protecting group, C represents

[0231] -LE p , where E p Is a solid support or a protected end group E, LG 3 represents a leaving group and N p represents a protected amino group; and

[0232] A5) Execution of the protecting group P of compound 6* 13 to obtain compound 7*,

[0233]

[0234] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 22 represents a protecting group,

[0235] C stands for -LE p , where E p is a solid support or a protected terminal group E, and N p represents a protected amino group; and

[0236] A6) reacting compound 7* with a monosaccharide 8* to obtain compound 9*,

[0237]

[0238]

[0239] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 -P 17 and P 22 represents a protecting group,

[0240] C stands for -LE p , where E p Is a solid support or a protected end group E, LG 4 represents a leaving group and N p represents a protected amino group; and

[0241] A7) Execution of the protective group P of compound 9* 15 to obtain compound 10*,

[0242]

[0243] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 , P 17 and P 22 represents a protecting group,

[0244] C stands for -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and

[0245] A8) reacting compound 10* with a monosaccharide 11* to obtain compound 12*,

[0246]

[0247] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 16 -P 22 represents a protecting group,

[0248] C stands for -LEp , where E p Is a solid support or a protected end group E, LG 5 represents a leaving group and N p represents a protected amino group; and

[0249] A9) optionally performing the protecting group P of compound 12* 21 to obtain compound 13* and reacting compound 13* with a phosphorylating agent to obtain compound 14*,

[0250]

[0251] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and

[0252] A10) converting the protected amino group of compound 12* or 14* into the corresponding acetylamino group to give compound 15* or 16*,

[0253]

[0254]

[0255] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 16 -P 24 represents a protecting group and C represents -LE p ,in

[0256] E p is a solid support or a protected end group; and

[0257] A11) performing the removal of all remaining protecting groups from compound 15* or 16* to obtain compound 17* or 18* of general formula (I),

[0258]

[0259] Another aspect of the present invention relates to the synthesis of sugars 17* or 18* of general formula (I), wherein the hexasaccharide intermediate 12* is obtained directly from compound 7* by carrying out step A6'.

[0260] A6') reacting compound 7* with disaccharide 19* to obtain compound 12*,

[0261]

[0262] Where P 16 -P 20 and P 21 Represents a protecting group, LG 6 represents a leaving group and N p represents a protected amino group.

[0263] Therefore, in one embodiment, a method for synthesizing sugar 17* or 18* of general formula (I) comprises steps A1), A2), A3), A4), A5), A6'), A9), A10) and A11).

[0264] Another aspect of the present invention relates to the synthesis of sugars 17* or 18* of general formula (I), wherein the hexasaccharide intermediate 12* is obtained directly from compound 1* by carrying out step A2'.

[0265] A2') reacting compound 1 with pentasaccharide 20* to obtain compound 12*,

[0266]

[0267] Where P 6 -P 12 , P 14 and P 16 -P 21 Represents a protecting group, LG 7 represents a leaving group and N p The pentasaccharide 20* can be obtained by reacting the compound 2* with the compound 5*, then with the compound 8*, and then with the compound 11*, or by reacting the compound 2* with the compound 5* and then with the compound 19*.

[0268] Therefore, in one embodiment, a method for synthesizing sugar 17* or 18* of general formula (I) comprises steps A1), A2'), A9), A10) and A11).

[0269] Compound 1* can be obtained from the corresponding protected mannose donor 21* via steps A1a), A1b) and A1c).

[0270] A1a) providing compound 21*,

[0271]

[0272] Where P 1 -P 4 represents a protecting group and LG 1 represents a leaving group; and

[0273] Conversion of the compound of formula 21* to the alcohol of formula 22*

[0274]

[0275] Where P 1 -P 4 represents a protecting group; and

[0276] A1b) reacting a compound of formula 22* with alcohol HO-LC in the presence of a phosphorylating agent to give compound 23*;

[0277]

[0278] Where P 1 -P 4 and P 22 represents a protecting group and C represents -L--E p , where E p Is a solid support or a protected end

[0279] Base E; and

[0280] The alcohol 22* in step A1a) can be prepared according to Brooks et al. (Tetrahedron 1995, 51, 7999) by reacting compound 21* with allyltrimethylsilane in the presence of a Lewis acid (J. Am. Chem Soc. 1982, 104, 4976; Tetrahedron Letters, 1985, 26, 1479), followed by isomerization to propenyl C-mannoside with bis(benzonitrile)palladium(II) chloride in refluxing toluene, Lemieux-Johnson oxidation with sodium periodate and osmium tetroxide, and reduction with sodium acetoxyborohydride to the alcohol 22* (see also Org. Biomol. Chem 2016, 14, 3913).

[0281] Alternatively, alcohol 22* in step A1a) can be prepared by reacting compound 21* with (iPrO)Me2SiCH2MgCl in the presence of copper (I) iodide (Org. Lett. 2004, 6, 119). In addition, alcohol 22* in step A1a) can be prepared by reacting compound 21* with a vinyl Grignard reagent, followed by oxidation of the vinyl Grignard reagent with osmium tetroxide and sodium periodate and reduction to alcohol 22* by a sodium borohydride reagent (such as sodium acetoxyborohydride).

[0282] In another embodiment, alcohol 22* is obtained from the corresponding glycoside by reaction with trimethylsulfoxide iodide and sodium hydride (J. Org. Chem. 2002, 67, 7439) or by reaction with propargyltrimethylsilane and BF3.OEt2 followed by ozonolysis and sodium borohydride reduction (Synlett 2005, 7, 1147).

[0283] A1c) Execution of the protective group P of compound 23* 2 to obtain compound 1*.

[0284] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I), wherein

[0285] n is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0286] T*- represents H- or phosphate group;

[0287] Z stands for

[0288] L represents a linker, and;

[0289] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0290] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0291] The method comprises the following steps:

[0292] B1) providing compound 13*,

[0293]

[0294] Where P 1 , P 3 , P 4 , P 6-P 12 , P 14 , P 16 -P 20 and P 22 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group;

[0295] And repeat the following steps n-1 times:

[0296] B1.1) reacting with a compound of formula 22* in the presence of a phosphorylating agent,

[0297] B1.2) Execution protection base P 2 removal of;

[0298] B1.3) executing steps A2)-A8) or steps A2)-A5) and A6') or step A2');

[0299] B1.4) Execution protection base P 21 removal of;

[0300] or

[0301] B2.1) reacting compound 13* with a compound of the following formula in the presence of a phosphorylating agent,

[0302]

[0303] B2.2) Execution protection base P 21 removal of;

[0304] B2.3) optionally repeating steps B2.1 and B2.2 one to eight times to synthesize the corresponding trisaccharide (n=3) into a decasaccharide (n=10);

[0305] To provide compound 24*:

[0306]

[0307] Where P 1 , P 3 , P 4 , P 6 -P 14 , P 16 -P 20 and P 22 Represents a protecting group, C represents -LE p , where E p Is a solid support or a protected end group E, N prepresents a protected amino group and n represents an integer from 2 to 10; and B2) optionally reacting compound 24* with a phosphorylating agent to obtain compound 25*,

[0308]

[0309] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p , where E p Is a solid support or a protected end group E, N p represents a protected amino group and n represents an integer from 2 to 10; and

[0310] B3) converting the protected amino group of compound 24* or 25* to the corresponding acetylamino group to give compound 26* or 27*,

[0311]

[0312]

[0313] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 represents a protecting group, C represents -L-

[0314] E p , where E p is a solid support or a protected end group E and n represents an integer from 2 to 10; and

[0315] B4) performing the removal of all remaining protecting groups from compound 26* or 27* to obtain compound 28* or 29* of general formula (I),

[0316]

[0317] wherein n represents an integer from 2 to 10 and L and E have the meanings as defined herein.

[0318] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I),

[0319]

[0320] in,

[0321] n is 1;

[0322] T*- represents H- or phosphate group;

[0323] Z stands for L represents a linker, and;

[0324] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0325] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0326] The method comprises the following steps:

[0327] C1) provides a monosaccharide of formula 30*, which can be obtained according to the process disclosed in Chem. Eur. J. 2015, 21, 7511-7519 or Synlett, 2005, 7, 1147-1151:

[0328]

[0329] Where P 1 , P 3 , P 4 and P 22 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected end group; and

[0330] C2) reacting a monosaccharide of formula 30* with a compound of formula 2* to give compound 31*:

[0331]

[0332]

[0333] Where P 1 , P 3 , P 4 -P 10 and P 22 Represents a protecting group, C represents -LE p , where E p Is a solid support or a protected end group E, LG2 represents a leaving group and N p represents a protected amino group; and

[0334] C3) Execution of the protective group P of compound 31* 5 to obtain compound 32*,

[0335]

[0336] Where P 1 , P 3 , P 4 , P 6 -P 10 and P 22 represents a protecting group, C represents

[0337] -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and

[0338] C4) reacting compound 32* with monosaccharide 5* to obtain compound 33*,

[0339]

[0340] Where P 1 , P 3 , P 4 , P 6 -P 14 and P 22 represents a protecting group, C represents

[0341] -LE p , where E p Is a solid support or a protected end group E, LG 3 represents a leaving group and N p represents a protected amino group; and

[0342] C5) Execution of the protective group P of compound 33* 13 to obtain compound 7*,

[0343]

[0344] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 22 represents a protecting group, C represents

[0345] -LEp , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and

[0346] C6) reacting compound 34* with a monosaccharide 8* to obtain compound 35*,

[0347]

[0348] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 -P 17 and P 22 represents a protecting group,

[0349] C stands for -LE p , where E p Is a solid support or a protected end group E, LG 4 represents a leaving group and N p express

[0350] protected amino groups; and

[0351] C7) Execution of the protective group P of compound 35* 15 to obtain compound 36*,

[0352]

[0353] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 , P 17 and P 22 represents a protecting group,

[0354] C stands for -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and

[0355] C8) reacting compound 36* with monosaccharide 11* to obtain compound 37*,

[0356]

[0357] Where P 1 , P 3 , P4 , P 6 -P 12 , P 14 and P 16 -P 22 represents a protecting group,

[0358] C stands for -LE p , where E p Is a solid support or a protected end group E, LG 5 represents a leaving group and N p represents a protected amino group; and

[0359] C9) optionally performing the protecting group P of compound 37* 21 to obtain compound 38* and reacting compound 38* with a phosphorylating agent to obtain compound 39*,

[0360]

[0361]

[0362] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and

[0363] C10) converting the protected amino group of compound 37* or 39* into the corresponding acetylamino group to obtain compound 40* or 41*,

[0364]

[0365] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 16 -P 24 represents a protecting group and C represents -LE p , where E p is a solid support or a protected end group; and

[0366] C11) performing the removal of all remaining protecting groups from compound 40* or 41* to obtain compound 42* or 43* of general formula (I),

[0367]

[0368] Another aspect of the present invention relates to the synthesis of sugars 42* or 43* of general formula (I), wherein the hexasaccharide intermediate 37* is obtained directly from compound 34* by performing step A6'). Therefore, in one embodiment, a method for synthesizing sugars 42* or 43* of general formula (I) comprises steps C1), C2), C3), C4), C5), A6'), C9), C10) and C11).

[0369] Another aspect of the present invention relates to the synthesis of sugars 42* or 43* of general formula (I), wherein the hexasaccharide intermediate 37* is obtained directly from compound 30* by performing step A2'. Therefore, in one embodiment, a method for synthesizing sugars 42* or 43* of general formula (I) comprises steps C1), A2'), C9), C10) and C11).

[0370] Therefore, another method for synthesizing the sugar of general formula (I) comprises the following steps:

[0371] C1) provides a monosaccharide of formula 30*:

[0372]

[0373] Where P 1 , P 3 , P 4 and P 22 Represents a protecting group, C represents -LE p , where E p Is a solid support or protected

[0374] terminal groups; and

[0375] C2') reacting compound 30* with pentasaccharide 20* to obtain compound 37*,

[0376]

[0377] Where P 6 -P 12 , P 14 and P 16 -P 21 Represents a protecting group, LG 7 represents a leaving group and N p represents a protected amino group.

[0378] C9) optionally performing the protecting group P of compound 37* 21to obtain compound 38* and reacting compound 38* with a phosphorylating agent to obtain compound 39*,

[0379]

[0380]

[0381] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group; and C10) converting the protected amino group of compound 37* or 39* to the corresponding acetylamino group to obtain compound 40* or 41*,

[0382]

[0383] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 16 -P 24 represents a protecting group and C represents -LE p , where E p

[0384] is a solid support or a protected end group; and

[0385] C11) performing the removal of all remaining protecting groups from compound 40* or 41* to obtain compound 42* or 43* of general formula (I),

[0386]

[0387] wherein L and E have the meanings as defined herein.

[0388] Compound 30* can be obtained from the corresponding protected mannose donor 21* in steps A1a), C1b), C1c) and C1d).

[0389] C1 b) converting the compound of formula 22* into the corresponding halide 44*

[0390]

[0391] Where P 1 -P 4 represents a protecting group and Hal is selected from -Br or -I; and

[0392] C1c) reacting a compound of formula 44* with an alcohol HO-LC in the presence of a phosphite to obtain compound 45*;

[0393]

[0394] Where P 1 -P 4 and P 22 represents a protecting group and C represents -LE p , where E p Is a solid support or a protected end

[0395] Base E; and

[0396] C1d) Execution of the protecting group P of compound 45* 2 to give compound 30*.

[0397] The conversion of the alcohol 22* to the corresponding halide 44* in step C1 b) can be achieved according to standard procedures, i.e. by reacting the alcohol 22* with CBr4 or I2 in the presence of PPh3, or alternatively by converting the alcohol 22* to a mesylate or triflate, followed by displacement with tetrabutylammonium bromide or tetrabutylammonium iodide.

[0398] The phosphite used in step C1c) is preferably a trialkyl phosphite, such as triethyl phosphite, which reacts with the halide 44* to form a phosphonate, which is then hydrolyzed to the phosphonic acid with a Lewis acid (e.g. bromotrimethylsilane) and then with water (Tetrahedron 1995, 51, 7999). The phosphonic acid is reacted with an alcohol HO-LC in the presence of trichloroacetonitrile to give compound 45*.

[0399] Alternatively, the phosphite used in step C1c) may be a phosphoramidite, for example a dialkyl or dibenzyl N,N-diethylphosphoramidite or a bis(diisopropylamino)-benzyloxy-phosphine, which reacts with compound 44* in an Arbuzow reaction and with the alcohol HO-LC under diethylamine release.

[0400] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I), wherein:

[0401] n is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0402] T*- represents H- or phosphate group;

[0403] Z stands for L represents a linker, and;

[0404] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0405] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0406] The method comprises the following steps:

[0407] D1) providing compound 38*,

[0408]

[0409] Where P 1 , P 3 , P 4 , P 6 -P 14 , P 16 -P 20 and P 22 represents a protecting group,

[0410] C stands for -LE p , where E p is a solid support or a protected terminal group E and N p represents a protected amino group;

[0411] And repeat the following steps n-1 times:

[0412] D1.1) reacting with a compound of formula 44* in the presence of a phosphite,

[0413] D1.2) Execution protection base P 2 removal of;

[0414] D1.3) executing steps C2)-C8) or steps C2)-C5) and A6') or step A2');

[0415] D1.4) Execution protection base P 21 removal of;

[0416] or

[0417] D2.1) reacting compound 38* with a compound of the formula:

[0418]

[0419] D2.2) Execution protection base P 21 removal of;

[0420] D2.3) Optionally repeat steps D2.1 and D2.2 one to eight times to synthesize the corresponding trisaccharide (n=3) into a decasaccharide

[0421] (n=10);

[0422] To provide compound 46*:

[0423]

[0424] Where P 1 , P 3 , P 4 , P 6 -P 14 , P 16 -P 20 and P 22 represents a protecting group,

[0425] C stands for -LE p , where E p Is a solid support or a protected end group E, N p represents a protected amino group and n represents

[0426] represents an integer from 2 to 10; and

[0427] D2) optionally reacting compound 46* with a phosphorylating agent to obtain compound 47*,

[0428]

[0429] Where P 1 , P 3 , P 4 , P 6 -P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p ,in

[0430] E p Is a solid support or a protected end group E, N p represents a protected amino group and n represents an integer from 2 to 10

[0431] number; and

[0432] D3) converting the protected amino group of compound 46* or 47* to the corresponding acetylamino group to obtain compound 48* or 49*,

[0433]

[0434] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected end group E and N represents an integer from 2 to 10; and D4) performing removal of all remaining protecting groups from compound 48* or 49* to obtain compound 50* or 51* of general formula (I),

[0435]

[0436] wherein n represents an integer from 2 to 10 and L and E have the meanings as defined herein.

[0437] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I), wherein n is 1;

[0438] T*- represents H- or phosphate group;

[0439] Z stands for L represents a linker, and;

[0440] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0441] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0442] The method comprises the following steps:

[0443] E1) providing a monosaccharide of formula 52*:

[0444]

[0445] Where P 1 , P 3 , P 4 and P 25 represents a protecting group; and

[0446] E2) reacting a monosaccharide of formula 52* with a compound of formula 2* to obtain compound 53*:

[0447]

[0448] Where P 1 , P 3 , P 4 -P 10 and P 25 Represents a protecting group, LG 2 represents a leaving group and N p Represents protected amine

[0449] base; and

[0450] E3) Execution of the protective group P of compound 53* 5 to obtain compound 54*,

[0451]

[0452] Where P 1 , P 3 , P 4 , P 6 -P 10 and P 25 represents a protecting group, and N p represents a protected amino group; and E4) reacting compound 54* with a monosaccharide 5* to obtain compound 55*,

[0453]

[0454] Where P 1 , P 3 , P 4 , P 6 -P 14 and P 25 Represents a protecting group, LG 3 represents a leaving group and N p Indicates protected

[0455] The amino group; and

[0456] E5) Execution of the protecting group P of compound 55* 13 to obtain compound 56*,

[0457]

[0458] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 25 represents a protecting group, and N prepresents a protected amino group; and

[0459] E6) reacting compound 56* with disaccharide 19* to obtain compound 57*,

[0460]

[0461] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 16 -P 25 Represents a protecting group, LG 6 represents a leaving group and N p

[0462] represents a protected amino group; and

[0463] E7) converting the protected amino group of compound 57* into the corresponding acetylamino group to give compound 58*,

[0464]

[0465] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 21 and P 25 represents a protecting group; and

[0466] E8) Execution of the protecting group P of compound 58* 25 The removal of 59* affords compound 59* and the phosphorylation agent

[0467] Compound 59* is reacted with alcohol HO-LC to obtain compound 15*.

[0468]

[0469] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 22 represents a protecting group, and

[0470] E9) optionally performing the protecting group P of compound 15* 21 The removal of to give compound 60* and the compound 60* and phosphorus

[0471] Acidifying agent to obtain compound 16*,

[0472]

[0473]

[0474] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected end group E; and

[0475] E10) removing all remaining protecting groups from compound 15* or 16* to obtain compound 17* or

[0476] 18*,

[0477]

[0478] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I), wherein:

[0479] n is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0480] T*- represents H- or phosphate group;

[0481] Z stands for L represents a linker, and;

[0482] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0483] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0484] The method comprises the following steps:

[0485] F1) providing compound 60*,

[0486]

[0487] Where P1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 Represents a protecting group, C represents -LE p ,in

[0488] E p is a solid support or a protected end group;

[0489] F2.1) reacting compound 60* with a compound of the following formula in the presence of a phosphorylating agent

[0490]

[0491] F2.2) Execution protection base P 21 removal of;

[0492] F3) Optionally repeat steps F2.1 and F2.2 n-2 times to synthesize the corresponding trimer (n=3) into a decamer

[0493] (n=10); to provide compound 26*:

[0494]

[0495] Where P 1 , P 3 , P 4 , P 6 -P 14 , P 16 -P 20 and P 22 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected end group E, and n represents an integer from 2 to 10; and

[0496] F4) optionally reacting compound 26* with a phosphorylating agent to obtain compound 27*,

[0497]

[0498] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P24 represents a protecting group, CC represents -LE p , where E p is a solid support or a protected end group E, and n represents an integer from 2 to 10; and F5) performing removal of all remaining protecting groups from compound 26* or 27* to obtain compound 28* or

[0499] 29*,

[0500]

[0501] wherein n represents an integer from 2 to 10 and L and E have the meanings as defined herein.

[0502] Another aspect of the present invention relates to a method for synthesizing a sugar of general formula (I), wherein:

[0503] n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0504] T*- represents H- or phosphate group;

[0505] Z stands for L represents a linker; and

[0506] E represents -NH2, -N3, -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONH-NH2, -SH, -OH or -SAc;

[0507] R′ represents -H, -Me, -Et, 4-nitrophenyl, pentafluorophenyl, or N-succinimidyl;

[0508] The method comprises the following steps:

[0509] G1) provides a monosaccharide of formula 52*:

[0510]

[0511] Where P 1 , P 3 , P 4 and P 25 represents a protecting group; and

[0512] G2) reacting a monosaccharide of formula 52* with a compound of formula 2* to obtain compound 3*:

[0513]

[0514] Where P 1 , P 3 , P 4 -P10 and P 25 Represents a protecting group, LG 2 represents a leaving group and N p Represents protected amine

[0515] base; and

[0516] G3) Execution of the protective group P of compound 53* 5 to obtain compound 54*,

[0517]

[0518] Where P 1 , P 3 , P 4 , P 6 -P 10 and P 25 represents a protecting group, and N p represents a protected amino group; and G4) reacting compound 54* with a monosaccharide 5* to obtain compound 55*,

[0519]

[0520]

[0521] Where P 1 , P 3 , P 4 , P 6 -P 14 and P 25 Represents a protecting group, LG 3 represents a leaving group and N p Indicates protected

[0522] The amino group; and

[0523] G5) Performing the protection group P of compound 55* 13 to obtain compound 56*,

[0524]

[0525] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 25 represents a protecting group, and N p represents a protected amino group; and

[0526] G6) reacting compound 56* with disaccharide 19* to obtain compound 57*,

[0527]

[0528] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 and P 16 -P 25 Represents a protecting group, LG 6 represents a leaving group and N p

[0529] represents a protected amino group; and

[0530] G7) converting the protected amino group of compound 57* into the corresponding acetylamino group to obtain compound 58*,

[0531]

[0532] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 21 and P 25 represents a protecting group; and

[0533] G8) Performing the protecting group P of compound 58* 25 Removal of to give compound 59* and in the presence of a phosphorylating agent

[0534] Compound 59* is reacted with alcohol HO-LC to obtain compound 15*.

[0535]

[0536] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 22 represents a protecting group, and

[0537] G9) repeating steps G9.1 and G9.2 n-1 times to synthesize the corresponding dimer (n=3) into a decamer (n=10);

[0538] G9.1) Execute protection base P 21 removal of

[0539] G9.2) reacting the product of step G9.1) with a compound of the formula

[0540]

[0541] , to provide compound 61*,

[0542]

[0543] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 22 Represents a protecting group, C represents -LE p , where E p is a solid support or a protected end group;

[0544] G10) optionally performing the protecting group P of compound 61* or compound 15* 21 Removal of to give compound 26* and reacting compound 26* with a phosphorylating agent to give compound 27* to provide compound 26*:

[0545]

[0546]

[0547] Where P 1 , P 3 , P 4 , P 6 -P 12 , P 14 , P 16 -P 20 and P 22 -P 24 represents a protecting group, CC represents -LE p , where E p is a solid support or a protected end group E, and n represents an integer from 1 to 10; and

[0548] G11) performing the removal of all remaining protecting groups from compound 26* or 27* to obtain compound 28* or 29* of general formula (I),

[0549]

[0550] wherein n represents an integer from 1 to 10 and L and E have the meanings as defined herein.

[0551] E prepresents a solid support or a protected end group. E represents -NH2, -N3,

[0552] -CN, -O-NH2, -CH=CH2, -C≡CH, -Br, -Cl, -I, -CO2R′, -CONHNH2, -SH, -OH or -SAc; and the corresponding protected terminal groups E p Indicates -N(P 26 )(P 27 ),-N3,-CN,-ON(P 26 )(P 27 ),-CH=CH2,-C≡CH,-Br,-Cl,-I,-CO2R′,

[0553] -CONHN(P 26 )(P 27 ),-SP s , or -Sac.

[0554] N p Preferably, Np is selected from -N3, -NH-CO-CCl3 and -NH-CO-O-CH2-CCl3(Troc).

[0555] P 1 ,P 2 ,P 3 ,P 4 ,P 5 ,P 6 ,P 7 ,P 8 ,P 9 ,P 10 ,P 11 ,P 12 ,P 13 ,P 14 ,P 15 ,P 16 ,P 17 ,P 18 ,P 19 ,P 20 ,P 21 ,P 22 ,P 23 ,P 24 ,P 25 ,P 26 and P 27 As used herein, the term "protecting group" refers to a group commonly used in organic synthesis, preferably used to protect hydroxyl, amino and thiol.

[0556] Preferably, the protecting group P can be removed under conditions that stabilize other protecting groups present in the molecule. 21 .

[0557] The amino protecting group is preferably stable under the conditions used to remove a hydroxy protecting group present in the molecule.

[0558] Preferably, the protecting group P 21 Hydroxyl protecting groups other than α-hydroxyl groups can preferably be removed by hydrogenation.

[0559] More preferably, P 1 ,P 2 ,P 3 ,P 4 ,P 5 ,P 6 ,P 7 ,P 8 ,P 9 ,P 10 ,P 11 ,P 12 ,P 13 ,P 14 ,P 15 ,P 16 ,P 17 ,P 18 ,P 19 ,P 20 ,P 21 ,P 22 ,P 23 ,P 24 and P 25 is a suitable protecting group for hydroxyl, more preferably, different suitable protecting groups for hydroxyl can be subsequently removed one by one by a series of suitable deprotection reactions. Preferred hydroxyl protecting groups are acetyl, phenyl, benzyl, isopropylidene, benzylidene, benzoyl, p-methoxybenzyl, p-methoxybenzylidene, phenyl, p-bromobenzylidene, p-nitrophenyl, allyl, acetyl, isopropyl, p-bromobenzyl, dimethoxytrityl, trityl, 2-naphthylmethyl, pivaloyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tert-butylmethoxy-phenylsilyl, triethylsilyl, trimethyl Silyl, 2-trimethylsilylethoxymethyl, 9-fluorenylmethoxycarbonyl, benzyloxymethyl, methoxymethyl, tert-butoxymethyl, methoxyethoxymethyl, levulinoyl, naphthyl, chloroacetyl, methylpyridyl, tert-hexyldimethylsilyl (thexyldimethylsilyl, TDS), (2-nitrophenyl)acetyl (NPAc), 2-(azidomethyl)benzoyl (AzmB).

[0560] Protecting groups can be divided into permanent protecting groups and temporary protecting groups. Permanent protecting groups are those that are stable throughout the synthesis and can be effectively removed at the end of the synthesis. In this case, permanent protecting groups include P 1,P 3 ,P 4 ,P 6 -P 12 ,P 14 ,P 16 -P 20 ,P 22 -P 26 .P 1 ,P 3 ,P 4 ,P 6 -P 12 ,P 14 ,P 16 -P 20 and P 22 -P 24 The hydroxyl group is masked during the entire synthesis, and the protecting group P 26 and P 27 Covering the terminal E p Preferably, the protecting group P 3 ,P 4 ,P 8 -P 12 ,P 14 ,P 16 -P 20 and P 22 -P 24 is benzyl, protecting group P 1 is benzoyl, protecting group P 7 and P 18 is acetyl, protecting group P 26 is benzyl and the protecting group P 27 It is benzyloxycarbonyl (Cbz).

[0561] Temporary protecting groups are typically orthogonal protecting groups that can be selectively removed at different levels of the synthesis to release the hydroxyl group for subsequent introduction of different substituents, including monosaccharides, other protecting groups present on the molecule, or other residues. In this case, the temporary protecting groups include P 2 ,P 5 ,P 13 ,P 15 ,P 21 and P 25 .

[0562] Temporary Protecting Group P 2 ,P 5 ,P 13 ,P 15 ,P 21 and P 25Preferably, it is selected from but not limited to: allyl, p-methoxybenzyl, 2-naphthylmethyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butylmethoxyphenylsilyl, triethylsilyl, trimethylsilyl, 2-trimethylsilylethoxymethyl, 9-fluorenylmethoxycarbonyl, tert-hexyldimethylsilyl, (2-nitrophenyl)acetyl, 2-(azidomethyl)benzoyl and levulinyl. Preferably, in the protective group P 1 ,P 3 ,P 4 ,P 6 -P 12 ,P 14 ,P 16 -P 20 ,P 22 -P 24 In the presence of 2 ,P 5 ,P 13 ,P 15 ,P 21 and P 25 Preferably, P 2 ,P 5 ,P 13 ,P 15 ,P 21 and P 25 In a preferred embodiment, the protecting group P 13 and P 21 represents 9-fluorenylmethoxycarbonyl, and the protecting group P 1 ,P 5 and P 15 Preferably, P 21 is selected from triisopropylsilyl, tert-butyldimethylsilyl, tert-butylmethoxyphenylsilyl. Preferably, P 25 It is 2-naphthylmethyl.

[0563] A judicious choice of protecting groups allows to obtain the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) appropriately, which is functionalized with a terminal group for subsequent conjugation to an immunogenic carrier or solid support. In addition, the choice of leaving group influences the stereochemical outcome of the glycosylation reaction in steps A1a), A2), A2'), A4), A6), A6'), A8), B1.3), C2), C4), C6), C8), D1.3), E2), E4) and E6).

[0564] Building blocks 2*, 5*, 8*, 11*, 19*, 20* and 21* are glycosylation agents. As used herein, the term glycosylation agent refers to a monosaccharide functionalized with a leaving group at the anomeric position, which, after activation with a suitable activator, provides an oxocarbonium intermediate capable of reacting with a nucleophile (e.g., a hydroxyl group). Thus, glycosylation agents 2*, 5*, 8*, 11*, 19*, 20* and 21* have a leaving group LG at the anomeric position. 1 ,LG 2 ,LG 3 ,LG 4 ,LG 5 ,LG 6 and LG 7 Examples of leaving groups suitable for use in the synthesis of the present invention are well known to those skilled in the art of carbohydrate chemistry and include halides, thioethers, imidates, acetates, and phosphates.

[0565] Preferably, the leaving group LG 1 ,LG 2 ,LG 3 ,LG 4 ,LG 5 ,LG 6 and LG 7 Selected from halogen (-Cl, -Br, -F, -I), -OC(=NH)-CCl3, -OC(=NPh)-CF3, -OAc, -SR L ,-SO-R L ,-SO-Ph,-SO-CH2-Ph,-SO-Tol,-SO-C6H4-(para-OCH3),-O-(CH2)3-CH=CH2,-OP(OR L )2,-O-PO(OR L )2,-O-CO-OR L ,-O-CO-SR L ,-O-CS-SR L , -O-CS-OR L , where R L It may be any alkyl or aryl group, preferably methyl, ethyl, propyl, isopropyl, phenyl or tolyl.

[0566] Preferably, the leaving group LG 1 ,LG 2 ,LG 3 ,LG 4 ,LG 5 ,LG 6 and LG 7 Select from the leaving group consisting of: SBox, STaz,

[0567]

[0568] The thioethers may also be substituted.

[0569] As described above, the provision of the oxocarbonium intermediate relies on activating the leaving group installed at the anomeric position of the glycosylating agent with a suitable or appropriate activator. It is well known to those skilled in the art that suitable activators for phosphates (i.e., phosphate activators) and imidates (i.e., imidate activators) are Lewis acids, such as silyl trifluoromethanesulfonate or silver trifluoromethanesulfonate, while suitable activators for thioethers (i.e., thioether activators) include, but are not limited to: NIS / TfOH, NIS / TMSOTf, NIS / BF3 . Et2O, NIS / AgOTf, DMTST / Tf2O, IDPC, BSP / Tf2O, Ph2SO / Tf2O. Examples of silyl trifluoromethanesulfonates include, but are not limited to, trimethylsilyl trifluoromethanesulfonate, tert-butyldimethyl trifluoromethanesulfonate, triisopropyl trifluoromethanesulfonate.

[0570] Preferably, LG 1 ,LG 2 ,LG 3 ,LG 4 ,LG 5 ,LG 6 and LG 7 is a thioether, and even more preferably when LG 1 ,LG 2 ,LG 3 ,LG 4 ,LG 5 ,LG 6 and LG 7 When selected from:

[0571]

[0572] Preferably, the coupling reaction between the sugars in steps A1a), A2), A2'), A4), A6), A6'), A8), B1.3), C2), C4), C6), C8), D1.3), E2), E4) and E6) is carried out by activation with NIS / TfOH or TMSOTf in a mixture of a non-polar solvent and a polar aprotic solvent at a temperature between -10°C and 10°C. Even more preferably, it is carried out in a mixture of a non-polar solvent and a polar aprotic solvent by treatment with NIS / TfOH at a temperature of about 0°C.

[0573] Preferred polar aprotic solvents are tetrahydrofuran, diethyl ether and dioxane. Preferred nonpolar solvents are toluene, halogenated solvents such as chloroform and dichloromethane. Preferred mixtures of nonpolar and polar aprotic solvents are: dichloromethane / tetrahydrofuran, dichloromethane / diethyl ether, toluene / diethyl ether, toluene / tetrahydrofuran.

[0574] The protecting group P carried out in steps A11), B4), C11), D4), E10) and F5) 1 ,P 3 ,P 4 ,P 6 -P 12 ,P 14 ,P 16 -P 20 ,P 22 -P 24 ,P 26 and P 27 The removal involves:

[0575] - first cleavage of a base-labile protecting group by treatment with a base in the presence of hydrogen peroxide in a solvent mixture. Preferably, the base is NaOMe or LiOH; and

[0576] - A second cleavage of the hydrogenation-sensitive protecting group is carried out by subjecting the compound to the action of hydrogen in the presence of a palladium catalyst in a solvent mixture.

[0577] The phosphorylating agent used in steps A9), B2), C9), D2), E9) and F2.1) is a compound capable of introducing a group P(O)(OH)2 into a reactive position in a compound in its free form or in the form of a monoester. Thus, in steps A9), B2), C9), D2), E9) and F2.1), the phosphate group is transferred to the hydroxyl group. Preferred phosphorylating agents for use in the present invention are diphenyl phosphite, bis(diisopropylamino)benzyloxyphosphine, benzyl N,N-diisopropyl-phosphonamidoester or N,N-diethyl-1,5-dihydro-3H-2,3,4-benzodioxophosphin-3-amine in combination with an activator such as 1H-tetrazole, followed by oxidation with an oxidant such as hydrogen peroxide or 3-chloroperbenzoic acid. In a preferred embodiment, in steps A9), B2), C9), D2), E9) and F2.1), the phosphorylating agent is a combination of bis(diisopropylamino)benzyloxyphosphine with 1H-tetrazole and 3-chloroperbenzoic acid. In a preferred embodiment, in steps A9), B2), C9), D2), E9) and F2.1), the phosphorylating agent is diphenyl phosphite.

[0578] The phosphorylating agent used in step A1 b) is preferably bis(diisopropylamino)-benzyloxyphosphine, benzyl N,N-diisopropylphosphonamidate or N,N-diethyl-1,5-dihydro-3H-2,3,4-benzodioxophosphine-3-amine. The preferred activating agent used in step A1 b) is 1H-tetrazole, 4,5-dicyanoimidazole, 2-benzylthiotetrazole, 5-ethylthiotetrazole, benzimidazole trifluoromethanesulfonate or imidazole trifluoromethanesulfonate. 1H-tetrazole is most preferred as the activating agent. The oxidation reaction is preferably carried out in the presence of an oxidizing agent such as hydrogen peroxide or 3-chloroperbenzoic acid.

[0579] Another aspect of the present invention relates to an intermediate compound for preparing a sugar of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b), wherein the intermediate compound has the general formula (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4g), (I4h), (I4i), (I4j), (I5a), (I5b) ,(I5c),(I5d),(I5e),(I5f),(I5g),(I5h),(I5i),(I5j),(I6a),(I6b),(I6c),(I6d),(I6e),(I6f),(I6g),(I6h),(I7a),(I7b),(I7c),(I7d),(I7e),(I7f),(I7g),(I7h),(I7i),(I7j),(I7k),(I7m),(I7n),(I7o),or(I7p):

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587] Where C stands for -LE p , wherein Ep is a solid support or a protected end group E,

[0588] P 1 ,P 2 ,P 3 ,P 4 ,P 5 ,P 6 ,P 7 ,P 8 ,P 9 ,P 10 ,P 11 ,P 12 ,P 13 ,P 14 ,P 15 ,P 16 ,P 17 ,P 18 ,P 19 ,P 20 ,P 21 ,

[0589] P 22 ,P 23 ,P 24 and P 25 represents a protecting group, Np represents a protected amino group, LG represents a leaving group and E and L have the same meanings as defined above.

[0590] More preferred are intermediate compounds of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b), wherein the intermediate compound has the general formula (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4g), (I4h), (I4i), (I4j), (I5a), (I5b), (I5c), Any one of (I5d),(I5e),(I5f),(I5g),(I5h),(I5i),(I5j),(I6a),(I6b),(I6c),(I6d),(I6e),(I6f),(I6g),(I6h),(I7a),(I7b),(I7c),(I7d),(I7e),(I7f),(I7g),(I7h),(I7i),(I7j),(I7k),(I7m),(I7n),(I7o) or (I7p).

[0591] In the formula (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4 g),(I4h),(I4i),(I4j),(I5a),(I5b),(I5c),(I5d),(I5e),(I5f),(I5g),(I5h),(I5i),(I In (I5j), (I6a), (I6b), (I6c), (I6d), (I6e), (I6f), (I6g), (I6h), (I7a), (I7b), (I7c), (I7d), (I7e), (I7f), (I7g), (I7h), (I7i), (I7j), (I7k), (I7m), (I7n), (I7o) or (I7p), preferably the linker -L- represents -L a –,–L a –L e –,–L a –L b –L e –, or –L a –L d –L e –

[0592] -L a - means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O) o -CH2;

[0593] -L b - means -O-;

[0594] -L d - means -(CH2) q -,-(CH(OH)) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0595] -L e - means -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0596] -CH2-(O-CH2-CH2) p1 -or-(CH2) p1-O-(CH2) p2 -;as well as

[0597] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0598] Particularly preferred intermediates are those of formula (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4g), (I4h), (I4i), (I4j), (I5a), (I5b), (I5c), (I5d), (I5e), (I5f), (I5g), (I5h), (I5i), (I5j), (I6a), (I6b), (I6c), (I6d), (I6e), (I6f), (I6g), (I6h), (I7a), (I7b), (I7c), (I7d), (I7e), (I7f), (I7g), (I7h), (I7i), (I7j), (I7k), (I7m), (I7n), (I7o) or (I7p) intermediates, wherein -L- represents -(CH2) o - and o is an integer selected from 2, 5 and 6.

[0599] P 1 ,P 2 ,P 3 ,P 4 ,P 5 ,P 6 ,P 7 ,P 8 ,P 9 ,P 10 ,P 11 ,P 12 ,P 13 ,P 14 ,P 15 ,P 16 ,P 17 ,P 18 ,P 19 ,P 20 ,P 21 ,P 22 ,P 23 ,P 24 and P 25The preferred hydroxy protecting groups are acetyl, phenyl, benzyl, isopropylidene, benzylidene, benzoyl, p-methoxybenzyl, p-methoxybenzylidene, p-methoxyphenyl, p-bromobenzylidene, p-nitrophenyl, allyl, acetyl, isopropyl, p-bromobenzyl, dimethoxytrityl, trityl, 2-naphthylmethyl, pivaloyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tert-butylmethoxyphenylsilyl, triethylsilyl, trimethylsilyl, 2-trimethylsilylethoxymethyl, 9-fluorenylmethoxycarbonyl, benzyloxymethyl, methoxymethyl, tert-butylmethyl, methoxyethoxymethyl, levulinyl.

[0600] Therefore, when the protecting group P 3 ,P 4 ,P 8 -P 12 ,P 14 ,P 16 -P 20 and P 22 -P 24 is benzyl or acetyl, the protecting group P 1 is benzoyl, protecting group P 7 and P 18 is acetyl, protecting group P 26 is benzyl and the protecting group P 27 When it is benzyloxycarbonyl (Cbz), the intermediates (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4g), (I4h), (I4i), (I4j), (I5a), (I5b), (I5c), (I5d), (I5e), (I5f), (I5g), (I5h ), (I5i), (I5j), (I6a), (I6b), (I6c), (I6d), (I6e), (I6f), (I6g), (I6h), (I7a), (I7b), (I7c), (I7d), (I7e), (I7f), (I7g), (I7h), (I7i), (I7j), (I7k), (I7m), (I7n), (I7o) or (I7p) are particularly preferred. Preferably, the protecting group P 21 is p-bromobenzyl or tert-butyldiphenylsilyl (TBDPS). Preferably, the protecting group P 25 It is a 2-naphthylmethyl group.

[0601] Preferably, Np is selected from -N3, -NH-CO-CCl3 and -NH-CO-O-CH2-CCl3 (Troc). Therefore, when Np is selected from -N3, -NH-CO-CCl3 and -NH-CO-O-CH2-CCl3 (Troc), intermediates (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4g), (I4h), (I4i), (I4j), (I5a), (I5b), (I5c), (I5d), (I5 e), (I5f), (I5g), (I5h), (I5i), (I5j), (I6a), (I6b), (I6c), (I6d), (I6e), (I6f), (I6g), (I6h), (I7a), (I7b), (I7c), (I7d), (I7e), (I7f), (I7g), (I7h), (I7i), (I7j), (I7k), (I7m), (I7n), (I7o) or (I7p) are preferred. When Np represents -NH-CO-O-CH2-CCl3(Troc), particularly preferred are the intermediates (I2a), (I2b), (I2c), (I2d), (I2e), (I2f), (I4a), (I4b), (I4c), (I4d), (I4e), (I4f), (I4g), (I4h), (I4i), (I4j), (I5a), (I5b), (I5c), (I5d), (I5e), (I5f), (I5g), (I5h), (I5i), (I5 ... (I5f), (I5g), (I5h), (I5i), (I5j), (I6a), (I6b), (I6c), (I6d), (I6e), (I6f), (I6g), (I6h), (I7a), (I7b), (I7c), (I7d), (I7e), (I7f), (I7g), (I7h), (I7i), (I7j), (I7k), (I7m), (I7n), (I7o) or (I7p).

[0602] Glycoconjugates

[0603] Another aspect of the invention relates to a conjugate comprising a saccharide of formula (I) covalently bound or covalently linked to an immunogenic carrier via the terminal group E of the -OLE group. In other words, another aspect of the invention relates to a saccharide of any of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) coupled to an immunogenic carrier via the terminal group E of the -OLE group. A conjugate comprising a saccharide of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) covalently bound or covalently linked to an immunogenic carrier via the terminal group E of the -OLE group is also defined as a conjugate obtained by reacting a saccharide of any of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) with an immunogenic carrier. Surprisingly, the conjugate was shown to be an effective vaccine for immunization against diseases associated with Clostridium difficile.

[0604] Sugars are known to those skilled in the art as general TI-2 (T cell independent-2) antigens and poor immunogens. TI-2 antigens are antigens that are recognized only by mature B cells through cross-linking of surface exposed immunoglobulin receptors. Without the help of T cells, no immunological memory is generated, no isotype switching from IgM to other IgG subclasses occurs, and no B cell affinity maturation occurs. In addition, sugars are poor immunogens in humans due to their structural homology with human glycolipids and glycoproteins. Due to their poor immunogenicity, sugars exhibit poor ability in both antibody production by B cells and in the formation of memory cells, which are essential features for the production of effective vaccines.

[0605] Thus, in order to produce an effective saccharide-based vaccine, a saccharide of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) is conjugated to an immunogenic carrier to provide a conjugate that exhibits enhanced immunogenicity compared to the saccharide. Thus, within the scope of the present application, conjugates comprising a saccharide fragment covalently linked to an immunogenic carrier via an O atom are also contemplated:

[0606]

[0607] wherein n, Z and T* have the meanings defined herein.

[0608] The conjugate comprises at least one synthetic sugar of formula (I) and an immunogenic carrier covalently bound to the at least one sugar (I).

[0609] Surprisingly, it was found that immunization with a conjugate comprising a saccharide of formula (I) covalently linked to an immunogenic carrier resulted in the production of high titers of antibodies specific for the carbohydrate portion of the saccharide of formula (I). The antibodies cross-reacted with native Clostridium difficile PS-II cell wall saccharides and exhibited opsonophagocytic and bactericidal activity, thereby conferring protection against Clostridium difficile bacteria.

[0610] As used herein, the term "immunogenic carrier" is defined as a structure that is conjugated to a saccharide to form a conjugate that exhibits enhanced immunogenicity compared to the saccharide itself. Thus, the conjugation of a saccharide of formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) to an immunogenic carrier actually stimulates an immune response against the saccharide of formula (I) without inducing an immune response against the immunogenic carrier.

[0611] Preferred immunogenic carriers are carrier proteins (CP) or glycosphingolipids with immunomodulatory properties. For those skilled in the art, carrier proteins (CP) are proteins that are non-toxic and non-reactogenic and that can be obtained in sufficient quantity and purity. The carrier protein is selected from the group consisting of: diphtheria toxoid, such as CRM 197 , mutated diphtheria toxoid, modified diphtheria toxoid, mutated and modified diphtheria toxoid, tetanus toxoid, modified tetanus toxoid, mutated tetanus toxoid, non-lipid cell surface lipoprotein (protein D) of non-typeable Haemophilus influenzae, outer membrane protein (OMP) complex of Neisseria meningitidis, bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH) or cholera toxoid (CT). As used herein, the term "toxoid" refers to a bacterial toxin (usually an exotoxin) whose toxicity has been inactivated or inhibited by chemical (formalin) or heat treatment, while other properties (usually immunogenicity) are maintained. As used herein, a mutated toxoid is a recombinant bacterial toxin that has been modified to be less toxic or even non-toxic by modifying the wild-type amino acid sequence. This mutation can be a substitution of one or more amino acids. This mutated toxoid presents on its surface a functional group that can react with the functional group Y of the interconnected molecule to provide a modified toxoid. Such functional groups are known to those skilled in the art and include, but are not limited to, primary amino functional groups of lysine residues, which can react with activated esters, isocyanate groups or aldehydes in the presence of reducing agents to form carboxylate functional groups of glutamic acid or aspartic acid residues which can be activated by carbodiimide, or to form thiols of cysteine ​​residues.

[0612] Activated esters include N-(γ-maleimidobutyryloxy)sulfosuccinimide ester (Sulfo-GMBS), succinimidyl (4-iodoacetyl) aminobenzoate (Sulfo-SIAB), succinimidyl-3-(bromoacetamido) propionate (SBAP), disuccinimidyl glutaramide (DSG), disuccinimidyl adipate (DSA), 2-pyridyldithiol-tetraoxatetradecane-N-hydroxysuccinimide (PEG-4-SPDP) (see Figure 2 ).

[0613] The cysteine ​​residues on the carrier protein can be converted to the corresponding dehydroalanine, which can be further reacted with a suitable interconnecting molecule to provide a modified carrier protein having a functional group X of the interconnecting molecule on its surface.

[0614] It is particularly preferred to combine the sugar of formula I with a non-toxic mutant diphtheria toxin CRM 197 Conjugated, the mutant diphtheria toxin CRM 197 The primary amine functional group of a lysine residue was used as the functional group.

[0615] Like wild-type diphtheria toxin, CRM 197 It is a single polypeptide chain of 535 amino acids (58 kD) consisting of two subunits linked by a disulfide bond that replaces a single amino acid, glutamic acid, with glycine. It is used as a carrier protein in many approved vaccines against diseases such as Prevnar.

[0616] Therefore, in a preferred embodiment of the present invention, the carrier protein presents on its surface a primary amino functional group of a lysine residue, which is capable of reacting with the functional group Y of the interconnecting molecule to provide a modified carrier protein having on its surface said functional group X of the interconnecting molecule, which is capable of reacting with the terminal amino group of the linker of the compound of general formula (I).

[0617] The functional group X of the interconnecting molecule is selected from the group comprising or consisting of: maleimide; α-iodoacetyl; α-bromoacetyl; and N-hydroxy-succinimide ester (NHS), aldehyde, imido ester, carboxylic acid, alkyl sulfonate, sulfonyl chloride, epoxide, anhydride, carbonate (see Figure 3 ).

[0618] Preferably, the sugar of formula I is conjugated to a non-toxic mutant diphtheria toxin CRM modified with maleimide 197 In another preferred embodiment, the sugar of Formula I is conjugated to a non-toxic mutant diphtheria toxin CRM modified with α-bromoacetamide.197 In the most preferred embodiment, the sugar of Formula I is conjugated to a non-toxic mutant diphtheria toxin CRM modified with N-hydroxysuccinimidyl adipate. 197 .

[0619] Preferred are conjugates of formula (IV),

[0620]

[0621] in,

[0622] c is between 2 and 18;

[0623] -E1- represents covalent bond -NH-, -O-NH-, -O-, -S-, -CO-,

[0624] -CH=CH-,-CONH-,-CO-NHNH-,

[0625]

[0626] -W-Selected from:

[0627] as well as

[0628]

[0629] a represents an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10,

[0630] b represents an integer selected from 1, 2, 3 and 4,

[0631] CP is a carrier protein; and

[0632] n, L, Z and T* have the meanings as defined herein.

[0633] Preferably, E1 is a covalent bond -NH-, -CH=CH-, -CONH-,

[0634]

[0635] Preferably, CP is CRM 197 Therefore, in one embodiment of the present invention, the conjugate has the general formula (IV), wherein CP is CRM 197 , and c, -E1-, W, n, L, Z and T* have the meanings as defined herein.

[0636] Preferably, in the general formula (IV), the linker -L- is selected from: -L a -,-L a -L e -,-L a-L b -L e -, and -L a -L d -L e -;

[0637] -L a -Selected from: -(CH2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2;

[0638] -L b - means -O-;

[0639] -L d -Selected from: -(CH2) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, and

[0640] -(CH2-CH2-O) q -CH2-;

[0641] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0642] -CH2-(O-CH2-CH2) p1 - and -(CH2) p1 -O-(CH2) p2 -;

[0643] and o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0644] Furthermore, the conjugates of the general formula (IV) are preferred, wherein -W- represents And a is an integer selected from 2, 3, 4, 5 and 6.

[0645] Particularly preferred are conjugates of formula (IV) wherein

[0646] Linker -L- is selected from: -L a -,-L a -L e -,-L a -L b -L e -, and -L a -L d-L e -;

[0647] -L a -Selected from: -(CH2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2;

[0648] -L b - means -O-;

[0649] -L d -Selected from: -(CH2) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, and

[0650] -(CH2-CH2-O) q -CH2-;

[0651] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0652] -CH2-(O-CH2-CH2) p1 - and -(CH2) p1 -O-(CH2) p2 -;

[0653] o, q, p1 and p2 are independently an integer selected from 1, 2, 3, 4, 5 and 6;

[0654] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0655] Even more preferred are conjugates of formula (IV) wherein:

[0656] n is selected from 1, 2 or 3;

[0657] Linker -L- is selected from: -L a -,-L a -L e -,-L a -L b -L e -, and -L a -L d -L e -;

[0658] -La -Selected from: -(CH2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2;

[0659] -L b - means -O-;

[0660] -L d -Selected from: -(CH2) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, and

[0661] -(CH2-CH2-O) q -CH2-;

[0662] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0663] -CH2-(O-CH2-CH2) p1 - and -(CH2) p1 -O-(CH2) p2 -;

[0664] o, q, p1 and p2 are independently an integer selected from 1, 2, 3, 4, 5 and 6;

[0665] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0666] Particularly preferred are conjugates of general formula (IV) wherein the linker -L- represents -(CH2) o -, o is an integer selected from 2, 3, 4, 5 and 6;

[0667] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0668] Particularly preferred are conjugates of the general formula (IV), wherein n represents an integer of 1, 2 or 3;

[0669] Connector-L-denotes-(CH2) o -,

[0670] o is an integer selected from 2, 3, 4, 5 and 6;

[0671] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0672] Particularly preferred are conjugates of the general formula (IV), wherein n represents an integer of 1, 2 or 3;

[0673] Connector-L-denotes-(CH2) o -,

[0674] o is an integer selected from 2, 3, 4, 5 and 6;

[0675] -W- means and a is an integer selected from 2, 3, 4, 5 and 6;

[0676] And Z represents Preferably, c is between 2 and 18, more preferably between 5 and 15, even more preferably between 8 and 12. Also preferably, n represents 1.

[0677] More preferred are conjugates of any one of formulae (IV-1) to (IV-4):

[0678]

[0679]

[0680] wherein L, E1, W, c, CP and n have the same meanings as defined above.

[0681] Particularly preferred are conjugates of formula (IV-2) wherein L is -(CH2)5-, E1 is -NH-, n is an integer selected from 1 or 2, and c and W have the same meanings as defined above.

[0682] Also preferred are conjugates of the general formula (V),

[0683]

[0684] in,

[0685] c is between 2 and 18;

[0686] -E1- represents covalent bond -NH-, -O-NH-, -O-, -S-, -CO-,

[0687] -CH=CH-,-CONH-,-CO-NHNH-,

[0688]

[0689] -W-Selected from:

[0690] as well as

[0691] a represents an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10,

[0692] b represents an integer selected from 1, 2, 3 and 4; and

[0693] n, L, Z and T* have the meanings as defined herein.

[0694] Conjugates of general formula (V) are particularly preferred, wherein:

[0695] Linker -L- is selected from: -L a -,-L a -L e -,-L a -L b -L e -, and -L a -L d -L e -;

[0696] -L a -Selected from: -(CH2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2;

[0697] -L b - means -O-;

[0698] -L d -Selected from: -(CH2) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, and

[0699] -(CH2-CH2-O) q -CH2-;

[0700] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0701] -CH2-(O-CH2-CH2) p1 - and -(CH2) p1 -O-(CH2) p2 -;

[0702] o, q, p1 and p2 are independently an integer selected from 1, 2, 3, 4, 5 and 6;

[0703] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0704] Even more preferred are conjugates of formula (V) wherein:

[0705] n is selected from 1, 2 or 3;

[0706] Linker -L- is selected from: -L a -,-L a -L e -,-L a -L b -L e -, and -L a -L d -L e -;

[0707] -L a -Selected from: -(CH2) o -,-(CH2-CH2-O) o -C2H4-,-(CH2-CH2-O) o -CH2;

[0708] -L b - means -O-;

[0709] -L d -Selected from: -(CH2) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, and

[0710] -(CH2-CH2-O) q -CH2-;

[0711] -L e -Selected from: -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0712] -CH2-(O-CH2-CH2) p1 - and -(CH2) p1 -O-(CH2) p2 -;

[0713] o, q, p1 and p2 are independently an integer selected from 1, 2, 3, 4, 5 and 6;

[0714] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0715] Particularly preferred are conjugates of general formula (V) wherein the linker -L- represents -(CH2) o -, o is an integer selected from 2, 3, 4, 5 and 6;

[0716] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0717] Particularly preferred are conjugates of the general formula (V), in which n represents an integer from 1, 2 or 3;

[0718] Connector-L-denotes-(CH2) o -,

[0719] o is an integer selected from 2, 3, 4, 5 and 6;

[0720] -W- means And a is an integer selected from 2, 3, 4, 5 and 6.

[0721] Particularly preferred are conjugates of the general formula (V) wherein n represents an integer from 1, 2 or 3; the linker -L- represents -(CH2) o -,

[0722] o is an integer selected from 2, 3, 4, 5 and 6;

[0723] -W- means and a is an integer selected from 2, 3, 4, 5 and 6:

[0724] And Z represents Particularly preferred are conjugates of the general formula (V), in which n represents an integer from 1, 2 or 3;

[0725] Connector-L-denotes-(CH2) o -,

[0726] o is an integer selected from 2, 3, 4, 5 and 6;

[0727] -W- means and a is an integer selected from 2, 3, 4, 5 and 6:

[0728] and T* represents a phosphate group.

[0729] Also preferred are conjugates of formula (IV) wherein the group -OLE is selected from the following:

[0730]

[0731]

[0732]

[0733]

[0734]

[0735] More preferred are conjugates of any one of formulae (V-1) to (V-4):

[0736]

[0737]

[0738] wherein L, E1, W, c and n have the same meanings as defined above.

[0739] More preferred are conjugates of any of formulae (IV), (IV-1)-(IV-4), (V) and (V-1)-(V-4), wherein n is an integer from 1 to 3.

[0740] More preferred are conjugates of any of formulae (IV), (IV-1)-(IV-4), (V) and (V-1)-(V-4), wherein c is selected from 4 to 10.

[0741] Preferably -W- represents

[0742] And a is an integer selected from 2, 3, 4, 5 and 6.

[0743] Therefore, conjugates of the general formula (IV), (IV-1)-(IV-4), (V) and (V-1)-(V-4) are particularly preferred, wherein -W- represents

[0744] And a is an integer selected from 2, 3, 4, 5 and 6.

[0745] Preferably, the linker -L- represents -L a –,–L a –L e –,–L a –L b –L e –, or –L a –L d –L e –;-L a - means -(CH2) o -,-(CH2-CH2-O) o -C2H4-, or -(CH2-CH2-O)o -CH2;

[0746] -L b - means -O-;

[0747] -L d - means -(CH2) q -,-(CH(OH)) q -,-(CF2) q -,-(CH2-CH2-O) q -C2H4-, or -(CH2-CH2-O) q -CH2-;

[0748] -L e - means -(CH2) p1 -,-(CF2) p1 -,-C2H4-(O-CH2-CH2) p1 -,

[0749] -CH2-(O-CH2-CH2) p1 -or-(CH2) p1 -O-(CH2) p2 -;as well as

[0750] o, q, p1 and p2 are independently integers selected from 1, 2, 3, 4, 5 and 6.

[0751] In the most preferred embodiment, E1 is a covalent bond -NH-, -CH=CH-, -CONH-,

[0752] Also preferred are conjugates of the general formulae (IV), (IV-1)-(IV-4), (V) and (V-1)-(V-4), wherein the group -OLE is selected from the following:

[0753]

[0754]

[0755]

[0756]

[0757]

[0758] In another embodiment, the immunogenic carrier is preferably a glycosphingolipid with immunomodulatory properties, more preferably (2S, 3S, 4R) -1- (α-D-galactopyranosyl) -2-hexosylaminooctadecyl-3, 4-diol. As used herein, the term glycosphingolipid with immunomodulatory properties refers to a suitable glycosphingolipid that can stimulate the immune system to respond to the target antigen but does not itself confer immunity as defined above.

[0759] As used herein, glycosphingolipids are compounds comprising a carbohydrate portion connected to sphingolipids α. Preferably, the carbohydrate portion is hexapyranose, most preferably α-D-galactopyranose. For those skilled in the art, sphingolipids are lipids containing a C18 amino alcohol connected to a fatty acid via an amide bond. The C18 amino alcohol is preferably substituted by a hydroxyl group, mono-, di- or poly-. Particularly preferably, the C18 amino alcohol is phytosphingosine. The fatty acid is preferably a monocarboxylic acid having a saturated alkyl chain ranging from 16 to 28, more preferably from 18 to 26. Glycosphingolipids with immunomodulatory properties include, but are not limited to (2S, 3S, 4R) -1- (α-D-galactopyranosyl) -2-hexosylaminooctadecyl-3,4-diol, which can stimulate the natural killer (NK) activity of natural killer T (NK) cells and the production of cytokines, and show strong (Proc. Natl Acad. Sci. USA, 1998, 95, 5690) in vivo.

[0760] The conjugate of the sugar of general formula I and the glycosphingolipid with immunomodulatory properties has the advantage of being thermally stable. In order to be suitable for conjugation, a functional group is introduced on the glycosphingolipid with immunomodulatory properties. The functional group is easy to react directly with the terminal amino group of the linker of the sugar of general formula I to provide the conjugate of the sugar of general formula I, or directly react with the functional group Y of the interconnecting molecule to provide a modified glycosphingolipid with immunomodulatory properties.

[0761] Preferably, the functional group is introduced into the C6 of the carbohydrate part of the glycosphingolipid with immunomodulatory properties. Therefore, the glycosphingolipid with immunomodulatory properties is functionalized with a functional group, which is easy to react with the terminal amino group of sugar or with the functional group Y of the interconnected molecule. The functional group that is easy to react with the amino group includes but is not limited to activated esters, isocyanate groups, aldehydes, epoxides, imidoesters, carboxylic acids, alkyl sulfonates and sulfonyl chlorides. The functional group of the glycosphingolipid that is easy to react with the functional group Y of the interconnected molecule to provide a modification of the functional group X of the interconnected molecule with immunomodulatory properties includes but is not limited to amines, alcohols, thiols, activated esters, isocyanate groups, aldehydes, epoxides, vinyls, imidoesters, carboxylic acids, alkyl sulfonates, sulfonyl chlorides, vinyls, alkynyls and azidos.

[0762] Preferably, the functional group introduced at C6 of the carbohydrate part of the glycosphingolipid with immunomodulatory properties is selected from the group including or comprising: amine, thiol, alcohol, carboxylic acid, vinyl, maleimide, α-iodoacetyl, α-bromoacetyl, N-hydroxysuccinimide ester (NHS), 2-pyridyldithiol.

[0763] The functional group X of the interconnecting molecule is selected from maleimide, α-iodoacetyl, α-bromoacetyl, N-hydroxy-succinimide ester (NHS), aldehyde, carboxylic acid, epoxide, alkyl sulfonate, sulfonyl chloride, anhydride, carbonate.

[0764] As used herein, the term "interconnecting molecule" refers to a bifunctional molecule comprising a functional group X and a functional group Y, wherein the functional group X is capable of reacting with the terminal amino group on the linker -L- and the functional group Y is capable of reacting with a functional group present on the immunogenic carrier or solid support.

[0765] Compared to vaccines containing isolated (not synthetic) mixtures of saccharides or conjugates thereof obtained by non-selective cleavage of C. difficile capsular polysaccharides, vaccines containing at least one conjugate of the invention cause fewer side effects and / or non-protective immune responses. In addition, compared to vaccines containing isolated mixtures of non-selectively cleaved capsular polysaccharides, the vaccines of the invention can be manufactured more easily according to GMP regulations and are easier to characterize, which makes stability and purity control and detection of impurity types and amounts easier.

[0766] It has been found that conjugates comprising a saccharide of any one of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b), in particular conjugates of any one of the general formula (IV), (IV-1)-(IV-4), (V) and (V-1)-(V-4) elicit a protective immune response in a human and / or animal host and are therefore useful for preventing and / or treating diseases associated with Clostridium difficile bacteria. Thus, conjugates comprising a saccharide of the general formula (I) conjugated to an immunogenic carrier are useful for preventing and / or treating diseases associated with Clostridium difficile bacteria, said bacteria containing one of the following saccharide fragments in their cell wall saccharides:

[0767] -6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1-;

[0768] -3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1;

[0769] -4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1;

[0770] -4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1;

[0771] -3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1.

[0772] Preferably, the bacterium containing one of the above-mentioned sugar fragments in its cell wall sugar is Clostridium difficile.

[0773] In a preferred embodiment, conjugates comprising a saccharide of formula I conjugated to an immunogenic carrier are useful for preventing and / or treating diseases associated with bacteria, in particular diseases associated with bacteria containing one of the following saccharide fragments in their cell wall polysaccharides: -6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1-; -3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-Gal NAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1;-4)-[β-D -Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)- α-D-Glc-(1;-3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3, and preferably a disease associated with Clostridium difficile, wherein the disease includes diarrhea, pseudomembranous colitis and paralytic ileus.

[0774] Pharmaceutical composition

[0775] Another aspect of the invention relates to a pharmaceutical composition or vaccine comprising at least one conjugate comprising a saccharide of formula (I) and / or a saccharide of formula (I) conjugated to an immunogenic carrier, and at least one pharmaceutically acceptable adjuvant and / or excipient. The pharmaceutical composition can be used to elicit a protective immune response in a human and / or animal host. Ideally, the pharmaceutical composition is suitable for use in humans.

[0776] In another aspect of the present invention, the pharmaceutical composition or vaccine further comprises at least one cell pore sugar or cell wall sugar fragment and / or a protein conjugate thereof of Clostridium difficile bacteria selected from the group comprising or consisting of Clostridium difficile strains 027, MOH718 and MOH900.

[0777] As used herein, the term "adjuvant" refers to an immunological adjuvant, i.e., a material used in a vaccine composition that modifies or enhances the effect of a given antigen contained in the vaccine by enhancing the immune response to the antigen without antigenic association therewith. For those skilled in the art, classically recognized examples of immunological adjuvants include, but are not limited to, oil emulsions (e.g., Freund's adjuvant), saponins, aluminum or calcium salts (e.g., alum), nonionic block polymer surfactants, and many others.

[0778] Pharmaceutical compositions are preferably in aqueous form, particularly for administration, but they may also be in non-aqueous liquid form or in dry form, such as gelatin capsules or lyophilized powders.

[0779] The pharmaceutical composition may contain one or more preservatives, such as thimerosal or 2-phenoxyethanol. Mercury-free compositions are preferred, and preservative-free vaccines may be prepared.

[0780] The pharmaceutical composition may contain physiological salts (e.g., sodium salts) to control tonicity. Sodium chloride (NaCl) is typical and may be present in an amount between 1 and 20 mg / ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, dehydrated sodium phosphate, magnesium chloride, calcium chloride, and the like.

[0781] The pharmaceutical composition may have an osmolality between 200 mOsm / kg and 400 mOsm / kg.

[0782] The pharmaceutical composition may include the compound (with or without an insoluble metal salt) in white water (e.g., wfi), but will typically include one or more buffers. Typical buffers include: phosphate buffer; Tris buffer; borate buffer; succinate buffer; histidine buffer (particularly with aluminum hydroxide adjuvant); or citrate buffer. Buffer salts are typically included in the range of 5-20 mM.

[0783] The pharmaceutical composition typically has a pH between 5.0 and 9.5 (eg, between 6.0 and 8.0).

[0784] The pharmaceutical compositions are preferably sterile and gluten-free.

[0785] The pharmaceutical compositions are suitable for administration to animal (especially human) patients and thus include both human and veterinary uses. They may be used in a method of eliciting an immune response in a patient comprising the step of administering the composition to the patient.

[0786] The pharmaceutical compositions of the present invention may be administered prior to exposure of a subject to C. difficile and / or after exposure of a subject to C. difficile bacteria.

[0787] In another aspect of the present invention, the present invention relates to the use of at least one saccharide of general formula (I) and / or at least one conjugate of at least one saccharide of general formula (I) conjugated to an immunogenic carrier for the manufacture of said pharmaceutical composition or said vaccine for the prevention and / or treatment of diseases associated with C. difficile bacteria, in particular, diseases associated with C. difficile bacteria are selected from the group comprising or consisting of: diarrhea, pseudomembranous colitis and paralytic ileus.

[0788] Preferably, the present invention relates to the use of at least one sugar of any one of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) and / or at least one conjugate comprising at least one sugar of any one of the general formula (I), (II), (II-a), (II-b), (III), (III-a) or (III-b) for the manufacture of said pharmaceutical composition or said vaccine.

[0789] More preferably, the present invention relates to the use of at least one of the saccharides I'a-1-I'a-11, I'b-1-I'b-11 and I'c-1-I'c-11 for the manufacture of said pharmaceutical composition or vaccine and / or the use of at least one conjugate comprising at least one of the saccharides I'a-1-I'a-11, I'b-1-I'b-11 and I'c-1-I'c-11 for the manufacture of said pharmaceutical composition or vaccine.

[0790] In particular, the present invention relates to the use of at least one conjugate of any one of the general formulae (IV), (IV-1)-(IV-4), (V) and (V-1)-(V-4) for the manufacture of said pharmaceutical composition or said vaccine.

[0791] The pharmaceutical composition can be prepared in unit dosage form. In some embodiments, the unit dosage has a volume between 0.1-1.0 mL (eg, about 0.5 mL).

[0792] The present invention also provides a delivery device (eg, a syringe, atomizer, spray, inhaler, skin patch, etc.) comprising a pharmaceutical composition of the present invention (eg, comprising a unit dose). The device can be used to administer the composition to a vertebrate subject.

[0793] The invention also provides a sterile container (eg, a vial) comprising a pharmaceutical composition of the invention (eg, comprising a unit dose).

[0794] The present invention also provides a unit dosage of the pharmaceutical composition of the present invention.

[0795] The present invention also provides a hermetically sealed container comprising the pharmaceutical composition of the present invention. Suitable containers include, for example, vials.

[0796] The pharmaceutical composition of the present invention can be prepared in various forms. For example, the composition can be prepared as an injection, as a liquid solution or as a suspension. Solid forms suitable for dissolving or suspending in a liquid vehicle before injection (e.g., a lyophilized composition or a spray-freeze-dried composition) can also be prepared. The composition can be prepared for topical administration, for example, as an ointment, cream, or powder. The composition can be prepared for oral administration, for example, as a tablet or capsule, as a spray, or as a syrup (optionally flavored). The composition can be prepared for pulmonary administration, for example, by an inhaler, using a fine powder or a spray. The composition can be prepared as a suppository. The composition can be prepared for administration to the nose, ear, or eye, for example, as a spray or drops. Injections for intramuscular administration are typical.

[0797] The pharmaceutical composition may comprise an effective amount of an adjuvant, ie, an amount effective to enhance the immune response to a co-administered C. difficile PS-II saccharide antigen when administered to an individual in a single dose or as part of a series.

[0798] This amount can vary depending on the health and physical condition of the individual to be treated, age, taxonomic group of the individual to be treated (e.g., non-human primates, primates, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection required, the formulation of the vaccine, the evaluation of the medical condition by the treating physician, and other relevant factors. This amount will fall within a relatively wide range that can be determined by routine experiments.

[0799] The formulation and administration of the vaccine of the present invention can be achieved according to any method known in the art.

[0800] A therapeutically effective dose of a conjugate according to the invention or a saccharide of formula (I) refers to the amount of the compound that results in at least partial immunity against the disease. The toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical, pharmacological and toxicological procedures in cell culture or experimental animals. The dose ratio between toxicity and therapeutic effect is the therapeutic index. The actual amount of the composition applied will depend on the subject being treated, the subject's weight, the severity of the disease, the mode of administration and the judgment of the prescribing physician.

[0801] Another aspect of the invention relates to a method for inducing an immune response against C. difficile in a human and / or animal host, the method comprising administering to the human and / or animal host a saccharide of formula (I) and / or its salt and / or its conjugate or a pharmaceutical composition thereof. The method for treating or preventing a disease caused by C. difficile in a human and / or animal host according to the invention comprises administering to the human and / or animal host at least one saccharide of formula (I) and / or its salt and / or its conjugate. Or a pharmaceutical composition thereof.

[0802] Immunological assays

[0803] Another aspect of the invention relates to a saccharide of general formula (I) for use as a marker in an immunological assay to detect antibodies directed against bacteria comprising in their cell wall polysaccharides one of the following saccharide fragments:

[0804] -6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,

[0805] 3)-α-D-Man-(1-;

[0806] -3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1;

[0807] -4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,

[0808] 4)-α-D-Glc-(1;

[0809] -4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1;

[0810] -3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,

[0811] 6)-β-D-Glc-(1.

[0812] Such assays include, for example, microarrays and ELISAs, which can be used to detect antibodies against bacteria that contain one of the above sugar fragments in their cell wall polysaccharides (eg, C. difficile).

[0813] The sugars of the present invention can be easily conjugated to a solid support to provide an immunological assay that can be used to detect antibodies against C. difficile. The solid support has functional groups on its surface that are susceptible to reacting with amino groups of sugars of formula (I) or with functional groups Y of interconnecting molecules to provide a modified solid support, thereby presenting functional groups X of interconnecting molecules on its surface that can further react with amino groups of sugars of formula (I). In one embodiment according to the present invention, the solid support is a microarray slide having functional groups on its surface that are susceptible to reacting with functional groups Y of interconnecting molecules to provide a modified microarray slide, thereby presenting functional groups X of interconnecting molecules on its surface. Examples of such microarray slides include, but are not limited to Epoxide coated glass slides or GAPS TM II coated slides.

[0814] In a preferred embodiment, the solid support is a microarray slide having functional groups on its surface that react readily with amino groups of a sugar of formula (I), more preferably with an ester activated by N-hydroxysuccinimide (NHS). Such a microarray slide is, for example, NHS slides. BRIEF DESCRIPTION OF THE DRAWINGS

[0815] Figure 1 The chemical structure of the repeating unit of the C. difficile PS-II cell wall sugar is shown.

[0816] Figure 2 Examples of functional groups X of interconnecting molecules according to the present invention are provided.

[0817] Figure 3 Examples of functional groups X of interconnecting molecules according to the present invention are provided.

[0818] Figure 4 The CRM of general formula (V-2) shown as a preferred compound of the present application 197 Conjugate.

[0819] Figure 5Two pathways are shown for cleavage of compound 33 by NaOH treatment. Pathway I shows cleavage at the phosphate group, where the phosphate group remains on the linker moiety, and compound LA, 5-aminopentyl dihydrogen phosphate, is formed. Pathway II shows cleavage on the phosphate group, where the phosphate group remains on the sugar moiety (compound 33B), and compound LB, 5-aminopentan-1-ol, is formed.

[0820] Figure 6 HPLC charts of the following compounds are shown from bottom to top: Compound 33 (standard), Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for four days, purified Compound 33B, Compound LB. Figure 6 As can be seen in Figure 3, compound 33 was completely stable under alkaline conditions for one day. After treatment with NaOH at room temperature for four days, 50% of compound 33 remained intact.

[0821] Figure 7 From bottom to top, the HPLC profiles of the following compounds are shown: Compound 33A (control), Compound 33 after treatment with 0.1 M sodium hydroxide solution at room temperature for one day and purification, Compound 33 (standard), Compound 33 after two months in water at 2°C-8°C, Compound 33 after two months in NaPi at 2°C-8°C [which is a synonym for PBS (phosphate buffered saline)], Compound 33 after two months in aluminum hydroxide gel and PBS at 2°C-8°C. Figure 7 As can be seen from the figure, compound 33 is completely stable at 2°C-8°C for two months.

[0822] Figure 8 From bottom to top, HPLC patterns of the following compounds are shown: Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 (standard), Compound 33 after two months in water at 25°C, Compound 33 after two months in NaPi at 25°C [which is a synonym for PBS (phosphate buffered saline)], and Compound 33 after two months in aluminum hydroxide gel and PBS at 25°C. Figure 8 As can be seen from the results, compound 33 is completely stable at 25 °C for two months.

[0823] Fig. 9From bottom to top, HPLC patterns of the following compounds are shown: Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 (standard), Compound 33 after two months in water at 37°C, Compound 33 after two months in NaPi at 37°C [which is a synonym for PBS (phosphate buffered saline)], and Compound 33 after two months in aluminum hydroxide gel and PBS at 37°C. Fig. 9 As can be seen from the results, compound 33 is completely stable at 37°C for two months.

[0824] Fig.10 From bottom to top, HPLC patterns of the following compounds are shown: Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 (control), Compound 92 (standard), Compound 92 after one week in water at 2-8°C, Compound 92 after one week in NaPi at 2-8°C [which is a synonym for PBS (phosphate buffered saline)], Compound 92 after one week in aluminum hydroxide gel and PBS at 2-8°C. Fig.10 As can be seen from the figure, compound 92 is completely stable at 2-8°C for one week.

[0825] Fig.11 From bottom to top, HPLC profiles of the following compounds are shown: Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 (control), Compound 92 (standard), Compound 92 after one week in water at 25°C, Compound 92 after one week in NaPi at 25°C [which is a synonym for PBS (phosphate buffered saline)], Compound 92 after one week in aluminum hydroxide gel and PBS at 25°C. Fig.11 As can be seen from the results, compound 92 is completely stable at 25 °C for one week.

[0826] Fig.12 From bottom to top, HPLC profiles of the following compounds are shown: Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 (control), Compound 92 (standard), Compound 92 after one week in water at 37°C, Compound 92 after one week in NaPi at 37°C [which is a synonym for PBS (phosphate buffered saline)], Compound 92 after one week in aluminum hydroxide gel and PBS at 37°C. Fig.12 As can be seen from the results, compound 92 is completely stable at 37°C for one week.

[0827] Fig.13From bottom to top, HPLC charts of the following compounds are shown: Compound 33A (control), Compound 33 treated with 0.1 M sodium hydroxide solution at room temperature for one day and purified, Compound 33 (control), Compound 54 (standard), Compound 54 after one week in water at 25°C, Compound 54 after one week in water at 2-8°C, and Compound 54 after one week in water at 37°C. Fig.13 As can be seen from the results, compound 54 is completely stable at 37°C for one week.

[0828] Fig.14 The following compound HPLC patterns are shown from bottom to top: Compound 33A (control), Compound 54 (standard), Compound 54 after being contained in aluminum hydroxide gel at 25°C for one week, Compound 54 after being contained in aluminum hydroxide gel at 2-8°C for one week, and Compound 54 after being contained in aluminum hydroxide gel at 37°C for one week. Fig.14 As can be seen in the Figure 1, when formulated with aluminum hydroxide gel, compound 54 was mostly adsorbed on aluminum hydroxide and no conceivable cleavage products were formed that could be detected by HPLC in the presence of aluminum hydroxide. Therefore, compound 54 was stable at 37°C for one week.

[0829] Fig.15 Shown is the sugar 33-CRM from C. difficile 197 ELISA titers of pooled sera from rabbits (n=4) immunized with formulation (36) on day 0, day 7, and day 42. Sera obtained from rabbits immunized with compound 36 were diluted 1:100, 1000 with 1% BSA-PBS. Diluted sera (100 μL) were added to each well of a microtiter plate coated with 0.5 μg of the corresponding 33-BSA conjugate (compound 37). Detection was performed using an HRP-conjugated goat anti-rabbit secondary antibody diluted to 1:10000 and developed using 3,3',5,5'-tetramethylbenzidine (TMB) as a substrate. The absorbance was measured at 450 nm and the data were plotted using GraphPad Prism software. On day 42, Fig.15 A clear immune response was observed.

[0830] Fig.16ELISA titers of rabbit antiserum against C.difficile strain 630 (pooled sera) are shown. As shown, rabbits (4 animals in each study group) were immunized subcutaneously four times (0th, 14th, 28th, 77th days) with 2.5 μg or 10 μg of polysaccharide antigen per injection with or without aluminum hydroxide (alum) adjuvant. PBS with alum was used as a negative control. The immunogen was conjugate 56. Pooled sera from different time points (0th, 7th, 21st, 35th, 77th and 84th days) were tested for total IgG of formalin-inactivated C.difficile bacteria (strain 630) coated on ELISA plates. The coated ELISA plates purchased from tgcBIOMICS GmbH were blocked for 2 hours with 200 μL of commercial blocking reagent (Roche, ref.11112589001) per well. The serum was diluted 1:100 with 1% (w / v) BSA in PBS and incubated for 1 hour in a volume of 100 μL per well. Total IgG was then detected using an HRP-conjugated goat anti-rabbit IgG secondary antibody (Sigma-Aldrich, ref. A4914) diluted to 1:10,000 in 1% (w / v) BSA in PBS for 30 min and developed using TMB substrate (Thermo Scientific, ref. 34028). The absorbance was measured at 450 nm in a microplate reader and the background-subtracted data were plotted using GraphPad Prism software. Fig.16 As can be seen, vaccination of rabbits with conjugate 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain 630. Furthermore, the addition of alum adjuvant resulted in higher overall IgG titers.

[0831] Fig.17ELISA titers of rabbit antisera against C.difficile strain 630 (individual sera) are shown. As shown, rabbits (4 animals in each study group) were immunized subcutaneously four times (0th, 14th, 28th, 77th days) with 2.5 μg or 10 μg of polysaccharide antigen per injection with or without aluminum hydroxide (alum) adjuvant. PBS with alum was used as a negative control. The immunogen was conjugate 56. Serum from different time points (0th, 7th, 35th, 77th and 84th days) was tested for total IgG of formalin-inactivated C.difficile bacteria (strain 630) coated on ELISA plates. The coated ELISA plates purchased from tgcBIOMICS GmbH were blocked for 2 hours with 200 μL of commercial blocking reagent (Roche, ref. 11112589001) per well. The serum was diluted 1:300 with 1% (w / v) BSA in PBS and incubated for 1 hour in a volume of 100 μL per well. Total IgG was then detected using an HRP-conjugated goat anti-rabbit IgG secondary antibody (Sigma-Aldrich, ref. A4914) diluted to 1:10,000 in 1% (w / v) BSA in PBS for 30 min and developed using TMB substrate (Thermo Scientific, ref. 34028). The absorbance was measured at 450 nm in a microplate reader and the background-subtracted data were plotted using GraphPad Prism software. Fig.17 As can be seen, vaccination of rabbits with conjugate 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain 630. Furthermore, the addition of alum adjuvant resulted in higher overall IgG titers.

[0832] Fig.18ELISA titers of rabbit antiserum against C. difficile strain R20291 are shown. Rabbits (4 animals per study group) were immunized subcutaneously four times (days 0, 14, 28, 77) with 2.5 μg or 10 μg of polysaccharide antigen per injection, as shown, with or without aluminum hydroxide (alum) adjuvant. PBS with alum was used as a negative control. The immunogen was conjugate 56. Sera from different time points (days 21, 35, 77, and 84) were tested for total IgG against formalin-inactivated C. difficile bacteria (strain R2029) coated on ELISA plates. Commercially available coated ELISA plates were blocked for 2 hours with 200 μL of commercial blocking reagent (Roche, ref. 11112589001) per well. The serum was diluted 1:100 with 1% (w / v) BSA in PBS and incubated for 1 hour in a volume of 100 μL per well. Total IgG was then detected using an HRP-conjugated goat anti-rabbit IgG secondary antibody (Sigma-Aldrich, ref. A4914) diluted to 1:10,000 in 1% (w / v) BSA in PBS for 30 min and developed using TMB substrate (Thermo Scientific, ref. 34028). The absorbance was measured at 450 nm in a microplate reader and the background-subtracted data were plotted using GraphPad Prism software. Fig.18 As can be seen in Figure 5, vaccination of rabbits with conjugate 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain R20291. In addition, the addition of alum adjuvant resulted in higher overall IgG titers.

[0833] Fig.19 Figure A shows ELISA titers of rabbit antisera (day 35) against C. difficile strain VPI10463. Rabbits (4 animals per study group) were immunized subcutaneously four times (days 0, 14, 28, 77) with 2.5 μg or 10 μg of glycan antigen per injection with or without aluminum hydroxide (alum) adjuvant as indicated. PBS with alum was used as a negative control. The immunogen was conjugate 56. Pooled sera from day 35 were tested for total IgG against formalin-inactivated C. difficile bacteria (strain VPI10463) coated on ELISA plates. Fig.19 As can be seen in Figure A, vaccination of rabbits with conjugate 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain VPI 10463. Furthermore, the addition of alum adjuvant resulted in higher overall IgG titers.

[0834] Fig.19Figure B shows ELISA titers of rabbit antisera (day 35) against C. difficile PS-II polysaccharide. Rabbits (4 animals per study group) were immunized subcutaneously four times (days 0, 14, 28, 77) with 2.5 μg or 10 μg of polysaccharide antigen per injection, as indicated, with or without aluminum hydroxide (alum) adjuvant. PBS with alum was used as a negative control. The immunogen was conjugate 56. Pooled sera from day 35 were tested for total IgG against isolated PS-II polysaccharide. Fig.19 As can be seen in Figure B, vaccination of rabbits with conjugate 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain VPI 10463. Furthermore, the addition of alum adjuvant resulted in higher overall IgG titers.

[0835] Fig.19 C in Figure 1 shows the ELISA titers of rabbit antisera (day 35) against C. difficile strain 630 with or without preincubation with isolated C. difficile PS-II polysaccharide. Rabbits (4 animals per study group) were immunized subcutaneously four times (days 0, 14, 28, 77) with 10 μg of polysaccharide antigen per injection in the presence of aluminum hydroxide (alum) adjuvant. Pooled sera from day 35 (diluted 1:100 in 1% (w / v) BSA in PBS) were incubated on ice for 30 min with 10 or 50 μg of isolated PS-II polysaccharide or with PBS. The sera were then incubated for 1 hour (100 μL / well) on commercially available coated ELISA plates (C. difficile strain 630) that had been previously blocked for 2 hours with 200 μL of commercial blocking reagent (Roche, ref. 11112589001) per well. Total IgG was then detected using an HRP-conjugated goat anti-rabbit IgG secondary antibody (Sigma-Aldrich, ref. A4914) diluted to 1:10,000 in 1% (w / v) BSA in PBS for 30 min and developed using TMB substrate (Thermo Scientific, ref. 34028). The absorbance was measured at 450 nm in a microplate reader and background-subtracted data were plotted using GraphPad Prism software. Fig.19 As can be seen in Figure C, PS-II polysaccharide can block the binding of rabbit antiserum to C. difficile bacteria in a dose-dependent manner, indicating that the antibacterial antibody response is specific to PS-II polysaccharide.

[0836] Fig. 20ELISA titers of rabbit antisera against C. difficile PS-II hexasaccharide 54 are shown. Rabbits (4 animals per study group) were immunized subcutaneously four times (days 0, 14, 28, 77) with 2.5 μg or 10 μg of glycan antigen per injection, as indicated, in the presence or absence of aluminum hydroxide (alum) adjuvant. PBS with alum was used as a negative control. The immunogen was conjugate 56. Pooled sera from different time points (days 0, 21, 35, 77, and 84) were tested for total IgG against the synthetic C. difficile PS-II hexasaccharide 54. Fig. 20 As can be seen in Figure 5, vaccination of rabbits with conjugate 56 induced IgG antibodies that bound to the synthetic immunogen 54. Furthermore, the addition of alum adjuvant resulted in higher overall IgG titers.

[0837] Fig.21 ELISA titers of rabbit antisera against C. difficile strain 630 are shown. Mice (7 or 8 animals per study group) were immunized subcutaneously twice (days 0, 14, 28) with conjugate 94 or conjugate 56 at a dose of 0.5 or 2 μg of glycan antigen per injection. PBS was used as a negative control, and aluminum hydroxide (alum) adjuvant was used for all immunizations. Pooled sera from days 21 and 35 were tested for total IgG against formalin-inactivated C. difficile bacteria (strain 630) coated on ELISA plates. Fig.21 As can be seen, vaccination of mice with conjugates 94 or 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain 630.

[0838] Fig. 22 ELISA titers of rabbit antisera against C. difficile strain R20291 are shown. Mice (7 or 8 animals per study group) were immunized subcutaneously twice (days 0, 14, 28) with conjugate 94 or 56 at a dose of 0.5 or 2 μg of glycan antigen per injection. PBS was used as a negative control, and aluminum hydroxide (alum) adjuvant was used for all immunizations. Pooled sera from days 21 and 35 were tested for total IgG against formalin-inactivated C. difficile bacteria (strain R20291) coated on ELISA plates. Fig. 22 As can be seen, vaccination of mice with conjugates 94 or 56 induced IgG antibodies that bound to the surface of C. difficile bacterial strain 630.

[0839] Fig.23ELISA titers of mouse antisera against synthetic C. difficile PS-II antigens are shown. Mice (7 or 8 animals per study group) were immunized subcutaneously twice (days 0, 14, 28) with conjugate 94 or conjugate 56 at a dose of 0.5 or 2 μg of glycan antigen per injection. PBS was used as a negative control, and aluminum hydroxide (alum) adjuvant was used for all immunizations. Pooled sera from days 21 and 35 were tested for total IgG against the corresponding synthetic C. difficile glycan antigens used for immunization. Fig.23 As can be seen, vaccination of mice with conjugates 94 or 56 induced IgG antibodies that bound to the synthetic immunogen. Furthermore, the addition of alum adjuvant resulted in higher overall IgG titers.

[0840] Fig.24 SEC chromatograms of two glycoconjugates 94 and 56 used in immunoassays are shown. Unconjugated CRM 197 Protein was used as a control.

[0841] Fig.25 Shown is an SDS-PAGE of C. difficile glycoconjugates 94 and 56 (2.5 μg per well) used for immunoassays separated on 10% polyacrylamide gels. 197 Protein was used as a control.

[0842] The following examples are included to illustrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors to function well in the practice of the present invention and therefore can be considered to constitute preferred modes of its practice. However, in light of this disclosure, it will be appreciated by those skilled in the art that many changes may be made to the specific embodiments disclosed without departing from the spirit and scope of the present invention and still obtaining similar or similar results.

[0843] In view of this description, further modifications and alternative embodiments of various aspects of the present invention will be apparent to those skilled in the art. Therefore, this description should be interpreted as illustrative only, and is to teach those skilled in the art to implement the general mode of the present invention. It should be understood that the form of the present invention shown and described herein will be regarded as an example of an embodiment. Elements and materials can replace those illustrated and described herein, parts and processes can be reversed, and certain features of the present invention can be utilized independently, all of which will be apparent to those skilled in the art after benefiting from this description of the present invention. Without departing from the spirit and scope of the present invention as described in the appended claims, the elements described herein may be changed. Example

[0844] A. Chemical synthesis

[0845] General information:

[0846] Unless otherwise stated, commercial grade solvents were used. Dry solvents were obtained from Waters Dry Solvent System. Solvents used for chromatography were distilled before use. Sensitive reactions were carried out in heat-dried glassware and under an argon atmosphere. Analytical thin layer chromatography (TLC) was performed on Kieselgel 60F254 glass plates pre-coated with 0.25 mm thick silica gel. By staining with vanillin solution (6% (w / v) vanillin and 10% (v / v) sulfuric acid contained in 95% ethanol) or Hanessian's stain (5% (w / v) ammonium molybdate, 1% (w / v) cerium (II) sulfate and 10% (v / v) sulfuric acid contained in water). Silica gel column chromatography was performed on Fluka Kieselgel 60 (230-400 mesh).

[0847] 1 H, 13 C and 2D NMR spectra were measured using a Varian 400-MR spectrometer at 296 K. Chemical shifts (d) are relative to the corresponding residual solvent peaks (CDCl3:d in 1 7.27 in H and 13 C NMR: 77.23; CD3OD: d 1 3.31 in H and 13 49.15 in C NMR) are reported in parts per million (ppm). The following abbreviations are used to indicate the multiplicity of the peaks: s singlet; d doublet; dd doublet; t triplet; dt triplet; q quartet; m multiplet. Coupling constants (J) are reported in Hertz (Hz). Optical rotation (OR) measurements were performed at λ = 589 nm using a Schmidt & Haensch UniPol L1000 polarimeter, and the concentration (c) in g / 100 mL in the solvent is noted in parentheses. High-resolution mass spectrometry (HRMS) was performed at the Free University Berlin, Mass Spectrometry Core Facility using an Agilent 6210ESI-TOF mass spectrometer. Infrared (IR) spectra were measured using a Perkin Elmer 100FTIR spectrometer.

[0848] A.1 Abbreviations

[0849] ACN Acetonitrile

[0850] AcOH Acetic acid

[0851] AIBN Azobisisobutyronitrile

[0852] Aluminum hydroxide gel Aluminum hydroxide gel adjuvant, Al: 10mg / mL (Brenntag)

[0853] Alloc Allyloxycarbonyl

[0854] aq. water-based

[0855] BH3 Borane

[0856] BBr3 Boron tribromide

[0857] Boc tert-Butyloxycarbonyl

[0858] BnBr Benzyl bromide

[0859] br. Width

[0860] CAS CAS Registry Number (CAS = Chemical Abstracts Service)

[0861] CHCl3 Chloroform

[0862] cHex Cyclohexane

[0863] d Double

[0864] dd double double

[0865] DCM Dichloromethane

[0866] DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone

[0867] DEAD Diethyl azodicarboxylate

[0868] DIPEA N,N-Diisopropyl-ethylamine

[0869] DMAP dimethylaminopyridine

[0870] DME Dimethoxyethane

[0871] DMF Dimethylformamide

[0872] DMSO Dimethyl sulfoxide

[0873] DPPA Diphenylphosphoryl azide

[0874] EDC·HCl N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride

[0875] ES Electrospray

[0876] Et2O Diethyl ether

[0877] EtOAc Ethyl acetate

[0878] FCS Fetal calf serum

[0879] FmocCl 9-Fluorenylmethoxycarbonyl chloride

[0880] GSDMD Glycosyltransferase-D

[0881] h hour

[0882] HCl

[0883] HEK293T embryonic kidney fibroblast cell line

[0884] H2O water

[0885] HOBt.H2O 1H-Benzo[d][1,2,3]triazol-1-ol hydrate

[0886] hPBMC Human peripheral blood mononuclear cells

[0887] IC 50 Half maximum inhibitory concentration

[0888] K2CO3 Potassium carbonate

[0889] LDH Lactate dehydrogenase

[0890] LiAlH4 Lithium Aluminum Hydride

[0891] m multiple

[0892] MeCN Acetonitrile

[0893] MeOH Methanol

[0894] MeI Methyl iodide

[0895] MgSO4 Magnesium sulfate

[0896] min

[0897] MS

[0898] Na2CO3 Sodium carbonate

[0899] NaCNBH3 Sodium cyanoborohydride

[0900] NaHCO3 Sodium bicarbonate

[0901] NaH Sodium hydride

[0902] NaOH Sodium hydroxide

[0903] NAP 2-naphthylmethyl

[0904] NapBr 2-Naphthylmethyl bromide

[0905] NaPi Buffer Phosphate Buffered Saline (PBS)

[0906] Na2SO4 Sodium sulfate

[0907] NBS N-bromosuccinimide

[0908] NCS N-Chlorosuccinimide

[0909] NET Neutrophil Extracellular Traps

[0910] NIS N-iodosuccinimide

[0911] NMR Nuclear Magnetic Resonance

[0912] PBBBr p-Bromobenzyl bromide

[0913] PBS = NaPi Phosphate Buffered Saline

[0914] Pd / C Palladium Carbon

[0915] Pd(PPh3)4Tetrakis(triphenylphosphine)palladium(0)

[0916] PMA Phorbol 12-myristate 13-acetate

[0917] PPh3 Triphenylphosphine

[0918] PTFE Polytetrafluoroethylene

[0919] q Quadruple

[0920] RBF Round Bottom Flask

[0921] rt room temperature

[0922] s Unit weight

[0923] sat. saturated sep Seventh

[0924] t triple

[0925] TBAF Tetrabutylammonium fluoride

[0926] TFA Trifluoroacetic acid

[0927] THF Tetrahydrofuran

[0928] THP1 acute monocytic leukemia cancer cell line

[0929] TLC Thin layer chromatography

[0930] TMSOTf Trimethylsilyl trifluoromethanesulfonate

[0931] TsOH tosic acid

[0932] Wt Weight

[0933] A.2 Synthesis of hexasaccharide 33

[0934] Synthesis 2

[0935]

[0936] NIS (3.0 equiv.) was added to a cooled solution of 1 (obtained according to Chem. Eur. J. 2014, 20, 3578-3583) in THF:H2O (4:1, 25 mL / 1 g) at 0°C. After 10 min, the reaction mixture was placed at rt and stirred for 2 h. After complete consumption of the starting material, THF was removed under reduced pressure, and the resulting crude residue was dissolved in EtOAc and washed with aq.Na2S2O3 and aq.NaHCO3. The separated organic layer was dried over Na2SO4, concentrated, and the crude product was purified by automated flash silica gel column chromatography (0-60% EtOAc in cyclohexane) to give the desired hemiacetal 2 (84%) as a foam. For C 38 H 38 O6Na + [M+Na] + HRMS (ESI+) calculated value: 613.2566, found: 613.2574.

[0937] Synthesis 3

[0938]

[0939] Ac2O (2.0 eq) and trimethylamine (6.0 eq) were added to a clear solution of 2 in DCM (10 mL / 1 g) and kept stirring at rt for 4 h. After complete consumption of the starting material, the solvent was removed under vacuum and the crude product was purified by automated flash column chromatography on silica gel (0-50% EtOAc in cyclohexane) to give the desired product 3 (94%) as a viscous liquid. 40 H 40 O7 + [M+Na] + HRMS (ESI+) calculated value: 655.2672, found value: 655.2679.

[0940] Synthesis 4

[0941]

[0942] At room temperature, allyltrimethylsilane (2.0 equivalents) was added to a clear solution of dry acetonitrile (20 mL / 1 g) of 3, and then TMSOTf (0.5 equivalents) was added dropwise. The flask was sealed and placed in an ultrasonic cleaning bath (frequency 80 Hz, 100% power 230 V, rt) until the reaction was confirmed to be complete by TLC (40 min). After the starting material was completely consumed, the reaction mixture was quenched with aq.NaHCO3, diluted with EtOAc and washed with brine. The separated organic layer was dried over Na2SO4, concentrated, and the crude product was purified by automatic rapid silica gel column chromatography (0-60% EtOAc in cyclohexane) to obtain the desired C-glycoside 4 (91%) as an oil. For C 41 H 42 O5Na + [M+Na] + HRMS (ESI+) calculated value: 637.2930, found value: 637.2929.

[0943] Synthesis 5

[0944]

[0945] PdCl2 (0.1 eq) was added to a degassed (30 min) solution of 4 in toluene (100 mL / 1 g). After the addition of PdCl2, the reaction mixture was degassed again for 30 min and stirred at 120 °C for 2.5 d. After complete consumption of the starting material, the reaction mixture was passed through a pad of celite and concentrated under reduced pressure. The crude residue was purified by automated flash silica gel column chromatography (0-50% EtOAc in cyclohexane) to afford compound 5 (70%) with double bond migration as a light yellow liquid. For C 41 H 42 O5Na + [M+Na] + HRMS (ESI+) calculated value: 637.2930, found value: 637.2942.

[0946] Synthesis 6

[0947]

[0948] At 0°C, DDQ (1.2 eq) was added to a biphasic solution of 5 in DCM:H2O (19:1, 20 mL / 1 g). After 10 min at 0°C, the reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. After complete consumption of the starting material, the reaction mixture was diluted with DCM and extracted with aq.NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated to give the crude product. The crude product was purified by automated flash silica gel chromatography (0-80% EtOAc in cyclohexane) to give the desired product 6 (94%) as a white oil. For C 30 H 34 O5Na + [M+Na] + HRMS (ESI+) calculated value 497.2304, found value 497.2312.

[0949] Synthesis 7

[0950]

[0951] Ac2O (2.0 eq) and trimethylamine (6.0 eq) were added to a clear solution of 6 in DCM (10 mL / 1 g) and stirred at rt for 4 h. After complete consumption of the starting material, the solvent was removed under vacuum and the crude product was purified by automated flash column chromatography on silica gel (0-50% EtOAc in cyclohexane) to give the desired product 7 (90%) as a viscous liquid. 32 H 36 O6Na + [M+Na] + HRMS (ESI+) calculated value: 539.2410, found value: 539.2419.

[0952] Synthesis 8

[0953]

[0954] At -78 ° C, ozone was bubbled into a cooled solution of 7 in DCM:MeOH (1: 1, 170 mL / 1 g) until a blue color persisted. To remove residual O3, pure O2 was bubbled through the reaction mixture until the solution became clear. Then, NaBH4 was added at -78 ° C, and the reaction mixture was stirred at the same temperature for 30 min. After complete consumption of the starting material, the reaction mixture was quenched with aq.NH4Cl at -78 ° C and washed with DCM. The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by automatic flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 8 as a light yellow liquid (60% over 2 steps). For C 30H 34 O7 + [M+Na] + HRMS (ESI+) calculated value 529.2202, found value 529.2220.

[0955] Synthesis 9

[0956]

[0957] To a solution of 8 in methanol (10 mL / 1 g) was added a solution of sodium methoxide in MeOH (0.5 M, 10 mL), and the mixture was kept stirring at rt for 1 h. After complete consumption of 8, AcOH (1 mL) was added until the pH of the reaction mixture was acidic. After neutralization, the reaction mixture was concentrated, and the crude residue was purified by flash column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 9 (90%) as a paste. 28 H 32 O6Na + [M+Na] + HRMS (ESI+) calculated value: 487.2097, found value: 487.2111.

[0958] 9-Alternative synthesis of compound 10

[0959]

[0960] Propargyltrimethylsilane (9.11 mL, 61.5 mmol, 2.0 equiv) was added to a clear solution of 3 (19.5 g, 30.8 mmol) in dry acetonitrile (390 mL) at room temperature, and then TMSOTf (2.8 mL, 15.4 mmol, 0.5 equiv) was added dropwise. The flask was sealed and placed in an ultrasonic cleaning bath (frequency 80 Hz, 100% power 230 V, 5-10 ° C) until the reaction was completed by TLC (40 min). After complete consumption of the starting material, the reaction mixture was quenched with aq.NaHCO3, diluted with EtOAc and washed with brine. The separated organic layer was dried over Na2SO4, concentrated, and the crude product was purified by automatic flash silica gel column chromatography (0-60% EtOAc in cyclohexane) to give the desired C-glycoside 10 (16.2 g, 86%) as an oil. For C 41 H 40 O5Na + [M+Na] + HRMS (ESI+) calculated value: 635.2773, found value: 635.2786.

[0961] 9-Alternative synthesis of compound 11

[0962]

[0963] DDQ (18.7 g, 82.0 mmol, 1.2 eq) was added to a biphasic solution of 10 (42 g, 68.5 mmol) in DCM:H2O (19:1, 950 mL) at 0°C. After 10 min at 0°C, the reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. After complete consumption of the starting material, the reaction mixture was diluted with DCM and extracted with aq.NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated to give the crude product. The crude product was purified by automated flash silica gel chromatography (0-80% EtOAc in cyclohexane) to give the desired product 11 (24 g, 74%, α-isomer only) as a white oil. For C 30 H 32 O5Na + [M+Na] + HRMS (ESI+) calculated value: 495.2147, found value: 495.2151.

[0964] 9-Alternative synthesis of compound 9

[0965]

[0966] Ozone was bubbled through a cooled solution of 11 (10.6 g, 22.4 mmol) in DCM:MeOH (1:1, 1 L) at -78 °C until a blue color persisted. To remove residual O3, pure O2 was bubbled through the reaction mixture until the solution became clear. Then, NaBH4 (5.1 g, 135.0 mmol, 6.0 equiv) was added at -78 °C, and the reaction mixture was gradually warmed to RT over 3 h and stirred at RT for 45 min. After complete consumption of the starting material, the reaction mixture was quenched with aq.NH4Cl and washed 3 times with DCM. The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 9 (8.4 g, 81% over 2 steps) as an oil (sticky white solid after vacuum drying). For C 28 H 32 O6Na + [M+Na] + HRMS (ESI+) calculated value: 487.2097, found value: 487.2106.

[0967] Synthesis of 12

[0968]

[0969] Sodium hydride (2.0 eq., 60% in mineral oil) was added to a stirred solution of 9 in THF (20 mL / 1 g) at 0 °C. After 10 min, NapBr (1.05 eq.) was added and the mixture was stirred at 0 °C for 24 h. After 24 h, the reaction mixture was quenched with MeOH, water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The obtained crude residue was purified by silica gel automated flash column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 12 (54%) as a paste. For C 39 H 40 O6Na + [M+Na] + HRMS (ESI+) calculated value: 627.2723, found value: 627.2748.

[0970] Synthesis of 14

[0971]

[0972] Use fresh activated molecular sieve at -78℃ Et3SiH (3.0 equiv.), TfOH (3.3 equiv.) were added to a cooled solution of DCM (10 mL / 1 g) of 13 (obtained according to Org. Lett. 2011, 13, 378-381). The reaction mixture was stirred at the same temperature for 4 h. After the starting material was completely consumed, the reaction mixture was quenched with Et3N (1 mL) and diluted with DCM. The solution was washed with aq. NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automatic rapid silica gel column chromatography (0-100% EtOAc in cyclohexane) to obtain the desired 4-OH compound 14 (83%) as a white solid. For C 51 H 54 Cl3NO 12 NaS + [M+Na] + HRMS (ESI+) calculated value: 1034.2300, found value: 1034.2406.

[0973] Synthesis of 15

[0974]

[0975] FmocCl (2.0 eq.) and pyridine (3.0 eq.) were added to a clear solution of 14 in DCM (10 mL / 1 g) and stirred at rt for 3.5 h. After complete consumption of the starting material, the reaction mixture was diluted with DCM and washed with brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 15 (93%) as a white solid. For C 66 H 64 Cl3NO 14 NaS + [M+Na] + The HRMS (ESI+) calculated value is 1256.2981, the found value is 1256.3125.

[0976] Synthesis of 16

[0977]

[0978] At -30℃ NIS (1.4 eq.) and TfOH (0.26 eq.) were added to a cooled solution of acceptor 15 (1.0 eq.) and donor 12 (1.2 eq.) in DCM (0.06 M) in the presence of MS. After 1.5 h, the starting material was completely consumed, then Et3N (1.4 eq.) was added and kept stirring at rt for 2 h. After 2 h, the reaction mixture was diluted with DCM and MS was filtered. The organic layer was washed with aq. Na2S2O3 and the separated organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired trisaccharide acceptor 16 as a white solid (58% over 2 steps). 84 H 88 Cl3NO 18 Na + [M+Na] + HRMS calculated (ESI+) 1528.4935, found 1528.5037.

[0979] Synthesis of 18

[0980]

[0981] At 0℃ NIS (1.5 eq.) and TfOH (0.4 eq.) were added to a cooled solution of acceptor 16 (1.0 eq.) and donor 17 (obtained according to J. Org. Chem. 2016, 81, 162-184) (1.5 eq.) in toluene: dioxane (4:1, 0.03 M) in the presence of MS. After 2 min, the reaction mixture was kept at rt and stirred for 30 min. After 30 min, the reaction mixture was quenched with Et3N, diluted with DCM and filtered for MS. The organic layer was washed with aq. Na2S2O3, and the separated organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired tetrasaccharide 18 (76%) as a white solid. For C 111 H 114 Cl3NO 23 Na + [M+Na] + The HRMS (ESI+) calculated value was 1958.6745 and the found value was 1958.6871.

[0982] Synthesis of 19

[0983]

[0984]

[0985] at -78°C over freshly activated molecular sieves In the presence of , Et3SiH (3.0 eq.), TfOH (3.3 eq.) were added to a cooled solution of 18 in DCM (10 mL / 1 g). The reaction mixture was stirred at the same temperature for 4 h. After complete consumption of the starting material, the reaction mixture was quenched with Et3N (1 mL) and diluted with DCM. The solution was washed with aq. NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated rapid silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired tetrasaccharide 19 (82%) as a white solid. For C 111 H 116 Cl3NO 23 Na + [M+Na] + The HRMS (ESI+) calculated value was 1960.6901 and the found value was 1960.7024.

[0986] Synthesis of 21

[0987]

[0988] Sodium hydride (2.0 eq., 60% in mineral oil) was added to a stirred solution of 20 (obtained according to Tetrahedron: Asymmetry, 2000, 11, 481-492) in DMF (10 mL / 1 g) at 0°C. After 10 min, PBBBr (1.1 eq.) was added and the mixture was placed at rt. After stirring at rt for 1 h, the reaction mixture was quenched with NH4Cl and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The resulting crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 21 (62%) as a paste. For C 36 H 35 BrO7NaS + [M+Na] + HRMS (ESI+) calculated value: 713.1185, found value: 713.1225.

[0989] Synthesis of 22

[0990]

[0991] NBS (1.1 eq.) and TMSOTf (0.1 eq.) were added to a cooled solution of 21 in DCM:H2O (20:1, 10 mL / 1 g) at 0°C. After 10 min, the reaction mixture was quenched with aq., NaHCO3 and diluted with DCM. The organic layer was washed with brine. The separated organic layer was dried over Na2SO4, concentrated, and the crude product was purified by automated flash silica gel column chromatography (0-60% EtOAc in cyclohexane) to give the desired hemiacetal 22 (70%) as a foam. For C 34 H 31 BrO8Na + [M+Na] + HRMS (ESI+) calculated value: 669.1100, found value: 669.1132.

[0992] Synthesis of 23

[0993]

[0994] CsCO (3.0 eq.), CFC(NPh)Cl (3.0 eq.) were added to a stirred solution of 22 in DCM (10 mL / 1 g) at 0°C. After 10 min, the mixture was placed at rt and stirred for 1 h. After complete consumption of 22, the reaction mixture was filtered and the filtrate was concentrated. The obtained crude residue was purified by automated flash silica gel column chromatography (0-60% EtOAc in cyclohexane) to give the desired imidate donor 23 (87%) as a foam.

[0995] Synthesis of 25

[0996]

[0997] Thioglycoside acceptor 24 was synthesized according to Danieli, E.; Lay, L.; Proietti, D.; Berti, F.; Costantino, P.; Adamo, R. Org Lett. 2011, 13, 378-381. TMSOTf (0.1 M, 0.2 eq.) in DCM was added to thioglycoside acceptor 24 (1.0 eq.) and freshly dried in DCM at -78°C. MS. After 2 min, a solution of imidate 23 (1.2 eq.) in DCM was added. After 1 h, the reaction mixture was quenched with Et3N and then filtered through a pad of celite. The filtrate was concentrated and the crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired disaccharide 25 as a solid (61%). 56 H 51 BrCl3NO 13 NaS + [M+Na] + HRMS (ESI+) calculated value: 1186.1207, found value: 1186.1314.

[0998] Synthesis of 26

[0999]

[1000] Use fresh activated molecular sieve at -78℃ Et3SiH (3.0 eq.), TfOH (3.3 eq.) were added to a cooled solution of 25 in DCM (10 mL / 1 g). The reaction mixture was stirred at the same temperature for 4 h. After complete consumption of the starting material, the reaction mixture was quenched with Et3N (1 mL) and diluted with DCM. The solution was washed with aq.NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automatic rapid silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired 4-OH compound 26 (80%) as a white solid. For C 56 H 53 Cl3NBrO 13 NaS + [M+Na] + The HRMS (ESI+) calculated value was 1188.1364 and the found value was 1188.1436.

[1001] Synthesis of 27

[1002]

[1003] AcCl (2.0 eq.) and pyridine (3.0 eq.) were added to a clear solution of 26 in DCM (10 mL / 1 g) at 0 °C and stirred at rt for 3.5 h. After complete consumption of the starting material, the reaction mixture was diluted with DCM and washed with brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired compound 27 (70%) as a white solid. 58 H 55 Cl3NBrO 14 NaS + [M+Na] + The HRMS (ESI+) calculated value was 1230.1469, and the found value was 1230.1563.

[1004] Synthesis of 28

[1005]

[1006] At -20℃ NIS (1.8 eq.) and TfOH (0.4 eq.) were added to a cooled solution of acceptor 19 (1.0 eq.) and donor 27 (1.8 eq.) in DCM (0.025 M) in the presence of MS. The reaction mixture was then gradually warmed to 0 °C over 3 h. After 3 h, the reaction mixture was quenched with Et3N, diluted with DCM and filtered for MS. The organic layer was washed with aq. Na2S2O3, and the separated organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired hexasaccharide 28 (65%) as a white solid. For C 163 H 165 Cl6N2BrO 37 Na + [M+Na] + The HRMS (ESI+) calculated value was 3060.8258, and the found value was 3060.8275.

[1007] Synthesis of 29

[1008]

[1009] To a clear solution of 28 in EtOAc (2.0 mM) was added Zn (100 equiv) and AcOH (100 equiv), and the reaction mixture was stirred at room temperature for 3 h. After complete consumption of the starting material, the reaction mixture was filtered through a celite pad and concentrated. The residue obtained after removal of the solvent was dissolved in EtOAc (2.0 mM), and Et3N (0.5 mL) and Ac2O (0.5 mL) were added. After stirring at rt for 2.5 d, the reaction mixture was concentrated. The crude product obtained after removal of the solvent was dissolved in THF and methanol. 0.5 M NaOMe (3 mL) was added to the clear solution and kept at reflux at 65 ° C. After 16 h, the reaction mixture was neutralized with AcOH and the solvent was removed. The crude residue was purified by automatic fast silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired hexasaccharide 29 as a white solid (74% over 3 steps). For C 143 H 155 N2BrO 31 Na + [M+Na] + The HRMS (ESI+) calculated value was 2500.9708 and the found value was 2500.9739.

[1010] Synthesis of 30

[1011]

[1012] Ac2O (8.0 eq) and trimethylamine (8.0 eq) were added to a clear solution of 29 in DCM (10 mL / 1 g) and stirred at rt for 16 h. After complete consumption of the starting material, the solvent was removed under vacuum and the crude product was purified by automated flash column chromatography on silica gel (0-100% EtOAc in cyclohexane) to give the desired product 30 (83%) as a viscous liquid. 151 H 163 N2BrO 35 Na + [M+Na] + HRMS (ESI+) calculated value: 2669.0131, found value: 2669.0407.

[1013] Synthesis of 31

[1014]

[1015] DDQ (1.1 eq) was added to a cooled solution of 30 in DCM:H2O at 0°C. After stirring the reaction mixture for 4 h at the same temperature, the reactant was diluted with DCM and extracted with NaHCO3 aq.sat. solution and brine. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated to give the crude product. The crude product was purified by silica gel automated flash column chromatography (0-100% EtOAc in cyclohexane) to give the desired product 31 (60%) as a viscous liquid. 140 H 155 N2BrO 35 Na + [M+Na] + The HRMS (ESI+) calculated value was 2527.9559 and the found value was 2527.9731.

[1016] Synthesis of 32

[1017]

[1018]

[1019] To a solution of 31 in DCM, bis(diisopropylamino)-benzyloxyphosphine (2.0 equiv.) and diisopropyl tetrazolium ammonium (1.5 equiv.) were added and the solution was stirred at rt for 1.5 h. Then, 5-azidopentanol (8.0 equiv.) and tetrazole (9.0 equiv. of a 0.45 M solution of CAN) were added and kept stirring at room temperature for 2 h. After 2 h, tert-butyl peroxide (6.0 equiv., 5.0-6.0 M solution in decane) was added and the reaction mixture was stirred for 1 h. After 1 h, the reaction mixture was diluted with DCM and quenched with a NaHCO3aq.sat. solution. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum to give a crude product. The crude product was purified by automated flash column chromatography on silica gel (0-100% EtOAc in cyclohexane) to afford the desired product 32 (37% over 3 steps) as a viscous liquid. 152 H 171 N5B 38 PH + [M+H] + The MALDI calculated value was 2786.0635 and the measured value was 2786.870.

[1020] Synthesis of 33

[1021]

[1022]

[1023] Pd / C (6 mg) was added to a clear solution of 32 (6 mg) in EtOAc:MeOH:H2O:AcOH. The heterogeneous mixture obtained was stirred at rt for 40 h under a hydrogen atmosphere. After 40 h, the reaction mixture was filtered through a PTFE filter and concentrated under vacuum on a rotary evaporator at 30°C bath temperature for 10 min to remove methanol, EtOAc, AcOH and water. The crude product obtained after removal of the solvent was dissolved in MeOH, water, and LiOH (2N in water) was added thereto at 0°C. The reaction mixture was stirred at 0°C for 3 h. After 3 h, the reaction mixture was quenched with AcOH (30 μL), and the solvent was removed under reduced pressure, and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile as solvents to give the desired final compound 33 as a white solid (80% over 2 steps). For C 46 H 82 N3PO 34 + [M-Na+2H] + The HRMS (ESI+) calculated value was 1252.4551 and the found value was 1252.4578.

[1024] Synthesis of 34

[1025]

[1026]

[1027] Pd / C (2 mg) was added to a clear solution of 29 in EtOAc:MeOH:H2O:AcOH and the obtained heterogeneous mixture was stirred at rt for 40 h under hydrogen atmosphere. After 40 h, the reaction mixture was filtered through a PTFE filter and concentrated under vacuum at 30°C bath temperature on a rotary evaporator for 10 min to remove methanol, EtOAc, AcOH and water. The crude product was purified by C18 reverse phase column chromatography using water and acetonitrile as solvents to give the desired final compound 34 as a white solid (82%). 41 H 70 N2O 31 + [M+Na] + HRMS (ESI+) calculated value: 1109.3860, found value: 1109.3853.

[1028] 33 and CRM 197 or BSA conjugated

[1029]

[1030]

[1031] Antigen 33 (1.0 eq) was dissolved in DMSO-H2O in a 2 mL vial at rt. Triethylamine (35.0 eq) was added thereto. The mixture was added to activated adipate-NHS ester (10 eq) in DMSO in an Eppendorf vial and stirred at rt for 3 h. Antigen-NHS ester was precipitated by adding 10 volumes of EtOAc and centrifuged, and the supernatant was carefully removed. The precipitate was washed with EtOAc (1 mL×3), dried, and taken out for the next step. NaPi buffer (~100 μL) of 1 mg protein was added dropwise to a reaction vial containing 50 μL NaPi buffer (pH 7.0) containing antigen-NHS ester 35. Finally, the vial was rinsed with 50 μL buffer solution and then completely transferred to the reaction vial. The reaction mixture was stirred at rt for 22 h. The antigen-protein conjugate solution was transferred to an Amicon Ultra-0.5 mL and centrifuged at room temperature for 6 minutes. Add 300 μL of buffer to the reaction vial, rinse and transfer to the filter and centrifuge again. Wash three additional times with 1X PBS solution. After the last wash, store the conjugate in 1X PBS solution at 2-8°C. Analyze the conjugate using MALDI (obtain 4-12 antigen loads on the protein), SDS-page, BCA estimation, SEC-HPLC.

[1032] A.3 Synthesis of hexasaccharide 54

[1033] Synthesis of 41

[1034]

[1035] TBDPSCl (1.1 eq) and trimethylamine (2.8 eq) were added to a clear solution of 20 in CHCN (10 mL / 1 g) and kept stirring at rt for 10 h. After complete consumption of the starting material, the solvent was removed under vacuum and the crude product was purified by automated flash column chromatography on silica gel (0-100% EtOAc in cyclohexane) to give the desired product 41 (93%) as a viscous liquid. 45 H 48 7S + [M+Na] + The HRMS (ESI+) calculated value was 783.2788 and the found value was 783.2767.

[1036] Synthesis of 42

[1037]

[1038] The procedure described for the synthesis of compound 22 was used for the synthesis of compound 42 (94%). 43 H44 8SiNa + [M+Na] + HRMS (ESI+) calculated value: 739.2703, found value: 739.2700.

[1039] Synthesis of 43

[1040]

[1041] To a cooled solution of 42 in DCM was added trichloroacetonitrile (6.0 eq.) and DBU (0.2 eq.) at 0°C. After 3 h at 0°C, the reaction was complete and the solvent was evaporated. The crude product was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired product 43 (83%) as a viscous liquid.

[1042] Synthesis of 44

[1043]

[1044] The procedure described for the synthesis of compound 25 was used for the synthesis of compound 44 (40%). 65 H 64 O 13 SiSNCl3Na + [M+Na] + HRMS (ESI+) calculated value: 1256.2801, found value: 1256.2645.

[1045] Synthesis of 45

[1046]

[1047] The procedure described for the synthesis of compound 26 was used for the synthesis of compound 45 (60%). 65 H 66 O 13 SiSNCl3Na + [M+Na] + HRMS (ESI+) calculated value: 1256.2987, found value: 1256.2974.

[1048] Synthesis of 46

[1049]

[1050] The procedure described for the synthesis of compound 27 was used for the synthesis of compound 46 (60%). 67 H 68 O 14 SiSNCl3Na + [M+Na]+ The HRMS (ESI+) calculated value is 1300.3064, the found value is 1300.3090.

[1051] Synthesis of 47

[1052]

[1053]

[1054] The procedure described for the synthesis of compound 28 was used for the synthesis of compound 47 (82%). 172 H 178 O 37 SiN2Cl6Na + [M+Na] + HRMS (ESI+) calculated value is 3127.9728, found value is 3127.9728.

[1055] Synthesis of 48

[1056]

[1057] The procedure described for the synthesis of compound 29 was used for the synthesis of compound 48 (50%). 152 H 168 O 31 SiN2Na + [M+Na] + The HRMS (ESI+) calculated value was 2568.1298 and the found value was 2568.1322.

[1058] Synthesis of 49

[1059]

[1060] The procedure described for the synthesis of compound 30 was used for the synthesis of compound 49 (80%). 160 H 176 O 35 SiN2Na + [M+Na] + HRMS (ESI+) calculated value: 2737.1754, found value: 2737.2001.

[1061] Synthesis of 50

[1062]

[1063]

[1064] The procedure described for the synthesis of compound 31 was used for the synthesis of compound 50 (70%).149 H 168 O 35 SiN2Na + [M+Na] + HRMS (ESI+) calculated value is 2596.1095, found values ​​are 2595.9954 and 2596.9997.

[1065] Synthesis of 51

[1066]

[1067] The procedure described for the synthesis of compound 32 was used for the synthesis of compound 51.

[1068] Synthesis of 52

[1069]

[1070] The premixed solution of TBAF and AcOH was added to a clear solution of 51 in THF at rt, and the reaction mixture was stirred at rt for 3 h. After complete consumption of the starting material, the reaction mixture was diluted with DCM and concentrated under vacuum to obtain the crude product. The crude product was purified by automated silica gel column chromatography using EtOAc (gradient, 0 to 100%) in n-hexane as eluent.

[1071] Synthesis of 53

[1072]

[1073] Dibenzyl N, N-diisopropylphosphoramidite (2.0 equiv.) and diisopropyl tetrazolium (1.5 equiv.) were added to a DCM solution of 52, and the solution was stirred at rt for 1.5 h. Then, tert-butyl peroxide (6.0 equiv., 5.0-6.0 M decane solution) was added, and the reaction mixture was stirred for 1 h. After 1 h, the reaction mixture was diluted with DCM and quenched with NaHCO3 aq.sat. solution. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum to obtain a crude product. The crude product was purified by automatic rapid silica gel column chromatography (0-100% EtOAc in cyclohexane) to obtain the desired product 53.

[1074] Synthesis of 54

[1075]

[1076] The procedure described for the synthesis of compound 33 was used for the synthesis of compound 54.

[1077] 54 and CRM 197 Conjugation with BSA

[1078]

[1079]

[1080] The procedures described for the synthesis of glycoconjugates 36 and 37 were used for the synthesis of 56 and 57.

[1081] A.4 Alternative synthesis of hexasaccharide 54

[1082] Synthesis of 58

[1083]

[1084] Diphenyl phosphite was added to a clear solution of 48 in pyridine and the reaction mixture was stirred at room temperature under nitrogen for 2 h. After 2 h, 1 M TEAB solution was added to the reaction mixture at 0 °C. After 5 min, the ice bath was removed and stirring was continued for another 2 h at rt. After complete consumption of the starting material, the reaction mixture was diluted with DCM and the organic layer was washed successively with 1 M TEAB solution and concentrated under reduced pressure. The crude product was purified by automated flash column chromatography (EA:DCM:MeOH with 2% Et3N) to give pure H-phosphonate derivative 58 (90%) as a viscous liquid. 155 H 184 N3PSiO 37 + [M] + The HRMS (ESI+) calculated value was 2740.2189, and the found value was 2740.2132.

[1085] Synthesis of 59

[1086]

[1087] H-phosphonate 58 (1.0 eq.) and linker (4.0 eq.) were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in py and PivCl (2.0 eq.) was added thereto. The reaction mixture was kept stirring at rt for 2 h. After 2 h, the reaction was cooled to -40 °C, a freshly prepared solution of I2 in Py:H2O (20:1) was added, and the reaction mixture was kept stirring at the same temperature for 1.5 h, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB), dried over Na2SO4, filtered and concentrated. The residue was purified by automated flash column chromatography (ethyl acetate:DCM:MeOH) and 2% trimethylamine as eluent to give the desired product 59 (70%) as a viscous liquid. For C 154 H 178 N5PNaSiO 38 + [M-Et3N+Na] + The Maldi (ESI+) calculated value was 2789.1635, and the found value was 2788.0.

[1088] Synthesis of 60

[1089]

[1090] To a solution of 59 in DCM and pyridine was added dropwise HF solution (70% in pyridine, 0.3 mL) at 0°C. The reaction mixture was stirred at the same temperature for 18 h. The reaction mixture was then diluted with DCM, washed with saturated aqueous NaHCO3 and TEAB buffer. The organic phase was separated and dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by automated flash column chromatography (ethyl acetate: DCM: MeOH) with 2% trimethylamine as eluent to give the desired product 60 as a viscous liquid. 138 H 160 N5PNaO 38 + [M-Et3N+Na] + The Maldi (ESI+) calculated value was 2550.7585 and the measured value was 2549.698.

[1091] Synthesis of 54

[1092]

[1093]

[1094] Dibenzyldiisopropylphosphoramidite (2.0 equiv.) and diisopropyltetrazolium ammonium (2.0 equiv.) were added to a DCM solution of 60, and the solution was stirred at room temperature for 1.5 h. Then, a 5.0-6.0 M decane solution (6.0 equiv.) of tert-butyl peroxide was added at room temperature, and the reaction mixture was stirred for 1 h. The reaction mixture was diluted with DCM and washed with NaHCO3aq.sat. solution and TEAB buffer. The aqueous layer was extracted with DCM (2×10 mL). The combined organic layers were dried over Na2SO4 (0.5 g), filtered, and the filtrate was concentrated under vacuum to give a crude product. The crude product was purified by automated flash chromatography using EtOAc:DCM:MeOH with 2% trimethylamine to give the desired product 61 as a viscous oil (91%). The title compound 54 was obtained from compound 61 in a yield of 60% by the process described for the synthesis of compound 33. For C 46 H 83 N3P2NaO 37 + [M+Na] - The HRMS (ESI+) calculated value is 1354.4078, the found value is 1354.9623.

[1095] A.5 Alternative synthesis of hexasaccharide 54

[1096] Synthesis of 62

[1097]

[1098] Me3N·BH3 (21.2 g, 291 mmol, 5.4 eq.), BF3·Et2O (42.2 mL, 291 mmol, 5.4 eq.) were added to a cooled solution of 24 (28.8 g, 54 mmol) in CH3CN (1.5 L) at 0°C. The reaction mixture was stirred at the same temperature for 1 h. After complete consumption of the starting material, the reaction mixture was quenched with Et3N (30 mL) and MeOH (50 mL). The reaction mixture was then diluted with EtOAc (1 L), washed with 1M HCl (3 times, sometimes it was difficult to see the 2 layers, then brine was added to get better), and then washed with aq.NaHCO3 until the pH of the organic layer became neutral. The separated organic layer was dried over Na2SO4, filtered and concentrated. The white solid product 62 (22 g, 76%) was pure for the next step. For C 22 H 24 Cl3NO6SNa + [M+Na] + HRMS (ESI+) calculated value: 558.0288, found value: 558.0332.

[1099] Synthesis of 64

[1100]

[1101] The procedure described for the synthesis of compound 2 was used for the synthesis of compound 64 (85%). 34 H 40 O6N + [M+NH4] + The HRMS (ESI+) calculated value is 558.2856, the found value is 558.2976.

[1102] Synthesis of 65

[1103]

[1104] To a stirred solution of 64 (24.5 g, 45.3 mmol) in anhydrous DCM (360 mL) at 0°C was added anhydrous DMF (1 mL, 13.6 mmol, 0.30 equiv) and (COCl)2 (10.3 mL, 118.0 mmol, 2.6 equiv) . After 5 min. the reaction mixture was placed at rt and stirred at rt for 2 h. After complete consumption of the starting material, the reaction mixture was cooled to 0°C and quenched with Et3N. The formed salt was filtered through a short pad of celite and washed with DCM (do not wash with large amounts of DCM as the salt will dissolve and pass through the celite). The filtrate was then concentrated under reduced pressure and purified by silica gel column chromatography using ethyl acetate: cyclohexane (0-40% with 2% Et3N) to afford the desired glycosyl chloride 65 (24 g, 96%) as a viscous liquid. For C 34 H 35 O5ClNa + [M+Na] + HRMS (ESI+) calculated value 581.2071, found value 581.2206.

[1105] Synthesis of 66

[1106]

[1107] To a cloudy solution of glycosyl chloride 65 (16.2 g, 28.9 mmol, 1.15 equiv) and acceptor 62 (13.5 g, 25.1 mmol) in acetonitrile (200 mL) and DCM (80 mL) was added AgO (8.8 g, 37.7 mmol, 1.5 equiv, dried under vacuum at 80 °C for 3 h before use) and 2-aminoethyl diphenyl borate (0.57 g, 2.51 mmol, 0.1 equiv). After stirring at rt for 16 h, the mixture was diluted with DCM (80 mL), acetone (80 mL) and filtered through celite, sand, and washed with DCM and acetone until the filtrate showed no product. All filtrate fractions were combined and concentrated. The residue was dissolved in EtOAc (300 mL) and kept at 55 °C until the solid dissolved and became a clear solution. The clear solution was then filtered through filter paper and washed with hot EtOAc and kept for recrystallization. After 1 h, a white solid crystallized and was separated from the solution to give the desired disaccharide 66 (22 g, 83%) as a white solid. 56 H 58 Cl3NO 11 SNa + [M+Na] + The HRMS (ESI+) calculated value was 1080.2696 and the found value was 1080.2904.

[1108] Synthesis of 67

[1109]

[1110] FmocCl (16.87 g, 63.2 mmol, 2.0 equiv) and pyridine (7.67 mL, 95.0 mmol, 3.0 equiv) were added to a clear solution of 66 (33.5 g, 31.6 mmol) in DCM (330 mL) and kept stirring at rt for 2 h. After complete consumption of the starting material, the reaction mixture was diluted with DCM and washed with brine. The organic layer was dried over Na2SO4, filtered and concentrated. The crude residue was purified by automated flash column chromatography on silica gel (0-100% EtOAc in cyclohexane) to give the desired compound 67 (34.7 g, 86%) as a white solid. For C 71 H 68 Cl3NO 13 SNa + [M+Na] + The HRMS (ESI+) calculated value was 1302.3375 and the found value was 1302.3694.

[1111] Synthesis of 69

[1112]

[1113] The procedure described for the synthesis of compound 2 was used for the synthesis of compound 69 (80%). 29 H 36 O7N + [M+NH4] + HRMS (ESI+) calculated value: 510.2492, found value: 510.2527.

[1114] Synthesis of 70

[1115]

[1116] To a stirred solution of 69 (18.0 g, 36.5 mmol) in anhydrous DCM (290 mL) was added anhydrous DMF (0.85 mL, 11.0 mmol, 0.30 equiv) and (COCl)2 (8.3 mL, 95.0 mmol, 2.6 equiv) at 0°C. After 5 min. The reaction mixture was placed at rt and stirred at rt for 2 h. After complete consumption of the starting material, the reaction mixture was cooled to 0°C and quenched with Et3N. The salt formed was filtered through a short celite pad and washed with DCM. The filtrate was then concentrated under reduced pressure and purified by silica gel column chromatography using ethyl acetate: cyclohexane (0-40% with 2% Et3N) to give the desired glycosyl chloride 70 (16.7 g, 89%) as a viscous liquid. For C 29 H 31 O6ClNa + [M+Na] + HRMS (ESI+) calculated value: 533.1707, found value: 533.1752.

[1117] Synthesis of 71

[1118]

[1119] To a turbid solution of glycosyl chloride 70 (16.5 g, 32.3 mmol, 1.15 equiv) and acceptor 62 (15.07 g, 28.1 mmol) in acetonitrile (200 mL) and DCM (80 mL) was added AgO (9.76 g, 42.1 mmol, 1.5 equiv, dried under vacuum at 80 °C for 3 h before use) and 2-aminoethyl diphenyl borate (0.63 g, 2.81 mmol, 0.1 equiv). After stirring at rt for 16 h, the mixture was diluted with DCM (80 mL), acetone (80 mL) and filtered through celite, sand, and washed with DCM and acetone until the filtrate showed no product. All filtrate fractions were combined and concentrated. The residue was dissolved in EtOAc (400 mL) and kept at 55 °C until the solid dissolved and became a clear solution. The clear solution was then filtered through filter paper and washed with hot EtOAc and kept for recrystallization. After 1 h, a white solid crystallized and was separated from the solution to give the desired disaccharide 71 (23 g, 81%) as a white solid. 51 H 54 Cl3NO 12 SNa + [M+Na] + HRMS (ESI+) calculated value: 1032.2330, found value: 1032.2423.

[1120] Synthesis of 72

[1121]

[1122] AcCl (40 mL) was added to a turbid solution of 71 (18.87 g, 18.66 mmol) in MeOH (200 mL) and DCM (200 mL) at 0°C. After 5 min, the ice bath was removed and stirring was maintained at rt. After stirring at room temperature for 3 h, the reaction mixture was diluted with DCM and washed with water and aq. NaHCO3. The separated organic layer was dried over Na2SO4, filtered and concentrated on a rotary evaporator to yield the desired compound 72 (18.09 g, quantitative) as a white solid. 49 H 52 Cl3NO 11 SNa + [M+Na] + HRMS (ESI+) calculated value: 990.2224, found value: 990.2301.

[1123] Synthesis of 73

[1124]

[1125] To a suspension of 72 (18.05 g, 18.6 mmol) in acetonitrile (370 mL) was added imidazole (3.56 g, 52.3 mmol, 2.8 equiv) and TBDPSCl (7.2 mL, 28.0 mmol, 1.5 equiv). After 5 minutes, the reaction mixture was completely clear and left to stir at rt for 30 minutes. After 30 minutes, the reaction mixture was diluted with EtOAc and washed with brine. The separated organic layer was dried over Na2SO4, filtered and concentrated. The crude residue obtained after removal of the solvent was purified by automated silica gel flash chromatography using ethyl acetate and cyclohexane as eluents to give the desired product 73 (20.9 g, 93%) as a solid. 65 H 70 Cl3NO 11 SSiNa + [M+Na] + HRMS (ESI+) calculated value: 1228.3402, found value: 1228.3481.

[1126] Synthesis of 74

[1127]

[1128] To a clear solution of 73 (18.69 g, 15.47 mmol) in DCM (200 mL) was added Et3N (19 mL, 139.0 mmol, 9.0 eq), acetic anhydride (4.4 mL, 46.4 mmol, 3.0 eq) and DMAP (0.189 g, 1.547 mmol, 0.1 eq) and kept stirring at rt for 18 h. After 18 h, the reaction mixture was diluted with DCM and washed with aq. NaHCO3. The separated organic layer was dried over Na2SO4 and concentrated. The crude residue obtained after removal of the solvent was purified by automated flash silica gel chromatography (cyclohexane-EtOAc) to give the desired product 74 as a foam (17.2 g, 89%). 67 H 72 Cl3NO 12 SSiNa + [M+Na] + HRMS (ESI+) calculated value: 1272.3478, found value: 1272.3530.

[1129] Synthesis of 76

[1130]

[1131] The procedure described for the synthesis of compound 16 was used for the synthesis of compound 76 (60% over 2 steps). 82 H 86 O 17NNaCl3 + [M+Na] + The HRMS (ESI+) calculated value is 1574.5329, the found value is 1574.5624.

[1132] Synthesis of 77

[1133]

[1134] The procedure described for the synthesis of compound 18 was used for the synthesis of compound 77 (80%). 116 H 122 O 22 N2Cl3 + [M+NH4] + The HRMS (ESI+) calculated value was 2000.7565 and the found value was 2000.7588.

[1135] Synthesis of 78

[1136]

[1137] The procedure described for the synthesis of compound 19 was used for the synthesis of compound 78 (80%). 116 H 124 O 22 N2Cl3 + [M+NH4] + The HRMS (ESI+) calculated value was 2001.7711, and the found value was 2001.6469.

[1138] Synthesis of 79

[1139]

[1140] The procedure described for the synthesis of compound 28 was used for the synthesis of compound 79 (79%). 177 H 186 O 34 N2Cl6Na + [M+Na] + HRMS (ESI+) calculated value: 3147.0689, found value: 3147.1184.

[1141] 80 Synthesis

[1142]

[1143] To a clear solution of 79 in EtOAc (2.0 mM) was added Zn (100 eq), AcOH (100 eq), AcO, and the reaction mixture was kept stirring at room temperature for 20 h. After complete consumption of the starting material, the reaction mixture was filtered through a pad of celite and concentrated. The crude residue was purified by automated flash silica gel column chromatography (0-100% EtOAc in cyclohexane) to afford the desired hexasaccharide 80 (69%) as a white solid. 175 H 188 N2O 32 Si + [M] + The HRMS (ESI+) calculated value was 2858.2948, and the found value was 2858.3062.

[1144] Synthesis of 81

[1145]

[1146]

[1147] The procedure described for the synthesis of compound 31 was used for the synthesis of compound 81 (73%). 164 H 180 O 32 N2Si + [M] + HRMS (ESI+) calculated value: 2718.2322, found value: 2718.2347.

[1148] Synthesis of 82

[1149]

[1150] The procedure described for the synthesis of compound 58 was used for the synthesis of compound 82 (87%). 164 H 181 O 34 N2SiP + [M-Et3N] + The HRMS (ESI+) calculated value was 2782.2036 and the found value was 2782.2077.

[1151] Synthesis of 83

[1152]

[1153] The procedure described for the synthesis of compound 59 was used for the synthesis of compound 83 (88%). 169 H 190 O 35 N5SiP + [M-Et3N]+ The HRMS (ESI+) calculated value was 2910.2815 and the found value was 2910.2841.

[1154] Synthesis of 84

[1155]

[1156] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 84 (90%). 153 H 172 O 35 N5P + [M-Et3N] + The HRMS (ESI+) calculated value was 2672.1638, and the found value was 2672.1759.

[1157] Synthesis of 33

[1158]

[1159] The procedure described for the synthesis of 33 from compound 32 was used for the synthesis of compound 33 (55%). 46 H 82 N3PO 34 + [M-Na+2H] + The HRMS (ESI+) calculated value was 1252.4551 and the found value was 1252.4574.

[1160] Synthesis of 85

[1161]

[1162] Dibenzyl N, N-diisopropylphosphoramidite (2.0 equiv.) and diisopropyl tetrazolium ammonium (1.5 equiv.) were added to a DCM solution of 84, and the solution was stirred at rt for 2.5 h. Then, tert-butyl peroxide (6.0 equiv., 5.0-6.0 M decane solution) was added, and the reaction mixture was stirred for 1 h. After 1 h, the reaction mixture was diluted with DCM and quenched with NaHCO3 aq.sat. solution. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum to give a crude product. The crude product was purified by automatic rapid silica gel column chromatography (0-100% EtOAc in cyclohexane) to give the desired product 85 (88%). For C 167 H 185 O 38 N5P2 + [M-Et3N] +HRMS (ESI+) calculated value 2932.2240, found value 2932.2147.

[1163] Synthesis of 54

[1164]

[1165] Pd / C (20 mg) was added to a clear solution of 85 (20 mg) in EtOAc:MeOH:H2O:DCM. The heterogeneous mixture obtained was stirred at rt for 40 h under a hydrogen atmosphere. After 40 h, the reaction mixture was filtered through a PTFE filter and concentrated under vacuum on a rotary evaporator at 30°C bath temperature for 10 min to remove methanol, EtOAc, DCM and water. The crude product obtained after removal of the solvent was dissolved in MeOH, water, and LiOH (2N in water) was added thereto at 0°C. The reaction mixture was stirred for 3 h at 0°C. After 3 h, the reaction mixture was quenched with AcOH, the solvent was removed under reduced pressure, and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile as solvents to obtain the desired final compound 54 in the form of a salt. The triethylamine salt was then exchanged with Dowex resin to obtain the desired compound with sodium salt as a white solid (40% over 3 steps). For C 46 H 83 N3P2O 37 + [M-Na+H] + HRMS (ESI+) calculated value: 1332.4214, found value: 1332.4242.

[1166] Synthesis of 86

[1167]

[1168] The procedure described for the synthesis of compound 58 was used for the synthesis of compound 86 (94%). 165 H 203 O 37 N7P2 + [M-2xEt3N+H] + HRMS (ESI+) calculated value: 2735.1318, found value: 2735.1356.

[1169] Synthesis of 87

[1170]

[1171] H-phosphonate 86 (1.0 eq.) and benzyl alcohol (10.0 eq.) were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in py and PivCl (5.0 eq.) was added thereto. The reaction mixture was kept stirring at rt for 2 h. After 2 h, the reaction was cooled to -40 °C, a solution of freshly prepared I2Py:H2O (20:1) was added, and the reaction mixture was kept stirring at the same temperature for 1.5 h, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB), dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and using 2% trimethylamine as eluent to obtain the desired product 87 (86%) as a viscous liquid. For C 160 H 179 N5P2O 38 + [M+H-2xEt3N] + The Maldi (ESI+) calculated value was 2842.1770 and the found value was 2842.1638.

[1172] Synthesis of 54

[1173]

[1174] Pd / C (20 mg) was added to a clear solution of 87 (20 mg) in EtOAc:MeOH:H2O:DCM. The heterogeneous mixture obtained was stirred at rt for 40 h under a hydrogen atmosphere. After 40 h, the reaction mixture was filtered through a PTFE filter and concentrated under vacuum on a rotary evaporator at 30°C bath temperature for 10 min to remove methanol, EtOAc, DCM and water. The crude product obtained after removal of the solvent was dissolved in MeOH, water, and LiOH (2N in water) was added thereto at 0°C. The reaction mixture was stirred for 3 h at 0°C. After 3 h, the reaction mixture was quenched with AcOH, the solvent was removed under reduced pressure, and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile as solvents to obtain the desired final compound 54 in the form of a salt. The triethylamine salt was then exchanged with Dowex resin to obtain the desired compound with a sodium salt as a white solid (70% over 3 steps). For C 46 H 83 N3P2O 37 + [M-3Na+4H] + HRMS (ESI+) calculated value: 1332.4214, found value: 1332.4232.

[1175] A.6 Synthesis of Dodecasaccharide 92

[1176] Synthesis of 88

[1177]

[1178] The procedure described for the synthesis of compound 32 was used for the synthesis of compound 88, the only change being that in the second step, compound 52 was used as the nucleophile instead of the linker.

[1179] Synthesis of 89

[1180]

[1181] The procedure described for the synthesis of compound 52 was used for the synthesis of compound 89.

[1182] Synthesis of 90

[1183]

[1184]

[1185] The procedure described for the synthesis of compound 33 was used for the synthesis of compound 90.

[1186] Synthesis of 91

[1187]

[1188] The procedure described for the synthesis of compound 53 was used for the synthesis of compound 91.

[1189] Synthesis of 92

[1190]

[1191] The procedure described for the synthesis of compound 33 was used for the synthesis of compound 92 (60%). 87 H 151 N5P2O 67 The HRMS (ESI+) calculated value of [(M-2Na+2H) / 2] was 1199.9019 and the found value was 1199.8950.

[1192] 92 and CRM 197 Conjugation with BSA

[1193]

[1194]

[1195] The procedures described for the synthesis of glycoconjugates 36 and 37 were used for the synthesis of 94 and 95.

[1196] A.7 Alternative synthesis of dodecasaccharide 92

[1197] Synthesis of 96

[1198]

[1199] H-phosphonate 58 (1.2 eq.) and acceptor 60 (1.0 eq.) were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, they were dissolved in py and PivCl (1.3 eq.) was added thereto. The reaction mixture was kept stirring at rt for 3 h. After 3 h, the reaction was cooled to -40 °C, a freshly prepared solution of I2 in Py:H2O (250 μL, 20:1) was added, and the reaction mixture was kept stirring at the same temperature for 1.5 h, after which it was placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed successively with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB), dried over Na2SO4, filtered and concentrated. The residue was purified by automated flash column chromatography (ethyl acetate:DCM:MeOH) with 2% trimethylamine as eluent to give the desired product 96 (70%) as a viscous liquid. For C 287 H 325 K2N7O 75 P2Si + [M-2Et3N+2K] + The MALDI (ESI+) calculated value was 5237.0351 and the measured value was 5237.718.

[1200] Synthesis of 97

[1201]

[1202] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 97 (70%). 271 H 309 N7O 75 P2 + [M] + The MALDI (ESI+) calculated value was 4926.3745 and the measured value was 4926.323.

[1203] Synthesis of 92

[1204]

[1205]

[1206] The procedure described for the synthesis of compound 61 was used for the synthesis of compound 98 (89%). The procedure described for the synthesis of compound 54 was used for the synthesis of compound 92 (60%). 87 H 152 N5P3NH4O 70 - [(M+NH4-2H) / 2] - The HRMS (ESI+) calculated value was 1247.8944 and the found value was 1247.8791.

[1207] A.8 Synthesis of hexasaccharide 112

[1208] Synthesis of 99

[1209]

[1210] MsCl and pyridine (py) were added to a clear solution of 8 in DCM at 0°C. The reaction mixture was stirred at room temperature overnight, then diluted with DCM, washed with aq. NaHCO3 solution, dried over Na2SO4 and concentrated to give a crude product. The residue was purified by automated silica gel chromatography (hexane / AcOEt) to give compound 99.

[1211] Synthesis of 100 and 101

[1212]

[1213] Sodium iodide was added to a clear solution of 99 in 2-butanone, and the reaction mixture was stirred at 100° C. overnight. Then, the solvent was removed, and the crude residue was dissolved in DCM, washed with aq. NaHSO 3 , dried over Na 2 SO 4 and concentrated to give the iodomethyl derivative 100. The iodo derivative was dissolved in freshly distilled trimethyl phosphite, and the solution was heated to 100° C. under vacuum (water pump) for 48 h. After concentration and silica gel chromatography, the phosphonate derivative 101 was obtained.

[1214] Synthesis of 102

[1215]

[1216] TEA and thiophenol were added to a clear THF solution of 101. The reaction mixture was stirred at room temperature for 24 h. After complete consumption of the starting material, the reaction mixture was diluted with TEA and concentrated to give a crude residue, which was purified by silica gel chromatography to afford 102.

[1217] Synthesis of 103

[1218]

[1219] Phosphonate 102, linker and triphenylphosphine were dissolved in THF and the solution was cooled to 0°C, and then DIAD was added thereto. The mixture was stirred at room temperature for 24 h. After 24 h, the solution was concentrated and the crude product was purified by silica gel chromatography to give 103.

[1220] Synthesis of 104

[1221]

[1222] TEA and thiophenol were added to a clear THF solution of 103. The reaction mixture was stirred at room temperature for 24 h. After complete consumption of the starting material, the reaction mixture was diluted with TEA and concentrated to give a crude residue, which was purified by silica gel chromatography to afford 104.

[1223] Synthesis of 105

[1224]

[1225] The phosphonate derivative 104 was dissolved in 0.05 M NaOMe in MeOH and stirred at rt for 10 min. The reaction mixture was then quenched with AcOH and the solvent removed under vacuum. The crude residue obtained was purified by silica gel chromatography to afford 105.

[1226] Synthesis of 106

[1227]

[1228] The reaction was carried out according to the synthesis of compound 16.

[1229] Synthesis of 107

[1230]

[1231] The reaction was carried out according to the synthesis of compound 18.

[1232] Synthesis of 108

[1233]

[1234] The reaction was carried out according to the synthesis of compound 19.

[1235] Synthesis of 109

[1236]

[1237] The reaction was carried out according to the synthesis of compound 28.

[1238] Synthesis of 110

[1239]

[1240] The reaction was carried out according to the synthesis of compound 29.

[1241] Synthesis of 111

[1242]

[1243] The reaction was carried out according to the synthesis of compound 30.

[1244] Synthesis of 112

[1245]

[1246] The reaction was carried out according to the synthesis of compound 33.

[1247] Conjugation of 112 with CRM197 or BSA

[1248] The reaction was carried out according to the conjugation of compound 33.

[1249] A.8 Synthesis of hexasaccharide 117

[1250] Synthesis of 116

[1251]

[1252] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 116 as a viscous liquid.

[1253] Synthesis of 117

[1254]

[1255] The reaction was carried out according to the synthesis of compound 31.

[1256] 117 and CRM 197 or BSA conjugated

[1257]

[1258] The reaction was carried out according to the conjugation of compound 33.

[1259] A.9 Synthesis of Hexasaccharide 122

[1260] Synthesis of 121

[1261]

[1262] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 121 as a viscous liquid.

[1263] Synthesis of 122

[1264]

[1265] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1266] 122 and CRM 19 7 or BSA conjugation

[1267]

[1268] The reaction was carried out according to the conjugation of compound 33.

[1269] A.10 Synthesis of hexasaccharide 127

[1270] Synthesis of 126

[1271]

[1272] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 126 as a viscous liquid.

[1273] Synthesis of 127

[1274]

[1275] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1276] 127 and CRM 197 or BSA conjugated

[1277]

[1278] The reaction was carried out according to the conjugation of compound 33.

[1279] A.11 Synthesis of hexasaccharide 132

[1280] Synthesis of 131

[1281]

[1282] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 131 as a viscous liquid.

[1283] Synthesis of 132

[1284]

[1285] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1286] 132 and CRM 197 or BSA conjugated

[1287]

[1288] The reaction was carried out according to the conjugation of compound 33.

[1289] A.12 Synthesis of Hexasaccharide 137

[1290] Synthesis of 136

[1291]

[1292] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 136 as a viscous liquid.

[1293] Synthesis of 137

[1294]

[1295] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1296] 137 and CRM 197 or BSA conjugated

[1297]

[1298] The reaction was carried out according to the conjugation of compound 33.

[1299] A.13 Synthesis of hexasaccharide 142

[1300] Synthesis of 141

[1301]

[1302] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 141 as a viscous liquid.

[1303] Synthesis of 142

[1304]

[1305] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1306] 142 and CRM 197 or BSA conjugated

[1307]

[1308] The reaction was carried out according to the conjugation of compound 33.

[1309] A.14 Synthesis of Hexasaccharide 147

[1310] Synthesis of 146

[1311]

[1312] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 ° C, a freshly prepared pyridine: H2O (20: 1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 146 as a viscous liquid.

[1313] Synthesis of 142

[1314]

[1315] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1316] 147 and CRM 197 or BSA conjugated

[1317]

[1318] The reaction was carried out according to the conjugation of compound 33.

[1319] A. Synthesis of 15-hexasaccharide 152

[1320] Synthesis of 151

[1321]

[1322] H-phosphonate 58 and joint were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring for 2 h at rt. After 2 h, the reaction was cooled to -40 °C, a freshly prepared pyridine:H2O (20:1) solution of I2 was added, and the reaction mixture was kept stirring for 1.5 h at the same temperature, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB) successively, dried over Na2SO4, filtered and concentrated. The residue was purified by automatic flash column chromatography (ethyl acetate: DCM: MeOH) and with 2% trimethylamine as eluent to obtain the desired product 151 as a viscous liquid.

[1323] Synthesis of 152

[1324]

[1325] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1326] 152 and CRM 197 or BSA conjugated

[1327]

[1328] SBAP (N-succinimidyl-3-(bromoacetylamino) propionate) was added to a stirred solution of the protein in sodium phosphate buffer (NaPi, pH 7.4) at room temperature. The reaction mixture was stirred at room temperature for 1 hour, then concentrated using membrane filtration and rebuffered in NaPi (pH 8.0). The NaPi solution of compound 152 was added to the solution of the activated protein and stirred at rt for 16 h. The glycoconjugate was then washed with sterile water and treated with I-cysteine ​​in sterile water. Purification of the glycoconjugate was achieved by membrane filtration.

[1329] A.16 Synthesis of Hexasaccharide 157

[1330] Synthesis of 156

[1331]

[1332] The H-phosphonate 58 and the linker were co-evaporated with pyridine and dried under vacuum for 30 min. Afterwards, it was dissolved in pyridine and PivCl was added thereto. The reaction mixture was kept stirring at rt for 2 h. After 2 h, the reaction was cooled to -40 °C, a freshly prepared solution of I2 in pyridine:H2O (20:1) was added, and the reaction mixture was kept stirring at the same temperature for 1.5 h, then placed at rt and stirred at rt for 15 min. Then, TEAB (10 mL) was added to the mixture and diluted with dichloromethane, washed with 10% aq. sodium thiosulfate, 1M aq. triethylammonium bicarbonate (TEAB), dried over Na2SO4, filtered and concentrated. The residue was purified by automated flash column chromatography (ethyl acetate:DCM:MeOH) and with 2% trimethylamine as eluent to give the desired product 156 as a viscous liquid.

[1333] Synthesis of 157

[1334]

[1335] The reaction was carried out according to the synthesis of compound 33 and the TBS deprotection procedure.

[1336] 157 and CRM197 or BSA conjugated

[1337]

[1338] The reaction was carried out according to the conjugation of compound 33.

[1339] A.17 Synthesis of Octadecasaccharides 162, 163, 164 and 165

[1340] Synthesis of 161

[1341]

[1342] The procedure described for the synthesis of compound 32 was used for the synthesis of compound 161, the only change here being that compound 89 was used as the nucleophile in the second step instead of the linker.

[1343] Synthesis of 162

[1344]

[1345] Where Z represents

[1346] Compound 162 was synthesized from compound 161 as described for compound 89 (removal of the TBDPS protecting group) and then as described for compound 90.

[1347] Synthesis of 163

[1348]

[1349] Where Z represents

[1350] Compound 163 was synthesized from compound 161 as described for compound 89 (removal of the TBDPS protecting group) and then as described for compounds 91 and 92.

[1351] Synthesis of 164

[1352]

[1353] Where Z represents

[1354] Phosphonate compound 164 was synthesized as described for compound 162.

[1355] Synthesis of 165

[1356]

[1357] Where Z represents

[1358] Phosphonate compound 165 was synthesized as described for compound 163.

[1359] A. Alternative Synthesis of 18-Octadecasaccharides 162 and 163

[1360] Synthesis of 166

[1361]

[1362] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 166.

[1363] Synthesis of 167

[1364]

[1365] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 167.

[1366] Synthesis of 162

[1367]

[1368] Compound 162 was synthesized from compound 167 as described for compound 33.

[1369] Synthesis of 168

[1370]

[1371] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 168.

[1372] Synthesis of 169

[1373]

[1374] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 169.

[1375] Synthesis of 170

[1376]

[1377] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 170.

[1378] Synthesis of 163

[1379]

[1380] Compound 163 was synthesized from compound 170 as described for compound 54.

[1381] A.19 Synthesis of tetracosaccharides 172 and 173

[1382] Synthesis of 172

[1383]

[1384] Where Z represents

[1385] Compound 172 was synthesized from dodecasaccharide 89 linked to dodecasaccharide 171.

[1386]

[1387] Following the procedure described for compound 88, deprotection of the TBDPS group was followed as described for compound 89, followed by complete deprotection as described for compound 90.

[1388] Synthesis of 173

[1389]

[1390] Where Z represents

[1391] Compound 173 was synthesized from dodecasaccharide 89 linked to dodecasaccharide 171 according to the procedure described for compound 88, following deprotection of the TBDPS group as described for compound 89, followed by complete deprotection as described for compound 92.

[1392] A.20 Alternative synthesis of tetracosaccharides 172 and 173

[1393] Synthesis of 174

[1394]

[1395] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 174.

[1396] Synthesis of 172

[1397]

[1398] Compound 172 was synthesized from compound 174 as described for compound 33.

[1399] Synthesis of 175

[1400]

[1401] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 175.

[1402] Synthesis of 176

[1403]

[1404] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 176.

[1405] Synthesis of 177

[1406]

[1407] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 177.

[1408] Synthesis of 173

[1409]

[1410] Compound 173 was synthesized from compound 177 as described for compound 54.

[1411] A.21 Synthesis of trisaccharides 179 and 183

[1412] Synthesis of 178

[1413]

[1414] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 178.

[1415] Synthesis of 179

[1416]

[1417] Compound 179 was synthesized from compound 178 as described for compound 33.

[1418] 180 Synthesis

[1419]

[1420] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 180.

[1421] Synthesis of 181

[1422]

[1423] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 181

[1424] Synthesis of 182

[1425]

[1426] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 182.

[1427] Synthesis of 183

[1428]

[1429] Compound 183 was synthesized from compound 182 as described for compound 54.

[1430] A.22 Synthesis of hexatriacontasaccharides 186 and 187

[1431] Synthesis of 185

[1432]

[1433] Where Z represents

[1434] Compound 185 was synthesized from octadecasaccharide 161 from which the TBDPS protecting group was selectively removed according to the procedure described for compound 89. Thereafter, the TBDPS-deprotected trisaccharide was reacted with compound 184 to afford saccharide 185.

[1435]

[1436] Synthesis of 186

[1437]

[1438] Where Z represents

[1439] Compound 186 was synthesized from sugar 185, which was converted according to the procedures described for compound 89 (removal of the TBDPS protecting group) and subsequently for compound 90 (removal of the TBDPS protecting group).

[1440] Synthesis of 187

[1441]

[1442] Where Z represents

[1443] Compound 187 was synthesized from sugar 185 following the procedure described for compound 89 (removal of the TBDPS protecting group), phosphorylation as described for compound 91 and subsequent complete deprotection transformation as described for compound 90.

[1444] A.23 Alternative synthesis of hexaconose 186 and 187

[1445] Synthesis of 188

[1446]

[1447] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 188.

[1448] Synthesis of 186

[1449]

[1450] Compound 186 was synthesized from compound 188 as described for compound 33.

[1451] Synthesis of 189

[1452]

[1453] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 189.

[1454] Synthesis of 190

[1455]

[1456] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 190.

[1457] Synthesis of 191

[1458]

[1459] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 191.

[1460] Synthesis of 187

[1461]

[1462] Compound 187 was synthesized from compound 191 as described for compound 54.

[1463] A.24 Synthesis of Oligosaccharides 193 and 197

[1464] Synthesis of 192

[1465]

[1466] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 192.

[1467] Synthesis of 193

[1468]

[1469] Compound 193 was synthesized from compound 192 as described for compound 33.

[1470] Synthesis of 194

[1471]

[1472] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 194.

[1473] Synthesis of 195

[1474]

[1475] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 195.

[1476] Synthesis of 196

[1477]

[1478] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 196.

[1479] Synthesis of 197

[1480]

[1481] Compound 197 was synthesized from compound 196 as described for compound 54.

[1482] A.25 Synthesis of Oligosaccharides 199 and 203

[1483] Synthesis of 198

[1484]

[1485]

[1486] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 198.

[1487] Synthesis of 199

[1488]

[1489] Compound 199 was synthesized from compound 198 as described for compound 33.

[1490] Synthesis of 200

[1491]

[1492] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 200.

[1493] Synthesis of 201

[1494]

[1495] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 201 .

[1496] Synthesis of 202

[1497]

[1498] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 202.

[1499] Synthesis of 203

[1500]

[1501] Compound 203 was synthesized from compound 202 as described for compound 54.

[1502] A.26 Synthesis of Oligosaccharides 205 and 209

[1503] Synthesis of 204

[1504]

[1505] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 204.

[1506] Synthesis of 205

[1507]

[1508] Compound 205 was synthesized from compound 204 as described for compound 33.

[1509] Synthesis of 206

[1510]

[1511] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 206.

[1512] Synthesis of 207

[1513]

[1514] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 207.

[1515] Synthesis of 208

[1516]

[1517] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 208.

[1518] Synthesis of 209

[1519]

[1520] Compound 209 was synthesized from compound 208 as described for compound 54.

[1521] A. Synthesis of 27 Oligosaccharides 211 and 215

[1522] Synthesis of 210

[1523]

[1524] The procedure described for the synthesis of compound 96 was used for the synthesis of compound 210.

[1525] Synthesis of 211

[1526]

[1527] Compound 211 was synthesized from compound 210 as described for compound 33.

[1528] Synthesis of 212

[1529]

[1530] The procedure described for the synthesis of compound 60 was used for the synthesis of compound 212.

[1531] Synthesis of 213

[1532]

[1533] The procedure described for the synthesis of compound 86 was used for the synthesis of compound 213.

[1534] Synthesis of 214

[1535]

[1536] The procedure described for the synthesis of compound 87 was used for the synthesis of compound 214.

[1537] Synthesis of 215

[1538]

[1539] Compound 215 was synthesized from compound 214 as described for compound 54.

[1540] B. Stability Study

[1541] Cleavage of the phosphate bond in compound 33 using NaOH

[1542] Next, the stability of the compounds of the invention was tested and evaluated. The task was to find out how stable compounds 33, 54, 90, 92, 112, 117, 162, 163, 164, 165, 172 and 173 were under the formulation conditions. Compound 33 was treated with 0.1M sodium hydroxide at room temperature before stability in aluminum hydroxide gel, PBS buffer and water. It was found that compound 33 was only cleaved very slowly under highly alkaline conditions. However, even after 4 days under such drastic conditions (10μg 33 in 200μL), only 50% of compound 33 was cleaved, while 50% of compound 33 was still observed to be intact in the HPLC chromatogram ( Figure 6 and 7 ).

[1543] Stability of compound 33 on aluminum hydroxide gel in PBS, PBS and water:

[1544] Next, the stability of compound 33 under formulation conditions was carefully studied. Each formulation vial contained 30 μg 33 contained in i) aluminum hydroxide gel contained in PBS or ii) PBS alone or iii) water (the total volume of the solution was 500 μL). NaPi is used as a synonym for PBS in this article. Each experiment used 60 μL of aluminum hydroxide gel containing 0.6 mg aluminum. The three formulated solutions were placed at 37 ° C, 25 ° C and 2-8 ° C for 14 days. Every 24h period, 50 μL solutions of i) aluminum hydroxide gel contained in PBS, ii) PBS alone and iii) water from each vial at 37 ° C, 25 ° C and 2-8 ° C were divided and analyzed by HPLC ( Figure 8 , 9 , 10). It is evident from these studies that compound 33 is stable over the entire temperature range of 2°C to 37°C. Figure 8 Shows stability at 2-8°C after 4 days, Fig. 9 Shows stability at 2-8°C after 14 days, Fig.10 Stability at 25°C after 4 days, Fig.11 Shows stability at 25°C after 14 days, Fig.12 showed stability at 37°C after 4 days, and Fig.13 Stability at 37°C after 14 days was shown.

[1545] Compared to the native polysaccharide PSII of C. difficile, compounds 33, 54, 90, 92, 112, 117, 162, 163, 164, 165, 172 and 173 were found to be sufficiently stable under the above formulation conditions.

[1546] It was also found that the native polysaccharide PSII of Clostridium difficile, which is composed of hexasaccharide phosphate repeating units as shown below, is unstable in NaOH treatment, unstable in acidic conditions such as acetic acid, and unstable in solutions at 2-8° C., 25° C., and 37° C. It was found that under these conditions, native PSII is rapidly degraded into degradation products that no longer induce immunological effects.

[1547]

[1548] Therefore, the above stability experiments clearly demonstrate that the compounds of the present invention are stable under conditions where native PSII breaks down into fragments that are no longer useful as vaccines, and that the compounds disclosed herein are stable in solution, do not require lyophilization and reconstitution, do not require refrigeration, and do not require the use of expensive working cold chain systems for production and transportation.

[1549] C. Biological Experiments

[1550] SDS-PAGE analysis.

[1551] The samples were mixed in a microcentrifuge tube and heated at 95°C for 5 min on a thermal cycler. After cooling to room temperature for 5 min, approximately 2.5 μg of sample was loaded into the corresponding wells of a 10% polyacrylamide gel along with 10 μL of marker. The samples were run at a constant voltage of 120 V for 1 h. GelCode was used according to the manufacturer's instructions. TM The gel was stained with blue safe protein stain. The gel was washed overnight with deionized water and scanned using a gel documentation system.

[1552] Size exclusion chromatography (SEC) of glycoconjugates.

[1553] Glycoconjugates used for immunological studies were analyzed by SEC to observe the mass difference between conjugated and unconjugated CRM proteins. Samples were diluted in 50 mM Tris, 20 mM NaCl, pH 7.2 and eluted on a Tosoh TSK G2000 column (SWxl, 7.8 mm x 30 cm, 5 μm) and a Tosoh The HPLC was run on an Agilent 1100 HPLC system with a guard column (SWxl 6.0 mm x 4 cm, 7 μm). The flow rate was maintained at 1 mL / min.

[1554] Production of Glycoconjugates

[1555] C. difficile PS-II synthetic antigen and carrier protein CRM 197Conjugated for immunoassays and conjugated with bovine serum albumin (BSA) as a coating antigen for ELISA (see A. Chemical Synthesis). The resulting conjugate was sterile filtered using a 0.2 μM membrane filter before use. The conjugate was analyzed by MALDI analysis. The sugar loading on the carrier protein was specifically calculated by subtracting the mass between the conjugated and unconjugated proteins using MALDI analysis. Protein content was estimated using the micro BCA method following the manufacturing instructions.

[1556] Glycoconjugate 36(33-CRM 197 )、56(54-CRM 197 ) and 94(92-CRM 197 )

[1557] C. difficile antigen glycoconjugates 36, 56, and 94 were analyzed for conjugation efficiency and antigen content for use in immunization studies. MALDI-TOF MS analysis of the glycoconjugates showed good conjugation efficiency. Conjugated and unconjugated CRMs 197 The mass differences between proteins generate each CRM 197 The molecules have a load of approximately 7.5 (56) and approximately 5 (94) antigens.

[1558] The glycoconjugates were also analyzed by 10% SDS-PAGE and SEC and compared with the unconjugated CRM 197 The protein showed a significant mass shift ( Fig.24 and 25 ).

[1559] Immunity Research

[1560] Study I - Immunological evaluation of a semisynthetic glycoconjugate of the C. diff antigen PS-II in rabbits immunized.

[1561] 1. Research objectives:

[1562] Evaluation of semisynthetic CRM using C.diff antigen PS-II 197 IgG antibody responses in rabbits immunized with conjugate vaccine 36.

[1563] 2. Materials:

[1564] ELISA Plates (High Binding, EIA / RIA Plates, 96-well, Flat Bottom with Low Evaporation Cover, Company: 3361)

[1565] Detection antibody: goat anti-rabbit IgG peroxidase conjugate (Sigma, #A4914)

[1566] Blocking solution: 1% FCS in PBS (v / v)

[1567] Antibody diluent: PBS + 1% BSA (w / v).

[1568] Washing buffer: PBS + 0.1% Tween 20 (PBS-T)

[1569] ·Developer: 1step TM Ultra TMB-ELISA developer. (ThermoScientific, Cat#:34028)

[1570] Stop solution: 2M sulfuric acid (H2SO4)

[1571] · Microplate reader: Anthos ht 2.

[1572] Software: WinRead 2.36 for absorbance measurements and GraphPadPrism for data graphing and analysis.

[1573] Incomplete Freund’s adjuvant (IFA). InvivoGen; Cat: vac-ifa-10, Batch No.: IFA-39-03; Expiration Date: September 2019

[1574] QuantiPro TM BCA assay kit (SIGMA) Product: QPBCA-1KT; Batch number: SLBR7451V; Product code: 1002296464

[1575] 3. Methods:

[1576] Preparation of vaccines for immunization

[1577] C.difficile PS-II glycoconjugate 36 was formulated in incomplete Freund's adjuvant (IFA) for immunization in rabbits. Incomplete Freund's adjuvant (IFA) from Invivogen was used to formulate vaccines for rabbit immunization studies. According to the manufacturing protocol. Antigen: The IFA concentration was maintained at 1:1. The antigen dose for each animal was maintained at 2.5 μg / 200 μL / animal (100 μL antigen + 100 μL IFA). The required calculated volume (50% of the final immunization volume) of IFA was placed in a 15mL sterile falcon. The calculated amount of diluted antigen solution (adjusting the volume to 50% of the final immunization volume with PBS) was placed in a 3mL sterile syringe equipped with a 20G needle. The DS solution was added to the falcon containing IFA and immediately vortexed for 15 seconds (5X). The color of the preparation changed from light yellow to milky white when vortexed, indicating that a stable emulsion was formed. The resulting vaccine preparation was vortexed briefly and aliquoted into 2 mL sterile tubes with the desired dose volume. Prior to immunization, the tubes containing the vaccine preparation were vortexed prior to injection into the animals.

[1578] Immunization schedule

[1579] Rabbit immunization was performed under specific pathogen-free conditions and food and water were provided ad libitum. Rabbits (n=4) were immunized subcutaneously with the vaccine formulation at an injection volume of 200 μL / rabbit. The antigen dose for rabbits was maintained at 2.5 μg of PS-II antigen per animal or a corresponding volume of PBS for negative control. Rabbits were immunized on days 0, 14, and 35. Blood was drawn on days 0, 7, and 42 to determine antibody titers.

[1580] 4. Enzyme-linked immunosorbent assay (ELISA) of serum using in-house antigen-coated plates

[1581] Coating plates with antigen

[1582] Antigen-BSA conjugate was used as coating antigen. Antigen-BSA conjugate was dissolved in phosphate buffered saline (PBS) at pH 7.4 at a concentration of 5 μg / mL. 100 μL was coated per well and incubated overnight at 4°C to obtain an antigen concentration of 0.5 μg / well.

[1583] washing

[1584] After overnight antigen adsorption, the plates were washed 1X with PBS-T (200 μL / well) and excess liquid was removed from each well by inverting the plate and tapping with a clean dry tissue towel.

[1585] Closed

[1586] The plates were blocked with 200 μL of commercial blocking solution and incubated for 2 h at rt.

[1587] washing

[1588] After blocking, the plates were washed 3X with PBS-T (200 μL / well) and excess liquid was removed from each well by inverting the plate and tapping with a clean dry paper towel.

[1589] Dilution and incubation of serum

[1590] The pooled serum (n=4 rabbits) from different time points of different experimental groups was diluted to their respective dilutions in antibody diluent (PBS+1% BSA). 100 μL of diluted serum samples from different experimental groups were added to the corresponding wells in duplicate and incubated for 2 h at rt on a shaker set at 250 rpm. 100 μL / well of antibody diluent (PBS+1% BSA) formed the experimental blank. After incubation with serum, the plate was washed 4X with PBS-T (200 μL / well), and the excess liquid in each well was removed by inverting the plate and patting with a clean dry paper towel.

[1591] Incubation (detection antibody)

[1592] The corresponding detection antibody anti-rabbit IgG HRP conjugate was diluted 1:10,000 in antibody diluent (PBS + 1% BSA) and added at 100 μL / well and incubated on a shaker at 250 rpm at rt for 1 h. After incubation with the detection antibody, the plate was washed 5X with PBS-T (200 μL / well) and excess liquid was removed from each well by inverting the plate and tapping with a clean dry paper towel.

[1593] Substrate addition

[1594] 100 μL of ready-to-use TMB substrate (normalized to RT from 4°C) was added to each well and incubated in the dark for 15 min. The blue color of the enzymatic reaction was terminated by adding 50 μL / well of 2M H2SO4 solution to obtain a yellow solution. The absorbance of the yellow solution was measured at 450 nm using a microplate reader.

[1595] result

[1596] The absorbance was analyzed by plotting graphs using Graphpad Prism software.

[1597] The ELISA data clearly showed that sera from rabbits immunized with C. difficile PS-II conjugate 36 could recognize the corresponding antigen (see Fig.15 ).

[1598] Study II – Immunological evaluation of a semisynthetic glycoconjugate of the C. diff antigen PS-II in rabbits and mice immunized.

[1599] 1. Research objectives:

[1600] Evaluation of C.diff PS-II Semi-Synthetic CRM 197 IgG antibody responses in rabbits and mice immunized with conjugate vaccines 56 and 94.

[1601] 2. Materials

[1602] ELISA Plates (High Binding, EIA / RIA Plates, 96-well, Flat Bottom with Low Evaporation Cover, Company: 3361)

[1603] Detection antibodies: goat anti-rabbit IgG peroxidase conjugate (Sigma, #A4914) and anti-human IgG (H+L)-HRP, Nordic Immunology, lot number: 6276

[1604] Blocking solution: Roche, Ref: 11112589001; Batch number: 21495200, Expiration date: July 2019.

[1605] Antibody diluent: PBS + 1% BSA (w / v)

[1606] Washing buffer: PBS + 0.1% Tween 20 (PBS-T)

[1607] ·Developer: 1step TM Ultra TMB-ELISA developer. (ThermoScientific, Cat#:34028)

[1608] Stop solution - 2M sulfuric acid (H2SO4)

[1609] · Microplate reader: Anthos ht 2.

[1610] Software: WinRead 2.36 for absorbance measurements and GraphPadPrism for data graphing and analysis

[1611] Alum: Aluminum Hydroxide Gel Adjuvant (Aluminum Hydroxide Gel 2%), Brenntag, Batch No.: 5447 Expiration Date: February 2020

[1612] QuantiPro TM BCA Assay Kit (SIGMA) Product: QPBCA-1KT; Batch No.: SLBR7451V; Product Code: 1002296464

[1613] ·Mini- TGX TMGel-10%, 10 wells (30 μL / well) Control number: 64175708

[1614] Precision Plus Dual Color, Cat: 1610374; Reference number: 641798899

[1615] Gel Code TM Blue safe protein stain; ThermoScientific; Ref: 1860957; Lot No: TA260266

[1616] C. diff coated ELISA plates for strain 630 (tgc BIOMICS lot number: 630-43411) and R20291

[1617] (tgc BIOMICS batch number: R20291-43559) Expiry date: 05 / 2020.

[1618] · Plasma from patients with C.diff positive disease.

[1619] 3. Methods

[1620] Vaccines formulated in aluminum hydroxide (alum) adjuvant for immunization

[1621] All formulations were prepared under sterile conditions. Glycoconjugates 56 and 94 (drug substances; DS) and PBS were mixed in appropriate pre-calculated proportions in 50 mL Falcon TM tube, which corresponds to the final formulation volume without the required volume of alum (0.25 mg / mL). This forms the DS-PBS mixture. Maintain the antigen / DS dose / animal at 2.5 μg / 500 μL / animal or 10 μg / 500 μL / animal (rabbit studies) or 0.5 μg / 100 μL / animal or 2 μg / 100 μL / animal (mouse studies). Gently mix the DS-PBS mixture using a serological pipette (5X). Add the corresponding volume of alum stock solution (10 mg / mL) to the DS-PBS mixture so that the final alum ratio is 1:40 or 0.250 mg / mL. Mix the mixture immediately by gently pipetting (20X) using a 5 mL serological pipette. Cover with Falcon TM Tube, use Wrapped and allowed to mix on a shaker at 250 rpm for 2 h at room temperature (RT). After 2 h of incubation time, the formulations were placed under a clean bench, aliquoted, and further stored at 4°C until further use. The sugar conjugates formulated in alum were characterized to determine the final alum concentration and pH of the formulations.

[1622] Immunization schedule

[1623] Mice and rabbits were immunized under specific pathogen-free conditions, and animals were provided with food and water ad libitum. Mice (7 or 8 rabbits per study group) and rabbits (n=4 per study group) were immunized subcutaneously with different antigen doses at an injection volume of 100 μL / mouse and 500 μL / rabbit using the vaccine formulation. Mice were immunized on days 0, 14, and 28, and blood was collected on days 21 and 35. Rabbits were immunized on days 0, 14, 28, and 77, and blood was collected on days 0, 7, 21, 35, 77, and 84. Serum was prepared from blood samples for serum antibody analysis.

[1624] 4. Perform enzyme-linked immunosorbent assay (ELISA) of serum using internal antigen-coated plates.

[1625] Coat plates with antigen:

[1626] Conjugates 54-BSA and 92-BSA were used as coating antigens. The corresponding conjugates were diluted to a concentration of 5 μg / mL in phosphate buffered saline (PBS) at pH 7.4. 100 μL was coated per well and incubated overnight at 4°C to obtain an antigen concentration of 0.5 μg / well. For coating of isolated PS-II polysaccharides, the polysaccharides were diluted to 50 μg / mL in PBS with 10 mM imidazole and coated at 100 μL / well for 5 h at 50°C.

[1627] washing:

[1628] After adsorption of antigen, the plates were washed 1X with PBS-T (200 μL / well) and excess liquid was removed from each well by inverting the plate and tapping with a clean dry paper towel.

[1629] Closure:

[1630] The plates were blocked with 200 μL of commercial blocking solution and incubated for 2 h at rt.

[1631] washing:

[1632] After blocking, the plates were washed 3X with PBS-T (200 μL / well) and excess liquid was removed from each well by inverting the plate and tapping with a clean dry paper towel.

[1633] Dilution and incubation of serum:

[1634] Pooled sera (n = 4 rabbits or n = 7-8 mice / group) from different experimental groups at different time points were diluted to their respective dilutions in antibody diluent (PBS + 1% BSA). 100 μL of diluted serum samples from different experimental groups were added to the corresponding wells in duplicate and incubated for 2 h at rt on an oscillator set at 250 rpm. In order to perform competitive ELISA experiments, the diluted sera were incubated on ice for 30 min with 10 or 50 μg of isolated PS-II polysaccharides or with PBS, and then added to the ELISA plate. 100 μL / well of antibody diluent (PBS + 1% BSA) formed the experimental blank. After incubation with the serum, the plate was washed 4X with PBS-T (200 μL / well), and the excess liquid in each well was removed by inverting the plate and patting with a clean dry paper towel.

[1635] Incubation with detection antibody:

[1636] The corresponding detection antibody, anti-rabbit or anti-mouse IgG HRP conjugate, was diluted 1:10,000 in antibody diluent (PBS + 1% BSA) and added at 100 μL / well and incubated at RT for 30 min at 250 rpm on a shaker. After incubation with the detection antibody, the plate was washed 5X with PBS-T (200 μL / well) and excess liquid was removed from each well by inverting the plate and tapping with a clean dry paper towel.

[1637] Substrate addition:

[1638] Add 100 μL of ready-to-use TMB (3,3',5,5'-tetramethylbenzidine) substrate (normalized to RT from 4°C) to each well and incubate in the dark for 15 min. The blue color of the enzymatic reaction is terminated by adding 50 μL / well of 2M H2SO4 solution to obtain a yellow solution. The absorbance of the yellow solution is measured at 450 nm using a microplate reader.

[1639] result:

[1640] The absorbance was analyzed by plotting graphs using GraphPad Prism software.

[1641] 5. Enzyme-linked immunosorbent assay (ELISA) of serum using commercial pre-coated plates

[1642] The procedure was identical to the ELISA protocol described above, except that the coating step was omitted.

[1643] result:

[1644] Serum IgG from immunized rabbits recognizes the immunogen ( Fig. 20 ), isolated PS-II polysaccharide ( Fig.19B in 19 and C in 19) and C. difficile strain 630 ( Fig.16 and 17 ), R20291( Fig.18 ) and VPI10463( Fig.19 A in Figure 1). Serum IgG from immunized mice recognizes the corresponding immunogen ( Fig.23 ) and C. difficile strain 630 ( Fig.21 ) and R20291( Fig. 22 ).

[1645] The data presented herein demonstrate that functional antibodies to the oligosaccharides of the invention as well as to native C. difficile PS-II polysaccharide (isolated and on the surface of the bacterium) were elicited in rabbits and mice following immunization with the conjugates of the invention, particularly conjugates 56 and 94. These findings suggest that these antibodies have the potential to confer protection from C. difficile infection.

[1646] The ELISA data further demonstrate that the conjugates of the invention are immunogenic and induce high antibody titers. Thus, the ELISA analysis shows that the saccharides of the invention are immunogenic in rabbits and mice and generate cross-reactive antibodies.

Claims

1. Sugar of general formula (I): in, n is an integer selected from 1 and 2, T*- represents -P(=O)(OH)2, -P(=O)(O - )(OH) or -PO3 2- ; Z stands for E represents amino group; –L– stands for -(CH2) o -as well as o is an integer selected from 1, 2, 3, 4, 5 and 6; or a pharmaceutically acceptable salt thereof.

2. The sugar according to claim 1, which is selected from the following: Where Z represents 3. The sugar of formula (I'a-4) or formula (I'b-4) according to claim 2, Where Z represents The saccharide or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the pharmaceutically acceptable salt is a sodium salt.

5. A conjugate comprising a saccharide according to any one of claims 1 to 4, covalently linked to an immunogenic carrier via the residue E of the -OLE group.

6. The conjugate according to claim 5, which has the general formula (IV): in, c is between 2 and 18; -E1- means -NH-; -W-Selected from: as well as a represents an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, b represents an integer selected from 1, 2, 3 and 4, CP is a carrier protein and n, L, Z and T* have the same meanings as defined in claim 1.

7. The conjugate of claim 6, wherein the carrier protein CP is selected from the group consisting of: diphtheria toxoid, mutated diphtheria toxoid, modified diphtheria toxoid, mutated and modified diphtheria toxoid, tetanus toxoid, modified tetanus toxoid, mutated tetanus toxoid, protein D of non-typeable Haemophilus influenzae, outer membrane protein complex of Neisseria meningitidis, bovine serum albumin, keyhole limpet hemocyanin, cholera toxoid, or CRM 197 .

8. The conjugate according to claim 7, which has the following formula (V-2): Wherein L is -(CH2)5-, E1 is -NH-, n is an integer selected from 1 or 2, c has the same meaning as defined in claim 7, and -W- means wherein a is an integer selected from 2, 3, 4, 5 and 6.

9. The conjugate according to claim 8, wherein the conjugate has the following formula:

10. Use of a saccharide according to any one of claims 1 to 4 or a conjugate according to any one of claims 5 to 9 for the manufacture of a medicament for use in generating a protective immune response in a human and / or animal host.

11. Use of a saccharide according to any one of claims 1 to 4 or a conjugate according to any one of claims 5 to 9 for the manufacture of a medicament for use in the prevention and / or treatment of diseases associated with bacteria containing one of the following saccharide fragments in their cell wall polysaccharides: -6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1-; -3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1-; -4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1,4)-α-D-Glc-(1-; -4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1,3)-β-D-GalNAc-(1-; and -3)-β-D-GalNAc-(1,4)-α-D-Glc-(1,4)-[β-D-Glc-(1,3)]-β-D-GalNAc-(1,3)-α-D-Man-(1,6)-β-D-Glc-(1-.

12. The use according to claim 10, wherein the bacterium is Clostridium difficile.

13. A pharmaceutical composition comprising a conjugate according to any one of claims 5 to 9 and / or a saccharide according to any one of claims 1 to 4, and at least one pharmaceutically acceptable adjuvant and / or excipient.

14. An intermediate compound for preparing a conjugate of general formula (V-2), wherein the intermediate compound is: